

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The rationale and design of a randomized controlled trial testing the effect of metformin administered with adjuvant personalized diet in individuals with prediabetes or type 2 diabetes mellitus

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037859
Article Type:	Protocol
Date Submitted by the Author:	25-Feb-2020
Complete List of Authors:	Htet, Thaw; Garvan Institute of Medical Research Godneva, Anastasia; Weizmann Institute of Science Liu, Zhixin; UNSW, Stats Central Chalmers, Eliza; Garvan Institute of Medical Research Kolobkov, Dmitry; Weizmann Institute of Science Snaith, Jennifer; Garvan Institute of Medical Research Richens, Renee; Garvan Institute of Medical Research Toth, Krisztina; Garvan Institute of Medical Research Danta, Mark; UNSW Hng, Tien-Ming; Blacktown Mount Druitt Hospital, Diabetes & Endocrinology Elinav, Eran; Weizmann Institute of Science, Segal, Eran; Weizmann Institute of Science Greenfield, Jerry; Garvan Institute of Medical Research Samocha-Bonet, Dorit; Garvan Institute of Medical Research, Diabetes Division
Keywords:	Diabetes & endocrinology < INTERNAL MEDICINE, NUTRITION & DIETETICS, Nutrition < TROPICAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **The rationale and design of a randomized controlled trial testing the effect of metformin**  
4  
5 **administered with adjuvant personalized diet in individuals with prediabetes or type 2**  
6  
7 **diabetes mellitus**  
8  
9

10  
11  
12 Thaw D Htet<sup>1,2,3\*</sup>, Anastasia Godneva<sup>4\*</sup>, Zhixin Liu<sup>5</sup>, Eliza Chalmers<sup>1</sup>, Dmitry Kolobkov<sup>4</sup>,  
13  
14 Jennifer R Snaith<sup>1,2,3</sup>, Renee Richens<sup>1</sup>, Krisztina Toth<sup>1</sup>, Mark Danta<sup>2,6</sup>, Tien-Ming Hng<sup>7,8</sup>,  
15  
16 Eran Elinav<sup>9</sup>, Eran Segal<sup>4</sup>, Jerry R Greenfield<sup>1,2,3</sup>, Dorit Samocha-Bonet<sup>1,2#</sup>  
17  
18

19  
20 Affiliations:  
21

- 22  
23 1 Diabetes and Metabolism, Garvan Institute of Medical Research, Sydney, Australia  
24  
25 2 St Vincent's Clinical School, University of NSW, Sydney, Australia  
26  
27 3 Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, Australia  
28  
29 4 Department of Computer Science and Applied Math, Weizmann Institute of Science,  
30  
31 Rehovot, Israel  
32  
33 5 Mark Wainwright Analytical Centre, UNSW, Sydney, Australia  
34  
35 6 Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia  
36  
37 7 Blacktown Mt Druitt Hospital, Western Sydney Local Health District, Sydney,  
38  
39 Australia  
40  
41 8 Blacktown Clinical School, Western Sydney University, Sydney, Australia  
42  
43 9 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel  
44  
45  
46  
47

48 \*Equally-contributing Authors  
49

50 #Corresponding Author: Dorit Samocha-Bonet, Garvan Institute of Medical Research,  
51  
52 384 Victoria Street, Darlinghurst, NSW 2010, Australia. Phone: +61 2 92958309, email:  
53  
54 d.samoخابonet@garvan.org.au  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction** Metformin and diets aimed at promoting healthy body weight are the first-line in treating type 2 diabetes mellitus (T2DM). Clinical practice, backed by clinical trials, suggests that many individuals do not reach glycaemic targets using this approach alone. The primary aim of the Personalised Medicine in Prediabetes – Towards Preventing Diabetes in Individuals at Risk (PREDICT) study is to test the efficacy of personalized diet as adjuvant to metformin in improving glycaemic control in individuals with dysglycemia.

**Methods and Analysis** PREDICT is a two-arm, parallel group, single-masked randomized controlled trial in adults with prediabetes or early-stage T2DM (with HbA1c up to 8.0%), not treated with glucose-lowering medication. PREDICT is conducted at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Enrolment of participants commenced in December 2018 and expected to complete in December 2021. Participants are commenced on metformin (Extended Release, titrated to a target dose of 1500 mg/d) and randomized with equal allocation to either (1) the Personalized Nutrition Project (PNP) algorithm-based diet or (2) low-fat high dietary fibre (LFHF) diet, designed to provide caloric restriction (75%) in individuals with body mass index  $>25$  kg/m<sup>2</sup>. Treatment duration is 6 months and participants visit the Clinical Research Facility 5 times over approximately 7 months. The primary outcome measure is glycated haemoglobin (HbA1c). The secondary outcomes are time of day of interstitial glucose  $<7.8$  mmol/L and glycaemic variability (continuous glucose monitoring), body weight and composition (dual-energy X-ray absorptiometry), markers of cardiovascular disease (blood pressure, lipid profile, pulse wave analysis), liver stiffness and fat (Fibroscan).

**Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional

1  
2  
3 Review Board (File 528-3, Rehovot, Israel). The findings will be published in peer-reviewed  
4  
5 open access medical journals.  
6  
7

8 The study has been registered at ClinicalTrials.gov (NCT03558867).  
9  
10

## 11 12 13 14 **Article Summary**

15  
16  
17 The PREDICT study is set to test a novel diet as an adjuvant to metformin. We expect improved  
18  
19 glycaemia with the combined metformin-personalized diet treatment. This study may result in  
20  
21 a novel management approach for people with, or predisposed to, type 2 diabetes requiring  
22  
23 metformin treatment.  
24  
25  
26  
27  
28  
29

## 30 **Strengths and limitations of this study**

- 31  
32
- 33 • The randomized controlled design testing a novel diet against standard of care may lead  
34 to a novel tool to manage dysglycemia in individuals requiring metformin  
35
  - 36 • Conducted in an adult Australian population, the study findings may not be applicable  
37 to other populations  
38
  - 39 • The algorithm used to devise the personalized diet relies on accurate recording of the  
40 dietary intake by the participants  
41
  - 42 • The dietary intervention requires use of a smartphone application which may limit its  
43 applicability to some populations  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **Key words:** Prediabetes, Type 2 diabetes, Metformin, Algorithm-based diet, Low fat diet,  
55  
56  
57 Randomized controlled trial  
58  
59  
60

**Word count: 3927**

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Type 2 diabetes mellitus (T2DM) and its preceding medical condition, prediabetes are significant risk factors for cardiovascular disease, and most affected individuals demonstrate additional metabolic risk factors, such as hypertension, dyslipidaemia, excess weight and fatty liver<sup>1</sup>. T2DM affects approximately 422 million adults globally, with an additional 352 million individuals at increased risk, having prediabetes<sup>2,3</sup>. Individuals diagnosed with prediabetes or T2DM are encouraged to adopt a healthy lifestyle and, if overweight to lose weight<sup>4</sup>. The majority of individuals with T2DM are treated with metformin, which is the 8<sup>th</sup> most prescribed medication in the United States<sup>5-7</sup>.

Metformin, an oral biguanide, is the first-line treatment for individuals with newly-diagnosed T2DM and, in some cases, for the prevention of diabetes in individuals with prediabetes<sup>6</sup>. Metformin is an ideal medication to initiate for management of T2DM or for prevention of diabetes, because it does not cause hypoglycaemia and has a favourable, albeit modest, effect on body weight<sup>8</sup>. Metformin monotherapy is insufficient to achieve glycaemic control in a large proportion of treated individuals<sup>3,9,10</sup>. Findings from the Diabetes Prevention Program (DPP) in individuals with prediabetes suggested that the glycaemic efficacy of metformin depends on the magnitude of weight loss<sup>11</sup>, explaining 64% of the diabetes risk reduction, with additional 17% explained by decreases in fasting insulin and pro-insulin at 3 years of follow up<sup>11,12</sup>.

The current treatment guidelines in T2DM recommend prescribing metformin in combination with a healthy lifestyle, enabling weight loss<sup>13</sup>. The most recent nutritional guidelines for individuals with T2DM or prediabetes are no longer supporting a universal ideal dietary macronutrient distribution; instead, the guidelines suggest individualized eating plans<sup>4</sup>.



1  
2  
3 In the pioneering Personalized Nutrition Project (PNP)<sup>14</sup>, Segal, Elinav and colleagues  
4 developed an algorithm that predicts an individual's postprandial glycaemic response (PPGR)  
5 to meals. The algorithm incorporates the individual's personal data (e.g. age, gender, body  
6 mass index [BMI]), blood tests (e.g. glycated haemoglobin [HbA1c]), dietary features,  
7 continuous glucose monitor (CGM)-derived data, and gut microbiome features, and trained on  
8 data previously collected in 800 individuals. Personally-tailored dietary plans based on the  
9 algorithm were trialled in a small group of individuals with prediabetes and shown to improve  
10 glycaemic variability and PPGR over 7 days<sup>14</sup>.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The primary objective of the Personalised Medicine in Prediabetes – Towards Preventing  
25 Diabetes in Individuals at Risk (PREDICT) Study is to compare glycaemic control, measured  
26 by HbA1c, following 6 months of metformin, prescribed with either (1) the PNP algorithm-  
27 based diet or (2) low-fat high dietary fibre (LFHF) diet, based on the Australian Healthy Eating  
28 Guide<sup>15</sup> and the American Association of Clinical Endocrinologists guide for medical care of  
29 patients with obesity<sup>16</sup>, in individuals with prediabetes or early-stage T2DM naive to glucose-  
30 lowering pharmacotherapy.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The secondary objectives of the PREDICT study are to compare the effect of metformin when  
44 prescribed with the PNP diet versus LFHF diet on: (1) time of interstitial glucose <7.8 mmol/L,  
45 (2) glycaemic variability, (3) weight, (4) body composition, (5) resting energy expenditure  
46 (REE), (6) markers of cardiovascular disease and (7) liver fat and fibrosis. The exploratory  
47 objectives of the study are to test the effect of the treatment on the gut microbiome.  
48  
49  
50  
51  
52  
53  
54  
55  
56

## 57 **METHODS**

### 58 **Study design, setting and population**

59  
60

1  
2  
3 The study is a two-arm, parallel group, single-masked randomized controlled trial (RCT).  
4  
5 Adults with prediabetes or early-stage T2DM who are not treated with glucose-lowering  
6  
7 medications are randomized, with equal allocation, to either the PNP or LFHF arms, both  
8  
9 administered with metformin Extended Release (XR) 1500 mg/d for 6 months. All the study  
10  
11 visits are performed at the Clinical Research Facility (CRF) at the Garvan Institute of Medical  
12  
13 Research (Sydney). Metagenomics and data processing for the personalized dietary  
14  
15 interventions are performed at the Weizmann Institute of Science (Rehovot).  
16  
17  
18  
19  
20  
21

## 22 **Patient and public involvement**

23  
24 Patients or the public were not involved in the design or other aspects of the research.  
25  
26  
27  
28  
29

## 30 **Eligibility**

31  
32 Adults (20-70 years old) with prediabetes or recently (in the past 6-months) diagnosed T2DM  
33  
34 with (HbA1c  $\leq$ 8.0%), not pregnant or planning to become pregnant during, and for at least 3  
35  
36 months after the study are recruited (Table 1). A wide age range was selected to encompass  
37  
38 different populations of individuals managing their prediabetes for short or long durations and  
39  
40 to increase the likelihood to recruit the sample size in a timely manner. The HbA1c cap at 8.0%  
41  
42 was selected to ensure that individuals with T2DM are relatively well-controlled. Individuals  
43  
44 with conditions or treatments that affect glycaemia (e.g. oral steroids), impact weight (e.g.  
45  
46 bariatric surgery, weight loss medications), or the gut microbiome (e.g. inflammatory bowel  
47  
48 disease, coeliac, frequent antibiotic treatment) will be excluded (Table 1).  
49  
50  
51  
52  
53  
54  
55

## 56 **Recruitment**

1  
2  
3 The study is advertised in general practitioners (GP), endocrinologists and dieticians' practices  
4 in the Sydney metropolitan area, and through targeted social media campaigns. A collaboration  
5 with Blacktown Mt Druitt Hospital (Western Sydney) has been established in 2019 for the  
6 purpose of recruitment. During a hospital screening program ran between 2016 – 2018, 17.3%  
7 and 30.2% of individuals visiting the Emergency Department (ED) at Blacktown Mt Druitt  
8 Hospital have had HbA1c values indicative of diabetes and prediabetes, respectively<sup>17</sup>. Since  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

September 2019, individuals visiting the ED who have had a blood test indicative of prediabetes receive a letter prompting them to contact the PREDICT team and encouraging they share the result with a GP.

To-date (February 2020), 38 participants were enrolled. Of the 38 participants enrolled, 20 completed, 13 are ongoing, and 5 withdrew before the end of the treatment (13% drop-out rate). Recruitment of participants is expected to complete in December 2021.

Participants contacting the team receive the participant information sheet via email or post. Experienced clinical research nurse/associate provides details about the study over the phone. Willing participants are referred to a commercial pathology to perform an oral glucose tolerance test (OGTT, 75 g) and HbA1c test. They are asked to sign a consent form after reading the participant information sheet explaining the possible risks of undergoing the OGTT and HbA1c tests prior to performing the blood tests. If the blood tests indicate either T2DM (with HbA1c  $\leq 8.0\%$ ), or impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or HbA1c  $\geq 5.7$ , they are invited to a screening and enrolment visit at the Garvan CRF.

A stool collection kit for metagenomics OMNIgene GUT (OMR-200; DNA Genotek) is mailed to participants prior to the screening/enrolment visit. Participants collect the sample according

1  
2  
3 to the manufacturer's instructions the day before the visit and keep the sample at room  
4 temperature. At the CRF, the sample is vortexed, centrifuged for a few seconds and material  
5 aliquoted into cryo vials and kept in -80C freezer. One vial is transferred to facilities at the  
6 Weizmann Institute of Science and stored at -20°C until DNA extraction.  
7  
8  
9  
10  
11  
12  
13  
14

15 The pre-treatment data are collected across the screening/enrolment and the baseline visits.  
16  
17  
18  
19

### 20 **Screening / enrolment procedures and measurements**

21

22 During the screening/enrolment visit, participants sign the study informed consent form and  
23 undergo medical examination by a physician. Participants have their weight, height, waist and  
24 hip circumference and blood pressure measured. Basal metabolic rate (BMR) is estimated using  
25 bioelectrical impedance (BIA, used for calculating the energy requirement, see "Energy  
26 target"). Blood samples are collected to evaluate liver (liver enzymes) and kidney (creatinine  
27 and eGFR) function and full blood count. Glucose monitor (FreeStyle Libre Pro, Abbott,  
28 Germany) is attached for a period of 14 days.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 A link to download the PNP smartphone application is sent to the participants prior to the  
43 screening/enrolment visit. They are asked to log-in to the app with a personal (re-identifiable)  
44 code provided by email, and to familiarize with the app in preparation for a training session  
45 with the dietician. During the screening/enrolment visit, the dietitian practices with the  
46 participants browsing the food database, selecting food and beverage items and indicating the  
47 amount consumed. Participants are taught to add frequently consumed foods to a favourites  
48 list, which makes future search of food items easier. When the CGM is on, participants are  
49 asked to carry on with their usual routine and to record all meals, snacks and drinks using the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 app. The period between the screening/enrolment and the baseline visits (4 – 6 weeks) serves  
4  
5 as the ‘run-in’ period.  
6  
7  
8  
9

## 10 **Randomization**

11  
12  
13 Randomization is performed between the screening/enrolment and baseline visits. Individuals  
14  
15 are randomized with 1:1 allocation into the 2 arms in rounds of approximately 4 individuals  
16  
17 each, with randomization performed within each round using the minimization program for  
18  
19 allocation of subjects to parallel groups, modified from Saghaei et al<sup>18</sup>. They are stratified by  
20  
21 gender, age (20-49 or 50-70 years), BMI (<25.0 or >25.1 kg/m<sup>2</sup>) and HbA1c (<5.7 or >5.8 %).  
22  
23 To avoid bias, the randomization is performed by a study investigator located at the Weizmann  
24  
25 Institute who does not interact with the study participants. The study nurses and physicians  
26  
27 who have direct contact with the participants are blinded to the randomization order, however  
28  
29 due to the nature of the intervention, the study dietician is not blinded to the treatment  
30  
31 allocation.  
32  
33  
34  
35  
36  
37  
38

## 39 **Baseline visit - Measurements**

40  
41 The baseline visit is performed approximately 4-6 weeks after the screening/enrolment visit  
42  
43 (Table 2). Participants attend the CRF following an overnight fast. Blood is drawn for serum  
44  
45 lipids measurement and anthropometric measures and blood pressure are taken. Arterial  
46  
47 stiffness (pulse wave analysis, AtCor Medical, Australia) is measured twice and average  
48  
49 recorded, as described<sup>19</sup>. This is followed by measurement of REE, carbohydrate and fat  
50  
51 oxidation over 30 minutes by indirect calorimetry (Quark, Cosmed, Italy)<sup>20</sup>. Body composition  
52  
53 is assessed using dual-energy X-ray absorptiometry (DXA, Lunar Prodigy, GE Healthcare).  
54  
55 Specifically, total body fat mass and fat-free mass (enCORE software), the android and gynoid  
56  
57 region, and visceral fat (CoreScan software, GE Healthcare) are recorded<sup>21</sup>. Liver steatosis  
58  
59  
60

1  
2  
3 (controlled attenuation parameter, CAP) and liver fibrosis (liver stiffness measurement, LSMs)  
4  
5 are assessed using FibroScan (Touch 502 by Echosens) by a trained technician. CAP and LSMs  
6  
7 have been reported to correlate closely with steatosis and fibrosis assessed using the gold-  
8  
9 standard liver biopsy<sup>22</sup>. A physical activity monitor (ActivePal, Pal Technologies) is applied  
10  
11 on the thigh for a period of 14 days. At the end of the baseline visit, the participants practice  
12  
13 using the app with the dietician.  
14  
15  
16  
17  
18  
19

### 20 **Prediction of postprandial glucose response using the algorithm**

21  
22 The prediction of PPGR in PREDICT follows the modelling framework described in Zeevi et  
23  
24 al<sup>14</sup> and is performed between the screening/enrolment and baseline visits. Time-stamped food  
25  
26 records from the app, CGM and other data collected during the enrolment visit at the Garvan  
27  
28 are shared with a mathematician at the Weizmann Institute of Science where data processing  
29  
30 occurs, on an Institutional secured server. The data, together with the stool metagenome  
31  
32 sequencing data are integrated with the Weizmann Institute's database to develop personalized  
33  
34 algorithms for predicting each individual's PPGR. A database of recipes of meals (n=233) and  
35  
36 smaller meals ("snacks", n=249) varying in macronutrient composition to generate feedback  
37  
38 on the PPGR to pre-consumed meals has been created. Using the participants' features,  
39  
40 personalized PPGR are calculated for every meal and snack in the database based on nutrient  
41  
42 composition, and energy-adjusted quintile cut-offs of PPGR are used to create personalized  
43  
44 meal ratings ranging from 1 to 5 (corresponding with "excellent", "good", "medium", "bad",  
45  
46 and "very bad"). The predictive model, originally trained on data collected in an Israeli adult  
47  
48 cohort<sup>14</sup>, has been shown to be predictive of PPGR in a U.S. cohort of healthy adults (n=327)  
49  
50 consuming a Western style diet<sup>23</sup>.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Interventions**

1  
2  
3 Both arms use the PNP mobile app to select meals/foods. In 2018, the app, developed at the  
4 Weizmann Institute of Science, was adapted to Australian consumers including the Australian  
5 food database (AUSNUT 2011–13)<sup>24</sup> of approximately 5,700 food items.  
6  
7  
8  
9

### 10 11 12 13 *Personalized diet (PNP diet arm)*

14  
15 Participants in the PNP diet arm receive personalized feedback on each of their food item/meal  
16 choice and asked to consult with the app in real-time to select the recommended meal for them.  
17  
18 The feedback is color-coded with a traffic light system; green (“good” and “excellent”), yellow  
19 (“medium”) and red (“bad” or “very bad”) PPGR (Figure 1 A and B). Participants are advised  
20 to aim for as many “good” and “excellent” scores, occasional “medium”, and to avoid “bad”  
21 and “very bad” scores. When receiving bad scores, they are advised to trial substituting, adding  
22 or removing ingredients from the meal to improve the score. In individuals with  
23 hypercholesterolemia, a special set of recipes containing reduced saturated fat are uploaded  
24 into the smartphone app.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 *Low-fat high fibre diet (LFHF) arm*

40  
41 The LFHF diet is designed to provide approximately 30% of the total daily energy intake from  
42 fat, of which up to 10% of the fat is saturated fat, 50-55% of energy from low glycaemic load  
43 carbohydrates, 20-25% from protein and 30 g/d of dietary fibre. A database of recipes (n=110  
44 meals and n=80 snacks) following the LFHF nutrient content has been created based on the  
45 AUSNUT 2013 recipes<sup>24</sup>. Food items such as sugary drinks, processed meat, candies, sugar  
46 and cream were excluded from the LFHF recipes. Similar to the PNP arm, recommended meals  
47 scaled to the individual’s energy target are uploaded into the participants’ app, taking into  
48 account the individual’s dietary restrictions and likes. Similar to the PNP arm, participants of  
49 the LFHF arm are encouraged to choose from the recipes uploaded for them or browse the food  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 database (5700 food items) to design their own meals, as long as they follow the general dietary  
4 guidelines. Participants of the LFHF arm are instructed to consult with the total daily energy  
5 and macronutrient breakdown charts to ensure they follow the recommended diet (Figure 1C).  
6  
7  
8  
9

### 10 11 12 13 *Energy target and using the app to select meals in real-time (both arms)*

14  
15 The energy requirement calculation is based on BMR estimated by BIA (Tanita, TBF-300 by  
16 Wedderburn) and on the Mifflin equation<sup>25</sup>. The two values are multiplied by a physical  
17 activity factor of 1.4 (lightly active) then averaged, and the value compared with the average  
18 daily energy intake of at least 7 days, extracted from the time-stamped meals recorded using  
19 the app. In participants with BMI >25 kg/m<sup>2</sup>, energy target of 75% is prescribed. Participants  
20 of both arms are encouraged to consume 3 bigger (breakfast, lunch, dinner) and 3 smaller  
21 (snack) meals spread throughout the day.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 35 *Metformin (both arms)*

36  
37 Metformin (XR) is dispensed by the St Vincent's Hospital Pharmacy (Sydney) at baseline (for  
38 a period of 3 months) and at the 3 months visit (to last until the end of the study). The target  
39 dose (1500 mg/d) is titrated over 3 weeks to minimize gastrointestinal intolerance. A target  
40 dose of 1000 mg/d is set for participants with mild to moderately decreased eGFR (45 – 59  
41 mL/min/1.73m<sup>2</sup>), or participants who cannot tolerate the higher dose. A standardized dose of  
42 1500 mg/d, rather than 2000 mg/d, was selected to suit both participants with prediabetes and  
43 T2DM, while minimising intolerance. Participants are instructed to take the medication with  
44 the evening meal and record it daily using a medication recording screen in the app or in paper  
45 log-books.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### **Monitoring and adherence evaluation (both arms)**

The dietician reviews scores calculated programmatically based on the frequency of using the app and on meeting the daily energy target, along with the time-stamped meals consumed by the participants daily. In the PNP arm, the score incorporates the proportion of meals achieving the desired (“excellent” and “good”) scores, while in the LFHF arm, the proportion of days in which dietary fat  $\leq 35\%$ , saturated fat  $\leq 10\%$ , carbohydrates  $\geq 45\%$ , and dietary fibre  $\geq 15$  g. The dietician contacts individuals who need encouragement to achieve better scores. Participants of the 2 treatment groups receive the same attention according to their adherence. Time devoted to each individual by the dietician is recorded for later analysis purposes. Satisfaction with the diet is assessed using the Diet Satisfaction Questionnaire<sup>26</sup> at 6 months (Table 2).

Adherence to the metformin is based on pill counting at the 6-months visit and on logs of daily dose using the app and/or log-books.

### **Physical activity and other confounders**

Participants are asked to maintain the same level of physical activity throughout the study. Physical activity is monitored at 2 time points during the study using ActivePal (Table 2). The device records time (start and duration) and type (quiet, standing and steps) of activity and 14-days’ worth of data, stored in the device, downloaded upon return. Information about background medications and nutritional supplements is collected before the start of the treatment using questionnaires (Table 2). Participants are asked to report any change in medications at each of the CRF visits and using the medication screen in the smartphone app.

### **Primary and secondary outcomes – Measurements**

1  
2  
3 Participants attend the CRF five times during the study, over approximately 7 months. Primary  
4 and secondary endpoint measures are collected before the start of the intervention (across 2  
5 visits: screening/enrolment and baseline) and at 3 and 6 months of treatment. Table 2 outlines  
6 the measurements obtained at each of the study visits/events.  
7  
8  
9  
10  
11  
12  
13  
14

### 15 **Study outcomes**

16  
17 The primary outcome measure is change in HbA1c from baseline to 6 months of treatment.  
18 Furthermore, a comprehensive glycaemia assessment is enabled through continuous glucose  
19 monitoring. Interstitial glucose concentrations are recorded every 15 min using CGM for 14  
20 days before the start of the intervention (in the run-in period) and after 3- and 6- months of  
21 intervention. The sensor stores the data for the duration of the recording, while the participants  
22 are blinded to the glucose readings. The data are downloaded upon return of the sensor. Time  
23 of the day with glucose readings below 7.8 mmol/L before versus after the treatment will be  
24 compared. Glycaemic variability<sup>27</sup>, including (1) mean amplitude of glucose excursion  
25 (MAGE, a measure of the variation of glucose concentrations from the mean), (2) the standard  
26 deviation and the (3) mean postprandial area under the curve will also be assessed.  
27 Furthermore, fasting plasma glucose, 1-hr and 2-hr plasma glucose post 75 g glucose  
28 assessment are repeated after 6 months and will be compared to the baseline values. HbA1c  
29 test is repeated 6 months after treatment cessation (at 12-months, Table 2), along with a short  
30 questionnaire, including weight, diet and medication status.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Weight, waist and hip circumferences are recorded at 3-months and 6-months of treatment and  
54 compared to baseline. Fat, fat-free mass and android/gynoid fat distribution and visceral fat  
55 measurements by DXA are repeated at 6 months treatment<sup>21</sup>. Similarly, REE and  
56 fat/carbohydrate oxidation is measured after 6 months of treatment.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Hepatic steatosis is common in prediabetes and T2DM<sup>1 28</sup> and prevention of liver  
7  
8 steatohepatitis is key target in individuals with prediabetes or T2DM. Metformin primarily  
9  
10 targets the liver, inhibiting lipogenesis and increasing fatty acid oxidation; therefore a  
11  
12 beneficial effect on liver lipid and fibrosis with metformin has been assumed<sup>29</sup>. However,  
13  
14 comprehensive meta-analyses of randomized clinical trials concluded that reduction in both  
15  
16 steatosis and fibrosis with metformin were underwhelming<sup>30 31</sup>. Liver fibroscan measure is  
17  
18 repeated after 6 months of treatment.  
19  
20  
21  
22  
23  
24  
25

26 Blood pressure and pulse wave analysis measurements are repeated at 3 and 6 months of  
27  
28 treatment and serum lipids measured after 6 months treatment.  
29  
30  
31  
32  
33

### 34 **Safety / Adverse events monitoring**

35  
36 Gastrointestinal side effects are the most common adverse effects of metformin and may occur  
37  
38 in 20-30% of individuals<sup>32 33</sup>. Specifically, abdominal discomfort, nausea, diarrhoea and  
39  
40 anorexia are common<sup>32</sup>. While the gastrointestinal adverse effects are transient, in  
41  
42 approximately 5% of individuals the symptoms may persist and result in cessation of  
43  
44 metformin<sup>33</sup>. Vitamin B12 concentrations may be lower with metformin, if metformin is  
45  
46 administered for a long duration<sup>34 35</sup>. The mechanism(s) responsible for the lower plasma B12  
47  
48 concentrations are unclear. A very rare, but potentially fatal complication of metformin use is  
49  
50 lactic acidosis, mainly in patients with renal impairment<sup>32 36</sup>. In PREDICT, individuals with  
51  
52 severe renal impairment are excluded. Metformin is titrated over 3 weeks to negate the potential  
53  
54 gastrointestinal side effects. Adverse events are recorded and monitored during the study visits.  
55  
56  
57  
58  
59  
60

## Statistical analysis

### *Sample size calculation*

Based on the primary outcome measure HbA1c, to detect a clinically meaningful difference of 0.4% in the change of HbA1c from baseline between the study arms at 6 months, assuming SD of 1% for both groups<sup>37</sup>, with 80% power at two sided significance level of 0.05, a sample size of 106 for each arm is required. Hence, with an estimated dropout rate of 20%, we aim to enrol 132 individuals to each arm, totalling 264 individuals in the study.

### *Analysis plan*

The intention-to-treat (ITT) approach will be used for efficacy analysis. A likelihood-based mixed model repeated measures (MMRM) approach will be used for the primary efficacy analysis. The primary outcome measure HbA1c at baseline, 3, and 6 months will be the dependent variable and intervention by time interaction will be the fixed effects, and participants will be treated as random effect. The primary time specific comparison will be the difference in least square mean between intervention (PNP) and control (LFHF) diet at 6 months' treatment. The differences between the groups after 3 months of treatment will also be examined. Missing data will be handled directly through maximum-likelihood estimation via mixed modelling. To control for potential confounding effects, demographic and clinical covariates (e.g. age, gender, baseline BMI and background medications) will be adjusted as necessary in the model. Piecewise linear mixed model will be used to compare trend change between arms in different periods (0-3 months, and 3-6 months). Different statistical analysis strategies including t-test, Mann-Whitney U test, Chi-square test, linear/generalized linear regression, and mixed model will be used based on the type and distribution of the outcome measures. Mediation analysis will be carried out to explore if the weight loss mediates the intervention effect on glycaemia, and estimate indirect and direct effects and the proportion

1  
2  
3 mediated (how much of the total intervention effect works through weight loss). We expect  
4 some degree of weight loss in all participants, as has been reported for metformin<sup>3 38 39</sup>.  
5  
6 Subgroup analyses can be further performed to explore the intervention effect in specific sub-  
7  
8 cohorts, for instance, the group of patients who achieve adherence standard; the group of  
9  
10 patients with BMI >25 kg/m<sup>2</sup> at baseline, etc.  
11  
12  
13  
14  
15  
16

### 17 **Laboratory testing**

18  
19  
20 HbA1c is analysed using high performance liquid chromatography (Bio-Rad D-100, Bio-Rad  
21  
22 Laboratories, Inc), plasma glucose using the Cobas 8000 (Roche), and liver and renal function  
23  
24 tests using the Atellica platform (Siemens). Serum lipid profile is analysed by a  
25  
26 spectrophotometric assay (Advia® 2400 Chemistry System [Siemens Medical Solutions  
27  
28 Diagnostics]), with low-density lipoprotein (LDL) calculated using the Friedewald equation.  
29  
30 Metagenomic DNA from the stool samples is purified using DNeasy PowerMag Soil DNA  
31  
32 extraction kit (Qiagen) optimized for Tecan automated platform. Next-Generation Sequencing  
33  
34 (NGS) libraries are prepared using Nextera DNA library prep (Illumina) and sequenced on a  
35  
36 NovaSeq sequencing platform (Illumina). Sequencing is performed with 100bp single end  
37  
38 reads with the depth of 10 million reads per sample. Host DNA is detected by mapping reads  
39  
40 to the Human genome with inclusive parameters, and those reads removed. Bacterial relative  
41  
42 abundance estimation is performed by mapping bacterial reads to species-level genome bins  
43  
44 (SGB) representative genomes<sup>40</sup>. Mapping is performed using Bowtie<sup>41</sup> and abundance  
45  
46 estimated by calculating the mean coverage of unique genomic regions across the 50 percent  
47  
48 most densely covered areas, as previously described<sup>42</sup>.  
49  
50  
51  
52  
53  
54  
55  
56  
57

### 58 **Confidentiality and data storage**

1  
2  
3 Each participant is associated with an individual program-generated code used to identify their  
4 study documents, data and specimens collected during the study. The re-identifiable code is  
5 documented in the participant's record and on all study documents. Study data are collected  
6 and managed using REDCap electronic data capture tools<sup>43 44</sup> hosted at the Garvan Institute of  
7 Medical Research. Some coded data are shared with essential personnel at the Weizmann  
8 Institute of Science on institutional Dropbox. Data collected in the form of paper hard copies  
9 are kept in locked cabinets and electronic files on a password protected folder with access  
10 granted to the Garvan study team. Re-identifiable blood, stool, plasma and serum samples will  
11 be kept at the Garvan Institute's freezer facility. All the study questionnaires are disseminated  
12 using REDCap.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Dissemination of results**

The results of the study will be disseminated to healthcare professionals via open access publications in medical journals, without any restrictions. Upon completion of data analysis, the participants will be invited to an information session at the Garvan Institute of Medical Research with the study Investigator(s) where the findings of the study will be shared and discussed. Individual letters are disseminated to the study participants after the 6 months treatment visit (approximately 7 – 8 months from study enrolment) summarising individual results (e.g. baseline and post treatment weight, body fat, liver fat, HbA1c, fasting, 1-hr and 2-hr plasma glucose concentrations). The participants are encouraged to share their individual results with the GP.

**Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional Review Board (File 528-3, Rehovot, Israel). Protocol modifications are communicated to the SVH HREC, the Weizmann IRB, the trial registry (ClinicalTrials.gov), the study investigators and the study participants (if relevant). De-identified participant data that underlie the findings reported in the research article will be available immediately following publication, ending 5 years following the article publication, to researchers who provide a methodologically sound proposal with the aim to achieve the aims reported in the approved project proposal. Data may be obtained from the Principal Investigator Dorit Samocha-Bonet or Associate Investigator Jerry Greenfield upon enquiries directed to [d.samochabonet@garvan.org.au](mailto:d.samochabonet@garvan.org.au) or [j.greenfield@garvan.org.au](mailto:j.greenfield@garvan.org.au).

### **Authors' contributions**

1  
2  
3 DS-B, JRG, ES and EE contributed to the conception and design of the study, TDH, NG and  
4  
5 DS-B drafted the manuscript, NG and ZL contributed to the study design and the statistical  
6  
7 plan, ZL contributed to the sample size estimation, NG, DK, RC, KT, EC, MD, JRS and T-MH  
8  
9 contributed to the collection of the data. All authors revised and approved the final version of  
10  
11 the manuscript and agree to be accountable for all aspects of the work.  
12  
13  
14  
15

### 16 **Funding**

17  
18 This work is supported by the Garvan Research Foundation and the St Vincent's Clinic  
19  
20 Foundation, Sydney, Australia.  
21  
22

23  
24 The study sponsor is the Garvan Institute of Medical Research, 384 Victoria Street,  
25  
26 Darlinghurst, NSW 2020, Australia, +61 2 92958100.  
27  
28

29  
30 The study sponsor and funding bodies have no role in the study design, collection,  
31  
32 management, analysis, and interpretation of data, writing of the report and the decision to  
33  
34 submit the report for publication.  
35  
36  
37  
38

### 39 **Conflict of interests**

40  
41 Eran Elinav and Eran Segal are paid consultants of the company DayTwo. Mark Danta has  
42  
43 received travel support and speaker fees from Gilead, Abbvie and Merck. All other authors  
44  
45 declare they have no conflict of interest.  
46  
47  
48  
49

### 50 **Acknowledgements**

51  
52 We would like to thank Dr David Jung from the University of NSW (Sydney, Australia) for  
53  
54 assistance in the setup of the REDCap data collection tool and Ms Rebecca Hickey for  
55  
56 performing the Fibroscan measurements.  
57  
58  
59  
60



### Figure legends

**Figure 1:** Screenshots of the smartphone application used daily by participants in the PREDICT study. Participants randomized to the personalized diet arm receive scores for each meal. Panels A and B depict two meal options selected by an individual in the study where 2 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

**Table 1:** Inclusion and Exclusion criteria

<b><i>Inclusion criteria</i></b>
Men and women 20-70 years of age
Prediabetes (IFG* or IGT* and/or HbA1c 5.7 – 6.4%) or Individuals diagnosed with T2DM in the last 6 months with HbA1c $\leq$ 8.0%
Willingness to provide written informed consent, participate and comply with the study
<b><i>Exclusion criteria</i></b>
Women planning pregnancy during the study or 3 months after study completion
Individuals with type 1 diabetes, neoplastic disease (in the last 3 years), cardiovascular event (-6 months), chronic gastrointestinal disorders
Established type 2 diabetes or type 2 diabetes diagnosed at recruitment with HbA1c > 8.0%
Normo-glycaemia
Liver enzymes ALT and/or AST >3 times normal range limit
eGFR < 45 mL/min/1.73m <sup>2</sup>
Current or recent (-6 months) treatment with an anti-diabetic medication, current treatment with an oral steroid or immunosuppressive medications, antibiotics (-3 months)
Participants who have had bariatric surgery
Participants with conditions that may interfere with the ability to understand the requirements of the study, refuse treatment with metformin or refuse to use the smartphone application

\*Impaired fasting glucose (IFG): FPG 5.6-6.9 mmol/L and/or impaired glucose tolerance (IGT): 2-h plasma glucose during 75-g oral glucose tolerance test (OGTT) 7.8-11.0 mmol/L

**Table 2:** Study timeline of activities and measurements taken at each of the study events and visits

	<i>Location and time</i>	<i>Measurements</i>
Pre-screening	Phone -35 +/- 10 days	<ul style="list-style-type: none"> <li>● Interview (by an experienced staff)</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c tests</li> </ul>
Screening/ enrolment (Non-fasting)	CRF -30 +/- 15 days	<ul style="list-style-type: none"> <li>● Informed consent signed</li> <li>● Medical history, medications &amp; medical examination</li> <li>● Blood (full blood count, liver and kidney function tests)</li> <li>● Height and weight (BMI calculated)</li> <li>● BIA (RMR)</li> <li>● Blood pressure</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Smartphone app training</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● Stool sample</li> <li>● *Study entry questionnaire</li> </ul>
Baseline (Fasting)	CRF 0, treatment clock starts	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin 3-months' supply with instructions and log-books</li> <li>● Smartphone app training, according to study arm allocation</li> </ul>
3-months (Fasting)	CRF +90 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Metformin 3-months' supply with log-books</li> <li>● Adverse events recording and monitoring</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> </ul>
5.5-months (Non-fasting)	CRF +166 days +/- 10 days	<ul style="list-style-type: none"> <li>● FreeStyle Libre Pro and ActivePal</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c</li> </ul>

6-months (Fasting)	CRF +180 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids, HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin- unused pills collected and counted</li> <li>● Adverse events recording</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> <li>● ##Diet Satisfaction Questionnaire</li> </ul>
12-months	Local pathology	<ul style="list-style-type: none"> <li>● HbA1c</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● **12-months questionnaire</li> </ul>

\*Questionnaire includes hunger/fullness, dietary habits and dislikes, physical activity, medications, dietary supplements, personal and family history of disease, food-frequency questionnaire

\*\*Questionnaire includes diet (are you following the diet you were allocated to?), metformin (are you continuing the metformin treatment and dosage) and current body weight

#Gut microbiome features from stool samples collected at 3 and 6 months will be compared to baseline (exploratory outcome)

## The Laboratory for the Study of Human Ingestive Behavior, Pennsylvania State University are the copyright holders of the Diet Satisfaction Questionnaire<sup>26</sup>


Abbreviations: BIA, bio impedance analysis; BMR, basal metabolic rate; DXA, dual-energy X-ray absorptiometry; REE, resting energy expenditure; RQ, respiratory quotient

## References

1. Stefan N, Fritsche A, Schick F, et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. *Lancet Diabetes Endocrinol* 2016;4(9):789-98. doi: 10.1016/S2213-8587(16)00082-6
2. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *The Lancet* 2016;387(10027):1513-30. doi: 10.1016/s0140-6736(16)00618-8
3. Samocha-Bonet D, Debs S, Greenfield JR. Prevention and Treatment of Type 2 Diabetes – A Pathophysiological-Based Approach. *Trends Endocrinol Metab* 2018;29(6):370-79.
4. Evert AB, Dennison M, Gardner CD, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. *Diabetes Care* 2019;42(5):731-54. doi: 10.2337/dci19-0014
5. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *The Lancet Diabetes & Endocrinology* 2018;6(5):361-69. doi: 10.1016/S2213-8587(18)30051-2
6. Bailey CJ. Metformin: historical overview. *Diabetologia* 2017;60(9):1566-76. doi: 10.1007/s00125-017-4318-z
7. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;41(12):2669-701. doi: 10.2337/dci18-0033
8. Florez JC. The pharmacogenetics of metformin. *Diabetologia* 2017;60(9):1648-55. doi: 10.1007/s00125-017-4335-y
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355(23):2427-43. doi: 10.1056/NEJMoa066224
10. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med* 2012;366(24):2247-56. doi: 10.1056/NEJMoa1109333
11. Lachin JM, Christophi CA, Edelstein SL, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. *Diabetes* 2007;56(4):1153-9. doi: 10.2337/db06-0918
12. Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia* 2017;60(9):1601-11. doi: 10.1007/s00125-017-4361-9
13. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2019;42(Supplement 1):S13-S28. doi: 10.2337/dc19-S002
14. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015;163(5):1079-94. doi: 10.1016/j.cell.2015.11.001
15. Australian Government National Health and Medical Research Council. Australian Guide to Healthy Eating 2015 [updated 01-05-2017. Available from: <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating2019>.
16. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract* 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL
17. Meyerowitz-Katz G, Seelan S, Gaur P, et al. Detecting the hidden burden of pre-diabetes and diabetes in Western Sydney. *Diabetes Research and Clinical Practice* 2019;151:247-51. doi: <https://doi.org/10.1016/j.diabres.2019.04.019>
18. Saghaei M, Saghaei S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. *J Biomed Sci Eng* 2011;4:734-39.

19. Kozan P, Blythe JC, Greenfield JR, et al. The Effect of Buffering High Acid Load Meal with Sodium Bicarbonate on Postprandial Glucose Metabolism in Humans-A Randomized Placebo-Controlled Study. *Nutrients* 2017;9(8) doi: 10.3390/nu9080861
20. Chen DL, Liess C, Poljak A, et al. Phenotypic Characterization of Insulin-Resistant and Insulin-Sensitive Obesity. *J Clin Endocrinol Metab* 2015;100(11):4082-91. doi: 10.1210/jc.2015-2712
21. Tang A, Coster ACF, Tonks KT, et al. Longitudinal Changes in Insulin Resistance in Normal Weight, Overweight and Obese Individuals. *J Clin Med* 2019;8(5) doi: 10.3390/jcm8050623
22. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2019;156(6):1717-30. doi: 10.1053/j.gastro.2019.01.042
23. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes. *JAMA Netw Open* 2019;2(2):e188102. doi: 10.1001/jamanetworkopen.2018.8102
24. Australian Food, Supplement and Nutrient Database (AUSNUT) 2011-2013: Food Standards Australia New Zealand.
25. Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr* 1990;51(2):241-7. doi: 10.1093/ajcn/51.2.241
26. James BL, Loken E, Roe LS, et al. Validation of the Diet Satisfaction Questionnaire: a new measure of satisfaction with diets for weight management. *Obes Sci Pract* 2018;4(6):506-14. doi: 10.1002/osp4.299
27. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther* 2009;11 Suppl 1:S55-67. doi: 10.1089/dia.2008.0132
28. Marjot T, Moolla A, Cobbold JF, et al. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. *Endocrine Reviews* 2019 doi: 10.1210/endrev/bnz009
29. Green CJ, Marjot T, Tomlinson JW, et al. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? *Diabetes Obes Metab* 2018 doi: 10.1111/dom.13592
30. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012;55(4):885-904. doi: 10.1007/s00125-011-2446-4
31. Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. *Medicine (Baltimore)* 2016;95(32):e4529. doi: 10.1097/MD.0000000000004529
32. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. *Drug Saf* 1999;20(6):489-503.
33. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. *Diabetologia* 2016;59(3):426-35. doi: 10.1007/s00125-015-3844-9
34. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *British Medical Journal* 2010;340:c2181. doi: 10.1136/bmj.c2181
35. Reinstatler L, Qi YP, Williamson RS, et al. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements. *Diabetes Care* 2012;35(2):327-33. doi: 10.2337/dc11-1582
36. DeFronzo R, Fleming GA, Chen K, et al. Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism* 2016;65(2):20-29. doi: <https://doi.org/10.1016/j.metabol.2015.10.014>

- 1  
2  
3 37. Jönsson T, Granfeldt Y, Ahrén B, et al. Beneficial effects of a Paleolithic diet on cardiovascular risk  
4 factors in type 2 diabetes: a randomized cross-over pilot study. *Cardiovascular Diabetology*  
5 2009;8(1):35. doi: 10.1186/1475-2840-8-35  
6  
7 38. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes  
8 with lifestyle intervention or metformin. *The New England Journal of Medicine*  
9 2002;346(6):393-403. doi: 10.1056/NEJMoa012512  
10  
11 39. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight  
12 loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374(9702):1677-86.  
13 doi: 10.1016/S0140-6736(09)61457-4  
14  
15 40. Pasolli E, Asnicar F, Manara S, et al. Extensive Unexplored Human Microbiome Diversity Revealed  
16 by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell*  
17 2019;176(3):649-62.e20. doi: 10.1016/j.cell.2019.01.001 [published Online First: 01/17]  
18  
19 41. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature Methods*  
20 2012;9(4):357-59. doi: 10.1038/nmeth.1923  
21  
22 42. Korem T, Zeevi D, Suez J, et al. Growth dynamics of gut microbiota in health and disease inferred  
23 from single metagenomic samples. *Science* 2015;349(6252):1101-06. doi:  
24 10.1126/science.aac4812  
25  
26 43. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community  
27 of software platform partners. *Journal of Biomedical Informatics* 2019;95:103208. doi:  
28 <https://doi.org/10.1016/j.jbi.2019.103208>  
29  
30 44. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-  
31 driven methodology and workflow process for providing translational research informatics  
32 support. *Journal of Biomedical Informatics* 2009;42(2):377-81. doi:  
33 <https://doi.org/10.1016/j.jbi.2008.08.010>  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Screenshots of the smartphone application used daily by participants in the PREDICT study. Participants randomized to the personalized diet arm receive scores for each meal. Panels A and B depict two meal options selected by an individual in the study where 2 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

190x112mm (300 x 300 DPI)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1 and 20 (Authors' contribution)
	5b	Name and contact information for the trial sponsor	20
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 5 - 6

4

5

6 6b Explanation for choice of comparators 5 - 6

7

8 Objectives 7 Specific objectives or hypotheses 6

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 7

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 6 - 7

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 7 and Table 1

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 11 – 13

23

24 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) 13

25

26 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 13 – 14

27

28 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 6 – 7 and Table 1

29

30

31

32 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 15 – 16

33

34

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) Table 2

41

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7 – 8
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9 – 10
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9 – 10
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9 – 10
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9 – 10
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14 – 16
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	14 – 16 and 17 (Statistical plan)
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18 – 19
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16 and Table 2
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Approval granted, details page 3
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	3
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9 and Table 2
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18 – 19
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	18 – 19
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	20 - 21
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	20
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Not uploaded, but are available upon request
32				
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	19
36				
37				

38  
39 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
40 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
41 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
42

# BMJ Open

## The rationale and design of a randomized controlled trial testing the effect of personalized diet in individuals with prediabetes or type 2 diabetes mellitus treated with metformin

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037859.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jul-2020
Complete List of Authors:	Htet, Thaw; Garvan Institute of Medical Research Godneva, Anastasia; Weizmann Institute of Science Liu, Zhixin; UNSW, Stats Central Chalmers, Eliza; Garvan Institute of Medical Research Kolobkov, Dmitry; Weizmann Institute of Science Snaith, Jennifer; Garvan Institute of Medical Research Richens, Renee; Garvan Institute of Medical Research Toth, Krisztina; Garvan Institute of Medical Research Danta, Mark; UNSW Hng, Tien-Ming; Blacktown Mount Druitt Hospital, Diabetes & Endocrinology Elinav, Eran; Weizmann Institute of Science, Segal, Eran; Weizmann Institute of Science Greenfield, Jerry; Garvan Institute of Medical Research Samocha-Bonet, Dorit; Garvan Institute of Medical Research, Diabetes Division
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Diabetes & endocrinology < INTERNAL MEDICINE, NUTRITION & DIETETICS, DIABETES & ENDOCRINOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **The rationale and design of a randomized controlled trial testing the effect of**  
4 **personalized diet in individuals with prediabetes or type 2 diabetes mellitus treated with**  
5 **metformin**  
6  
7  
8  
9

10  
11  
12 Thaw D Htet<sup>1,2,3\*</sup>, Anastasia Godneva<sup>4\*</sup>, Zhixin Liu<sup>5</sup>, Eliza Chalmers<sup>1</sup>, Dmitry Kolobkov<sup>4</sup>,  
13 Jennifer R Snaith<sup>1,2,3</sup>, Renee Richens<sup>1</sup>, Krisztina Toth<sup>1</sup>, Mark Danta<sup>2,6</sup>, Tien-Ming Hng<sup>7,8</sup>,  
14 Eran Elinav<sup>9</sup>, Eran Segal<sup>4</sup>, Jerry R Greenfield<sup>1,2,3</sup>, Dorit Samocha-Bonet<sup>1,2#</sup>  
15  
16  
17  
18  
19

20 Affiliations:

- 21  
22  
23 1 Diabetes and Metabolism, Garvan Institute of Medical Research, Sydney, Australia  
24  
25 2 St Vincent's Clinical School, University of NSW, Sydney, Australia  
26  
27 3 Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, Australia  
28  
29 4 Department of Computer Science and Applied Math, Weizmann Institute of Science,  
30 Rehovot, Israel  
31  
32  
33 5 Mark Wainwright Analytical Centre, UNSW, Sydney, Australia  
34  
35 6 Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia  
36  
37 7 Blacktown Mt Druitt Hospital, Western Sydney Local Health District, Sydney,  
38 Australia  
39  
40  
41 8 Blacktown Clinical School, Western Sydney University, Sydney, Australia  
42  
43  
44 9 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel  
45  
46  
47

48 \*Equally-contributing Authors

49  
50 #Corresponding Author: Dorit Samocha-Bonet, Garvan Institute of Medical Research,  
51 384 Victoria Street, Darlinghurst, NSW 2010, Australia. Phone: +61 2 92958309, email:  
52 d.samocheonet@garvan.org.au  
53  
54  
55  
56  
57  
58  
59  
60



## Abstract

**Introduction** Metformin and diets aimed at promoting healthy body weight are the first-line in treating type 2 diabetes mellitus (T2DM). Clinical practice, backed by clinical trials, suggests that many individuals do not reach glycaemic targets using this approach alone. The primary aim of the Personalised Medicine in Prediabetes – Towards Preventing Diabetes in Individuals at Risk (PREDICT) study is to test the efficacy of personalized diet as adjuvant to metformin in improving glycaemic control in individuals with dysglycemia.

**Methods and Analysis** PREDICT is a two-arm, parallel group, single-masked randomized controlled trial in adults with prediabetes or early-stage T2DM (with HbA1c up to 8.0%), not treated with glucose-lowering medication. PREDICT is conducted at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Enrolment of participants commenced in December 2018 and expected to complete in December 2021. Participants are commenced on metformin (Extended Release, titrated to a target dose of 1500 mg/d) and randomized with equal allocation to either (1) the Personalized Nutrition Project (PNP) algorithm-based diet or (2) low-fat high dietary fibre (LFHF) diet, designed to provide caloric restriction (75%) in individuals with body mass index  $>25$  kg/m<sup>2</sup>. Treatment duration is 6 months and participants visit the Clinical Research Facility 5 times over approximately 7 months. The primary outcome measure is glycated haemoglobin (HbA1c). The secondary outcomes are (1) time of interstitial glucose  $<7.8$  mmol/L and (2) glycaemic variability (continuous glucose monitoring), (3) body weight, (4) fat mass and (5) abdominal visceral fat volume (dual-energy X-ray absorptiometry), serum (6) low-density lipoprotein (LDL)-cholesterol (7) high-density lipoprotein (HDL)-cholesterol and (8) triglycerides concentrations, (9) blood pressure, and (10) liver fat (Fibroscan).

1  
2  
3 **Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human  
4 Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional  
5 Review Board (File 528-3, Rehovot, Israel). The findings will be published in peer-reviewed  
6 open access medical journals.  
7  
8  
9

10  
11  
12  
13 The study has been registered at ClinicalTrials.gov (NCT03558867).  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study**

- 20  
21  
22 • The randomized controlled design testing a novel diet against standard of care may lead  
23 to a novel tool to manage dysglycemia in individuals requiring metformin  
24  
25
- 26  
27 • Conducted in an adult Australian population, the study findings may not be applicable  
28 to other populations  
29  
30
- 31  
32 • The algorithm used to devise the personalized diet relies on accurate recording of the  
33 dietary intake by the participants  
34  
35
- 36  
37 • The dietary intervention requires use of a smartphone application which may limit its  
38 applicability to some populations  
39  
40  
41  
42  
43

44 **Key words:** Prediabetes, Type 2 diabetes, Metformin, Algorithm-based diet, Low fat diet,  
45 Randomized controlled trial  
46  
47  
48  
49

50 **Word count:** 3927  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Type 2 diabetes mellitus (T2DM) and its preceding medical condition, prediabetes are significant risk factors for cardiovascular disease, and most affected individuals demonstrate additional metabolic risk factors, such as hypertension, dyslipidaemia, excess weight and fatty liver<sup>1</sup>. T2DM affects approximately 422 million adults globally, with an additional 352 million individuals at increased risk, having prediabetes<sup>2,3</sup>. Individuals diagnosed with prediabetes or T2DM are encouraged to adopt a healthy lifestyle and, if overweight to lose weight<sup>4</sup>. The majority of individuals with T2DM are treated with metformin, which is the 8<sup>th</sup> most prescribed medication in the United States<sup>5-7</sup>.

Metformin, an oral biguanide, is the first-line treatment for individuals with newly-diagnosed T2DM and, in some cases, for the prevention of diabetes in individuals with prediabetes<sup>6</sup>. Metformin is an ideal medication to initiate for management of T2DM or for prevention of diabetes, because it does not cause hypoglycaemia and has a favourable, albeit modest, effect on body weight<sup>8</sup>. Metformin monotherapy is insufficient to achieve glycaemic control in a large proportion of treated individuals<sup>3,9,10</sup>. Findings from the Diabetes Prevention Program (DPP) in individuals with prediabetes suggested that the glycaemic efficacy of metformin depends on the magnitude of weight loss<sup>11</sup>, explaining 64% of the diabetes risk reduction, with additional 17% explained by decreases in fasting insulin and pro-insulin at 3 years of follow up<sup>11,12</sup>.

The current treatment guidelines in T2DM recommend prescribing metformin in combination with a healthy lifestyle, enabling weight loss<sup>13</sup>. The most recent nutritional guidelines for individuals with T2DM or prediabetes are no longer supporting a universal ideal dietary macronutrient distribution; instead, the guidelines suggest individualized eating plans<sup>4</sup>.

1  
2  
3 In the pioneering Personalized Nutrition Project (PNP)<sup>14</sup>, Segal, Elinav and colleagues  
4 developed an algorithm that predicts an individual's postprandial glycaemic response (PPGR)  
5 to meals. The algorithm incorporates the individual's personal data (e.g. age, gender, body  
6 mass index [BMI]), blood tests (e.g. glycated haemoglobin [HbA1c]), dietary features,  
7 continuous glucose monitor (CGM)-derived data, and gut microbiome features, and trained on  
8 data previously collected in 800 individuals. Personally-tailored dietary plans based on the  
9 algorithm were trialled in a small group of individuals with prediabetes and shown to improve  
10 glycaemic variability and PPGR over 7 days<sup>14</sup>.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The primary objective of the Personalised Medicine in Prediabetes – Towards Preventing  
25 Diabetes in Individuals at Risk (PREDICT) Study is to compare glycaemic control, measured  
26 by HbA1c, following 6 months of metformin, prescribed with either (1) the PNP algorithm-  
27 based diet or (2) low-fat high dietary fibre (LFHF) diet, based on the Australian Healthy Eating  
28 Guide<sup>15</sup> and the American Association of Clinical Endocrinologists guide for medical care of  
29 patients with obesity<sup>16</sup>, in individuals with prediabetes or early-stage T2DM naive to glucose-  
30 lowering pharmacotherapy.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The secondary objectives of the PREDICT study are to compare the effect of the PNP diet  
44 versus LFHF diet when prescribed with metformin on: (1) time of interstitial glucose <7.8  
45 mmol/L, (2) glycaemic variability, (3) weight, (4) body fat mass, (5) abdominal visceral fat  
46 volume, (6) serum low-density lipoprotein (LDL)-cholesterol concentration (7) serum high-  
47 density lipoprotein (HDL)-cholesterol concentration, (8) serum triglycerides concentration, (9)  
48 blood pressure (10) liver fat. The exploratory objectives of the study are to test the effect of the  
49 treatment on the gut microbiome.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Study design, setting and population

The study is a two-arm, parallel group, single-masked randomized controlled trial (RCT). Adults with prediabetes or early-stage T2DM who are not treated with glucose-lowering medications are randomized, with equal allocation, to either the PNP or LFHF diet arms, in both arms participants are commenced on metformin Extended Release (XR) 1500 mg/d treatment for 6 months. All the study visits are performed at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Metagenomics and data processing for the personalized dietary interventions are performed at the Weizmann Institute of Science (Rehovot).

### Patient and public involvement

Patients or the public were not involved in the design or other aspects of the research.

### Eligibility

Adults (20-70 years old) with prediabetes or recently (in the last 6-months) diagnosed T2DM with (HbA1c  $\leq$ 8.0%), not pregnant or planning to become pregnant during, and for at least 3 months after the study are recruited (Table 1). A wide age range was selected to encompass different populations of individuals managing their prediabetes for short or long durations and to increase the likelihood to recruit the sample size in a timely manner. The HbA1c cap at 8.0% was selected to ensure that individuals with T2DM are relatively well-controlled. Blood tests indicative of normo-glycaemia, HbA1c above 8.0%, liver enzymes (ALT and/or AST) over 3 times the normal range limit and eGFR lower than 45 mL/min/1.73m<sup>2</sup> are grounds for exclusion. Individuals treated with glucose-lowering medication other than metformin in the

1  
2  
3 last 24 months, or metformin in the last 3 months, will be excluded. Individuals with conditions  
4  
5 or treatments that affect glycaemia (e.g. oral steroids), impact weight (e.g. bariatric surgery,  
6  
7 weight loss medications), or the gut microbiome (e.g. inflammatory bowel disease, coeliac,  
8  
9 frequent antibiotic treatment) will be excluded. Participants who have had a cardiovascular  
10  
11 event in the previous 6 months, or received an investigational new drug within the last 6 months  
12  
13 will be excluded. Participants with conditions that may interfere with the ability to understand  
14  
15 the requirements of the study and those who refuse treatment with metformin or refuse to use  
16  
17 the smartphone application will be excluded (Table 1).  
18  
19  
20  
21  
22  
23

## 24 **Recruitment**

25  
26 The study is advertised in general practitioners (GP), endocrinologists and dieticians' practices  
27  
28 in the Sydney metropolitan area, and through targeted social media campaigns. A collaboration  
29  
30 with Blacktown Mt Druitt Hospital (Western Sydney) has been established in 2019 for the  
31  
32 purpose of recruitment. During a hospital screening program ran between 2016 – 2018, 17.3%  
33  
34 and 30.2% of individuals visiting the Emergency Department (ED) at Blacktown Mt Druitt  
35  
36 Hospital have had HbA1c values indicative of diabetes and prediabetes, respectively<sup>17</sup>. Since  
37  
38 September 2019, individuals visiting the ED who have had a blood test indicative of  
39  
40 prediabetes receive a letter prompting them to contact the PREDICT team and encouraging  
41  
42 they share the result with a GP.  
43  
44  
45  
46  
47  
48  
49

50 To-date (February 2020), 38 participants were enrolled. Of the 38 participants enrolled, 20  
51  
52 completed, 13 are ongoing, and 5 withdrew before the end of the treatment (13% drop-out rate).  
53  
54 Recruitment of participants is expected to complete in December 2021.  
55  
56  
57  
58  
59  
60

1  
2  
3 Participants contacting the team receive the participant information sheet (Supplementary  
4 material) via email or post. Experienced clinical research nurse/associate provides details about  
5 the study over the phone. Willing participants are referred to a commercial pathology to  
6 perform an oral glucose tolerance test (OGTT, 75 g) and HbA1c test. They are asked to sign a  
7 consent form after reading the participant information sheet explaining the possible risks of  
8 undergoing the OGTT and HbA1c tests prior to performing the blood tests. If the blood tests  
9 indicate either T2DM (with HbA1c  $\leq 8.0\%$ ), or impaired fasting glucose (IFG) or impaired  
10 glucose tolerance (IGT) or HbA1c  $\geq 5.7$ , they are invited to a screening and enrolment visit at  
11 the Garvan Clinical Research Facility.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 A stool collection kit for metagenomics OMNIgene GUT (OMR-200; DNA Genotek) is mailed  
28 to participants prior to the screening/enrolment visit. Participants collect the sample according  
29 to the manufacturer's instructions the day before the visit and keep the sample at room  
30 temperature. At the Clinical Research Facility, the sample is vortexed, centrifuged for a few  
31 seconds and material aliquoted into cryo vials and kept in -80C freezer. One vial is transferred  
32 to facilities at the Weizmann Institute of Science and stored at  $-20^{\circ}\text{C}$  until DNA extraction.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The pre-treatment data are collected across the screening/enrolment and the baseline visits.  
44  
45  
46  
47

### 48 **Screening / enrolment procedures and measurements**

49

50  
51 During the screening/enrolment visit, participants sign the study informed consent form  
52 (Supplementary material) and undergo medical examination by a physician. Participants have  
53 their weight, height, waist and hip circumference and blood pressure measured. Basal  
54 metabolic rate (BMR) is estimated using bioelectrical impedance (BIA, used for calculating  
55 the energy requirement, see "Energy target"). Blood samples are collected to evaluate liver  
56  
57  
58  
59  
60

1  
2  
3 (liver enzymes) and kidney (creatinine and eGFR) function and full blood count. Glucose  
4  
5 monitor (FreeStyle Libre Pro, Abbott, Germany) is attached for a period of 14 days.  
6  
7  
8  
9

10 A link to download the PNP smartphone application is sent to the participants prior to the  
11 screening/enrolment visit. They are asked to log-in to the app with a personal (re-identifiable)  
12 code provided by email, and to familiarize with the app in preparation for a training session  
13 with the dietician. During the screening/enrolment visit, the dietitian practices with the  
14 participants browsing the food database, selecting food and beverage items and indicating the  
15 amount consumed. Participants are taught to add frequently consumed foods to a favourites  
16 list, which makes future search of food items easier. When the CGM is on, participants are  
17 asked to carry on with their usual routine and to record all meals, snacks and drinks using the  
18 app. The period between the screening/enrolment and the baseline visits (4 – 6 weeks) serves  
19 as the ‘run-in’ period.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **Randomization**

37  
38 Randomization is performed between the screening/enrolment and baseline visits. Individuals  
39 are randomized with 1:1 allocation into the 2 arms in rounds of approximately 4 individuals  
40 each, with randomization performed within each round using the minimization program for  
41 allocation of subjects to parallel groups, modified from Saghaei et al<sup>18</sup>. They are stratified by  
42 gender, age (20-49 or 50-70 years), BMI (<25.0 or >25.1 kg/m<sup>2</sup>) and HbA1c (<5.7 or >5.8 %).  
43 To avoid bias, the randomization is performed by a study investigator located at the Weizmann  
44 Institute who does not interact with the study participants. The study nurses and physicians  
45 who have direct contact with the participants are blinded to the randomization order, however  
46 due to the nature of the intervention, the study dietician is not blinded to the treatment  
47 allocation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Baseline visit - Measurements

The baseline visit is performed approximately 4-6 weeks after the screening/enrolment visit (Table 2). Participants attend the Clinical Research Facility following an overnight fast. Blood is drawn for serum lipids measurement and anthropometric measures and blood pressure are taken. Arterial stiffness (pulse wave analysis, AtCor Medical, Australia) is measured twice and average recorded, as described<sup>19</sup>. This is followed by measurement of resting energy expenditure, carbohydrate and fat oxidation over 30 minutes by indirect calorimetry (Quark, Cosmed, Italy)<sup>20</sup>. Body composition is assessed using dual-energy X-ray absorptiometry (DXA, Lunar Prodigy, GE Healthcare). Specifically, total body fat mass and fat-free mass (enCORE software), the android and gynoid region, and visceral fat (CoreScan software, GE Healthcare) are recorded<sup>21</sup>. Liver steatosis (controlled attenuation parameter, CAP) and liver fibrosis (liver stiffness measurement, LSMs) are assessed using FibroScan (Touch 502 by Echosens) by a trained technician. CAP and LSMs have been reported to correlate closely with steatosis and fibrosis assessed using the gold-standard liver biopsy<sup>22</sup>. A physical activity monitor (ActivePal, Pal Technologies) is applied on the thigh for a period of 14 days. At the end of the baseline visit, the participants practice using the app with the dietician.

## Prediction of postprandial glucose response using the algorithm

The prediction of PPGR in PREDICT follows the modelling framework described in Zeevi et al<sup>14</sup> and is performed between the screening/enrolment and baseline visits. Time-stamped food records from the app, CGM and other data collected during the enrolment visit at the Garvan are shared with a mathematician at the Weizmann Institute of Science where data processing occurs, on an Institutional secured server. The data, together with the stool metagenome sequencing data are integrated with the Weizmann Institute's database to develop personalized

1  
2  
3 algorithms for predicting each individual's PPGR. A database of recipes of meals (n=233) and  
4 smaller meals ("snacks", n=249) varying in macronutrient composition to generate feedback  
5 on the PPGR to pre-consumed meals has been created. Using the participants' features,  
6 personalized PPGR are calculated for every meal and snack in the database based on nutrient  
7 composition, and energy-adjusted quintile cut-offs of PPGR are used to create personalized  
8 meal ratings ranging from 1 to 5 (corresponding with "excellent", "good", "medium", "bad",  
9 and "very bad"). The predictive model, originally trained on data collected in an Israeli adult  
10 cohort<sup>14</sup>, has been shown to be predictive of PPGR in a U.S. cohort of healthy adults (n=327)  
11 consuming a Western style diet<sup>23</sup>.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **Interventions**

28  
29 Both arms use the PNP mobile app to select meals/foods. In 2018, the app, developed at the  
30 Weizmann Institute of Science, was adapted to Australian consumers including the Australian  
31 food database (AUSNUT 2011–13)<sup>24</sup> of approximately 5,700 food items.  
32  
33  
34  
35  
36  
37  
38

### 39 *Personalized diet (PNP diet arm)*

40  
41 Participants in the PNP diet arm receive personalized feedback on each of their food item/meal  
42 choice and asked to consult with the app in real-time to select the recommended meal for them.  
43 The feedback is color-coded with a traffic light system; green ("good" and "excellent"), yellow  
44 ("medium") and red ("bad" or "very bad") PPGR (Figure 1 A and B). Participants are advised  
45 to aim for as many "good" and "excellent" scores, occasional "medium", and to avoid "bad"  
46 and "very bad" scores. When receiving bad scores, they are advised to trial substituting, adding  
47 or removing ingredients from the meal to improve the score. In individuals with  
48 hypercholesterolemia, a special set of recipes containing reduced saturated fat are uploaded  
49 into the smartphone app.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Low-fat high fibre diet (LFHF) arm*

The diet comparator chosen in the present study (the standard of care, LFHF) follows the Australian Healthy Eating Guide<sup>15</sup> principles. The LFHF diet is designed to provide approximately 30% of the total daily energy intake from fat, of which up to 10% of the fat is saturated fat, 50-55% of energy from low glycaemic load carbohydrates, 20-25% from protein and 30 g/d of dietary fibre. The diet is rich in legumes, poor in white grains and added sugar. Overall, the comparator diet chosen is considerably different from the diet of the average adult Australian<sup>25</sup>. A database of recipes (n=110 meals and n=80 snacks) following the LFHF nutrient content has been created based on the AUSNUT 2013 recipes<sup>24</sup>. Food items such as sugary drinks, processed meat, candies, sugar and cream were excluded from the LFHF recipes. Similar to the PNP arm, recommended meals scaled to the individual's energy target are uploaded into the participants' app, taking into account the individual's dietary restrictions and likes. Similar to the PNP arm, participants of the LFHF arm are encouraged to choose from the recipes uploaded for them or browse the food database (5700 food items) to design their own meals, as long as they follow the general dietary guidelines. Participants of the LFHF arm are instructed to consult with the total daily energy and macronutrient breakdown charts to ensure they follow the recommended diet (Figure 1C).

### *Energy target and using the app to select meals in real-time (both arms)*

The energy requirement calculation is based on BMR estimated by BIA (Tanita, TBF-300 by Wedderburn) and on the Mifflin equation<sup>26</sup>. The two values are multiplied by a physical activity factor of 1.4 (lightly active) then averaged, and the value compared with the average daily energy intake of at least 7 days, extracted from the time-stamped meals recorded using the app. In participants with BMI >25 kg/m<sup>2</sup>, energy target of 75% is prescribed. Participants

1  
2  
3 of both arms are encouraged to consume 3 bigger (breakfast, lunch, dinner) and 3 smaller  
4  
5 (snack) meals spread throughout the day.  
6  
7  
8  
9

#### 10 *Metformin (relevant to both study arms)*

11  
12  
13 Metformin (XR) is dispensed by the St Vincent's Hospital Pharmacy (Sydney) at baseline (for  
14  
15 a period of 3 months) and at the 3 months visit (to last until the end of the study). The target  
16  
17 dose (1500 mg/d) is titrated over 3 weeks to minimize gastrointestinal intolerance. A target  
18  
19 dose of 1000 mg/d is set for participants with mild to moderately decreased eGFR (45 – 59  
20  
21 mL/min/1.73m<sup>2</sup>), or participants who cannot tolerate the higher dose. A standardized dose of  
22  
23 1500 mg/d, rather than 2000 mg/d, was selected to suit both participants with prediabetes and  
24  
25 T2DM, while minimising intolerance. Participants are instructed to take the medication with  
26  
27 the evening meal and record it daily using a medication recording screen in the app or in paper  
28  
29 log-books.  
30  
31  
32  
33  
34  
35  
36

#### 37 **Monitoring and adherence evaluation (relevant to both study arms)**

38  
39 The dietician reviews scores calculated programmatically based on the frequency of using the  
40  
41 app and on meeting the daily energy target, along with the time-stamped meals consumed by  
42  
43 the participants daily. In the PNP arm, the score incorporates the proportion of meals achieving  
44  
45 the desired (“excellent” and “good”) scores, while in the LFHF arm, the proportion of days in  
46  
47 which dietary fat  $\leq 35\%$ , saturated fat  $\leq 10\%$ , carbohydrates  $\geq 45\%$ , and dietary fibre  $\geq 15$  g. The  
48  
49 dietician contacts individuals who need encouragement to achieve better scores. Participants  
50  
51 of the 2 treatment groups receive the same attention according to their adherence. Time devoted  
52  
53 to each individual by the dietician is recorded for later analysis purposes. Satisfaction with the  
54  
55 diet is assessed using the Diet Satisfaction Questionnaire<sup>27</sup> at 6 months (Table 2).  
56  
57  
58  
59  
60

1  
2  
3 Adherence to the metformin is based on pill counting at the 6-months visit and on logs of daily  
4  
5 dose using the app and/or log-books.  
6  
7  
8  
9

### 10 **Physical activity and other confounders**

11  
12  
13 Participants are asked to maintain the same level of physical activity throughout the study.  
14  
15 Physical activity is monitored at 2 time points during the study using ActivePal (Table 2). The  
16  
17 device records time (start and duration) and type (quiet, standing and steps) of activity and 14-  
18  
19 days' worth of data, stored in the device, downloaded upon return. Information about  
20  
21 background medications and nutritional supplements is collected before the start of the  
22  
23 treatment using questionnaires (Table 2). Participants are asked to report any change in  
24  
25 medications at each of the study visits and using the medication screen in the smartphone app.  
26  
27  
28  
29  
30  
31

### 32 **Primary and secondary outcomes – Measurements**

33  
34 Participants attend the Clinical Research Facility five times during the study, over  
35  
36 approximately 7 months. Primary and secondary endpoint measures are collected before the  
37  
38 start of the intervention (across 2 visits: screening/enrolment and baseline) and at 3 and 6  
39  
40 months of treatment. Table 2 outlines the measurements obtained at each of the study  
41  
42 visits/events.  
43  
44  
45  
46  
47  
48

### 49 **Study outcomes**

50  
51 The primary outcome measure is change in HbA1c from baseline to 6 months of treatment.  
52  
53 Furthermore, a comprehensive glycaemia assessment is enabled through continuous glucose  
54  
55 monitoring. Interstitial glucose concentrations are recorded every 15 min using CGM for 14  
56  
57 days before the start of the intervention (in the run-in period) and after 3- and 6- months of  
58  
59  
60

1  
2  
3 intervention. The sensor stores the data for the duration of the recording, while the participants  
4 are blinded to the glucose readings. The data are downloaded upon return of the sensor. Time  
5 of the day with glucose readings below 7.8 mmol/L before versus after the treatment will be  
6 compared. Glycaemic variability<sup>28</sup>, including (1) mean amplitude of glucose excursion  
7 (MAGE, a measure of the variation of glucose concentrations from the mean), (2) the standard  
8 deviation and the (3) mean postprandial area under the curve will also be assessed.  
9  
10 Furthermore, fasting plasma glucose, 1-hr and 2-hr plasma glucose post 75 g glucose  
11 assessment are repeated after 6 months and will be compared to the baseline values. HbA1c  
12 test is repeated 6 months after treatment cessation (at 12-months, Table 2), along with a short  
13 questionnaire, including weight, diet and medication status.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Weight, waist and hip circumferences are recorded at 3-months and 6-months of treatment and  
30 compared to baseline. Fat, fat-free mass and android/gynoid fat distribution and visceral fat  
31 measurements by DXA are repeated at 6 months treatment<sup>21</sup>. Similarly, resting energy  
32 expenditure and fat/carbohydrate oxidation is measured after 6 months of treatment.  
33  
34  
35  
36  
37  
38  
39  
40

41 Hepatic steatosis is common in prediabetes and T2DM<sup>1 29</sup> and prevention of liver  
42 steatohepatitis is key target in individuals with prediabetes or T2DM. Metformin primarily  
43 targets the liver, inhibiting lipogenesis and increasing fatty acid oxidation; therefore a  
44 beneficial effect on liver lipid and fibrosis with metformin has been assumed<sup>30</sup>. However,  
45 comprehensive meta-analyses of randomized clinical trials concluded that reduction in both  
46 steatosis and fibrosis with metformin were underwhelming<sup>31 32</sup>. Liver fibroscan measure is  
47 repeated after 6 months of treatment.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Blood pressure and pulse wave analysis measurements are repeated at 3 and 6 months of  
4  
5 treatment and serum lipids measured after 6 months treatment.  
6  
7  
8  
9

### 10 11 **Safety / Adverse events monitoring** 12

13  
14 Gastrointestinal side effects are the most common adverse effects of metformin and may occur  
15  
16 in 20-30% of individuals<sup>33 34</sup>. Specifically, abdominal discomfort, nausea, diarrhoea and  
17  
18 anorexia are common<sup>33</sup>. While the gastrointestinal adverse effects are transient, in  
19  
20 approximately 5% of individuals the symptoms may persist and result in cessation of  
21  
22 metformin<sup>34</sup>. Vitamin B12 concentrations may be lower with metformin, if metformin is  
23  
24 administered for a long duration<sup>35 36</sup>. The mechanism(s) responsible for the lower plasma B12  
25  
26 concentrations are unclear. A very rare, but potentially fatal complication of metformin use is  
27  
28 lactic acidosis, mainly in patients with renal impairment<sup>33 37</sup>. In PREDICT, individuals with  
29  
30 severe renal impairment are excluded. Metformin is titrated over 3 weeks to negate the potential  
31  
32 gastrointestinal side effects. Adverse events are recorded and monitored during the study visits.  
33  
34  
35  
36  
37  
38  
39

### 40 **Statistical analysis** 41

#### 42 *Sample size calculation* 43

44  
45 Based on the primary outcome measure HbA1c, to detect a clinically meaningful difference of  
46  
47 0.4% in the change of HbA1c from baseline between the study arms at 6 months, assuming SD  
48  
49 of 1% for both groups<sup>38</sup>, with 80% power at two sided significance level of 0.05, a sample size  
50  
51 of 106 for each arm is required. Hence, with an estimated dropout rate of 20%, we aim to enrol  
52  
53 132 individuals to each arm, totalling 264 individuals in the study.  
54  
55  
56  
57  
58

#### 59 *Analysis plan* 60

1  
2  
3 The intention-to-treat (ITT) approach will be used for efficacy analysis. A likelihood-based  
4 mixed model repeated measures (MMRM) approach will be used for the primary efficacy  
5 analysis. The primary outcome measure HbA1c at baseline, 3, and 6 months will be the  
6 dependent variable and intervention by time interaction will be the fixed effects, and  
7 participants will be treated as random effect. The primary time specific comparison will be the  
8 difference in least square mean between intervention (PNP) and control (LFHF) diet at 6  
9 months' treatment. The differences between the groups after 3 months of treatment will also  
10 be examined. Missing data will be handled directly through maximum-likelihood estimation  
11 via mixed modelling. To control for potential confounding effects, demographic and clinical  
12 covariates (e.g. age, gender, baseline BMI and background medications) will be adjusted as  
13 necessary in the model. To account for reduced metformin dose due to intolerance or eGFR 45  
14 – 60 mL/min/1.73m<sup>2</sup>, metformin dose status (1500 mg/d [normal] dose / reduced dose) will be  
15 also adjusted in the model. Piecewise linear mixed model will be used to compare trend change  
16 between arms in different periods (0-3 months, and 3-6 months). Different statistical analysis  
17 strategies including t-test, Mann-Whitney U test, Chi-square test, linear/generalized linear  
18 regression, and mixed model will be used based on the type and distribution of the outcome  
19 measures. Mediation analysis will be carried out to explore if the weight loss mediates the  
20 intervention effect on glycaemia, and estimate indirect and direct effects and the proportion  
21 mediated (how much of the total intervention effect works through weight loss). We expect  
22 some degree of weight loss in all participants, as has been reported for metformin<sup>3 39 40</sup>. The  
23 effect of the diet intervention mediated by metformin adherence on the study outcomes will  
24 also be tested. Subgroup analyses can be further performed to explore the intervention effect  
25 in specific sub-cohorts, for instance, the group of participants who have diabetes at baseline,  
26 the group of participants who achieve adherence standard and maintain the desired metformin  
27 dose; the group of participants with BMI >25 kg/m<sup>2</sup> at baseline, etc. The potential impact of  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 the COVID-19 pandemic on the study outcomes may be explored, including comparisons of  
4 adherence and outcomes across groups of participants enrolled and followed-up pre-, during,  
5 and post- pandemic period. Sensitivity analysis related to the impact of COVID-19 may be  
6 conducted.  
7  
8  
9  
10  
11  
12  
13  
14

### 15 **Laboratory testing**

16  
17  
18 HbA1c is analysed using high performance liquid chromatography (Bio-Rad D-100, Bio-Rad  
19 Laboratories, Inc), plasma glucose using the Cobas 8000 (Roche), and liver and renal function  
20 tests using the Atellica platform (Siemens). Serum lipid profile is analysed by a  
21 spectrophotometric assay (Advia® 2400 Chemistry System [Siemens Medical Solutions  
22 Diagnostics]), with low-density lipoprotein (LDL) calculated using the Friedewald equation.  
23 Metagenomic DNA from the stool samples is purified using DNeasy PowerMag Soil DNA  
24 extraction kit (Qiagen) optimized for Tecan automated platform. Next-Generation Sequencing  
25 (NGS) libraries are prepared using Nextera DNA library prep (Illumina) and sequenced on a  
26 NovaSeq sequencing platform (Illumina). Sequencing is performed with 100bp single end  
27 reads with the depth of 10 million reads per sample. Host DNA is detected by mapping reads  
28 to the Human genome with inclusive parameters, and those reads removed. Bacterial relative  
29 abundance estimation is performed by mapping bacterial reads to species-level genome bins  
30 (SGB) representative genomes<sup>41</sup>. Mapping is performed using Bowtie<sup>42</sup> and abundance  
31 estimated by calculating the mean coverage of unique genomic regions across the 50 percent  
32 most densely covered areas, as previously described<sup>43</sup>.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

### 56 **Confidentiality and data storage**

57  
58  
59  
60

1  
2  
3 Each participant is associated with an individual program-generated code used to identify their  
4 study documents, data and specimens collected during the study. The re-identifiable code is  
5 documented in the participant's record and on all study documents. Study data are collected  
6 and managed using REDCap electronic data capture tools<sup>44 45</sup> hosted at the Garvan Institute of  
7 Medical Research. Some coded data are shared with essential personnel at the Weizmann  
8 Institute of Science on institutional Dropbox. Data collected in the form of paper hard copies  
9 are kept in locked cabinets and electronic files on a password protected folder with access  
10 granted to the Garvan study team. Re-identifiable blood, stool, plasma and serum samples will  
11 be kept at the Garvan Institute's freezer facility. All the study questionnaires are disseminated  
12 using REDCap.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Dissemination of results**

29  
30 The results of the study will be disseminated to healthcare professionals via open access  
31 publications in medical journals, without any restrictions. Upon completion of data analysis,  
32 the participants will be invited to an information session at the Garvan Institute of Medical  
33 Research with the study Investigator(s) where the findings of the study will be shared and  
34 discussed. Individual letters are disseminated to the study participants after the 6 months  
35 treatment visit (approximately 7 – 8 months from study enrolment) summarising individual  
36 results (e.g. baseline and post treatment weight, body fat, liver fat, HbA1c, fasting, 1-hr and 2-  
37 hr plasma glucose concentrations). The participants are encouraged to share their individual  
38 results with the GP.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human  
55 Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional  
56 Review Board (File 528-3, Rehovot, Israel). Protocol modifications are communicated to the  
57  
58  
59  
60

1  
2  
3 SVH HREC, the Weizmann IRB, the trial registry (ClinicalTrials.gov), the study investigators  
4 and the study participants (if relevant). De-identified participant data that underlie the findings  
5 reported in the research article will be available immediately following publication, ending 5  
6 years following the article publication, to researchers who provide a methodologically sound  
7 proposal with the aim to achieve the aims reported in the approved project proposal. Data may  
8 be obtained from the Principal Investigator Dorit Samocha-Bonet or Associate Investigator  
9 Jerry Greenfield upon enquiries directed to [d.samochabonet@garvan.org.au](mailto:d.samochabonet@garvan.org.au) or  
10 [j.greenfield@garvan.org.au](mailto:j.greenfield@garvan.org.au).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Authors' contributions**

26 DS-B, JRG, ES and EE contributed to the conception and design of the study, TDH, NG and  
27 DS-B drafted the manuscript, NG and ZL contributed to the study design and the statistical  
28 plan, ZL contributed to the sample size estimation, NG, DK, RC, KT, EC, MD, JRS and T-MH  
29 contributed to the collection of the data. All authors revised and approved the final version of  
30 the manuscript and agree to be accountable for all aspects of the work.  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Funding**

41 This work is supported by the Garvan Research Foundation and the St Vincent's Clinic  
42 Foundation, Sydney, Australia.  
43  
44  
45  
46

47 The study sponsor is the Garvan Institute of Medical Research, 384 Victoria Street,  
48 Darlinghurst, NSW 2020, Australia, +61 2 92958100.  
49  
50  
51

52 The study sponsor and funding bodies have no role in the study design, collection,  
53 management, analysis, and interpretation of data, writing of the report and the decision to  
54 submit the report for publication.  
55  
56  
57  
58  
59  
60

### Conflict of interests

Eran Elinav and Eran Segal are paid consultants of the company DayTwo. Mark Danta has received travel support and speaker fees from Gilead, Abbvie and Merck. All other authors declare they have no conflict of interest.

### Acknowledgements

We would like to thank Dr David Jung from the University of NSW (Sydney, Australia) for assistance in the setup of the REDCap data collection tool and Ms Rebecca Hickey for performing the Fibroscan measurements.

### Figure legends

**Figure 1:** Screenshots of the smartphone application used daily by participants in the PREDICT study. Participants randomized to the personalized diet arm receive scores for each meal. Panels A and B depict two meal options selected by an individual in the study where 2 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

**Table 1:** Inclusion and Exclusion criteria

<b><i>Inclusion criteria</i></b>
Men and women 20-70 years of age
Prediabetes (IFG* or IGT* and/or HbA1c 5.7 – 6.4%) or Individuals diagnosed with T2DM in the last 6 months with HbA1c ≤ 8.0%
Willingness to provide written informed consent, participate and comply with the study
<b><i>Exclusion criteria</i></b>
Women planning pregnancy during the study or 3 months after study completion
Individuals with type 1 diabetes, neoplastic disease (in the last 3 years), cardiovascular event (-6 months), chronic gastrointestinal disorders
Liver enzymes ALT and/or AST >3 times normal range limit
eGFR < 45 mL/min/1.73m <sup>2</sup>
Normo-glycaemia
HbA1c > 8.0%
Current or recent (within 24 months) treatment with a glucose lowering medication other than metformin, current or recent (within 3 months) treatment with metformin, current treatment with an oral steroid, immunosuppressive medications, antibiotics (within 3 months)
Alcohol or substance abuse
Participants who had received an investigational new drug within the last 6 months
Participants involved in another clinical study
Participants who have had bariatric surgery
Participants who actively lose weight
Participants with conditions that may interfere with the ability to understand the requirements of the study, refuse treatment with metformin or refuse to use the smartphone application

\*Impaired fasting glucose (IFG): FPG 5.6-6.9 mmol/L and/or impaired glucose tolerance (IGT): 2-h plasma glucose during 75-g oral glucose tolerance test (OGTT) 7.8-11.0 mmol/L

**Table 2:** Study timeline of activities and measurements taken at each of the study events and visits

	<i>Location and time</i>	<i>Measurements</i>
Pre-screening	Phone -35 +/- 10 days	<ul style="list-style-type: none"> <li>● Interview (by an experienced staff)</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c tests</li> </ul>
Screening/ enrolment (Non-fasting)	Clinical Research Facility -30 +/- 15 days	<ul style="list-style-type: none"> <li>● Informed consent signed</li> <li>● Medical history, medications &amp; medical examination</li> <li>● Blood (full blood count, liver and kidney function tests)</li> <li>● Height and weight (BMI calculated)</li> <li>● BIA (RMR)</li> <li>● Blood pressure</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Smartphone app training</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● Stool sample</li> <li>● *Study entry questionnaire</li> </ul>
Baseline (Fasting)	Clinical Research Facility 0, treatment clock starts	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin 3-months' supply with instructions and log-books</li> <li>● Smartphone app training, according to study arm allocation</li> </ul>
3-months (Fasting)	Clinical Research Facility +90 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Metformin 3-months' supply with log-books</li> <li>● Adverse events recording and monitoring</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> </ul>
5.5-months (Non-fasting)	Clinical Research Facility +166 days +/- 10 days	<ul style="list-style-type: none"> <li>● FreeStyle Libre Pro and ActivePal</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c</li> </ul>

6-months (Fasting)	Clinical Research Facility +180 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids, HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin- unused pills collected and counted</li> <li>● Adverse events recording</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> <li>● ##Diet Satisfaction Questionnaire</li> </ul>
12-months	Local pathology	<ul style="list-style-type: none"> <li>● HbA1c</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● **12-months questionnaire</li> </ul>

\*Questionnaire includes hunger/fullness, dietary habits and dislikes, physical activity, medications, dietary supplements, personal and family history of disease, food-frequency questionnaire

\*\*Questionnaire includes diet (are you following the diet you were allocated to?), metformin (are you continuing the metformin treatment and dosage) and current body weight

#Gut microbiome features from stool samples collected at 3 and 6 months will be compared to baseline (exploratory outcome)

## The Laboratory for the Study of Human Ingestive Behavior, Pennsylvania State University are the copyright holders of the Diet Satisfaction Questionnaire<sup>27</sup>

Abbreviations: BIA, bio impedance analysis; BMR, basal metabolic rate; DXA, dual-energy X-ray absorptiometry; REE, resting energy expenditure; RQ, respiratory quotient


## References

1. Stefan N, Fritsche A, Schick F, et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. *Lancet Diabetes Endocrinol* 2016;4(9):789-98. doi: 10.1016/S2213-8587(16)00082-6
2. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *The Lancet* 2016;387(10027):1513-30. doi: 10.1016/s0140-6736(16)00618-8
3. Samocha-Bonet D, Debs S, Greenfield JR. Prevention and Treatment of Type 2 Diabetes – A Pathophysiological-Based Approach. *Trends Endocrinol Metab* 2018;29(6):370-79.
4. Evert AB, Dennison M, Gardner CD, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. *Diabetes Care* 2019;42(5):731-54. doi: 10.2337/dci19-0014
5. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *The Lancet Diabetes & Endocrinology* 2018;6(5):361-69. doi: 10.1016/S2213-8587(18)30051-2
6. Bailey CJ. Metformin: historical overview. *Diabetologia* 2017;60(9):1566-76. doi: 10.1007/s00125-017-4318-z
7. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;41(12):2669-701. doi: 10.2337/dci18-0033
8. Florez JC. The pharmacogenetics of metformin. *Diabetologia* 2017;60(9):1648-55. doi: 10.1007/s00125-017-4335-y
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355(23):2427-43. doi: 10.1056/NEJMoa066224
10. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med* 2012;366(24):2247-56. doi: 10.1056/NEJMoa1109333
11. Lachin JM, Christophi CA, Edelstein SL, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. *Diabetes* 2007;56(4):1153-9. doi: 10.2337/db06-0918
12. Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia* 2017;60(9):1601-11. doi: 10.1007/s00125-017-4361-9
13. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2019;42(Supplement 1):S13-S28. doi: 10.2337/dc19-S002
14. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015;163(5):1079-94. doi: 10.1016/j.cell.2015.11.001
15. Australian Government National Health and Medical Research Council. Australian Guide to Healthy Eating 2015 [updated 01-05-2017. Available from: <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating2019>.
16. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract* 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL
17. Meyerowitz-Katz G, Seelan S, Gaur P, et al. Detecting the hidden burden of pre-diabetes and diabetes in Western Sydney. *Diabetes Research and Clinical Practice* 2019;151:247-51. doi: <https://doi.org/10.1016/j.diabres.2019.04.019>
18. Saghaei M, Saghaei S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. *J Biomed Sci Eng* 2011;4:734-39.



19. Kozan P, Blythe JC, Greenfield JR, et al. The Effect of Buffering High Acid Load Meal with Sodium Bicarbonate on Postprandial Glucose Metabolism in Humans-A Randomized Placebo-Controlled Study. *Nutrients* 2017;9(8) doi: 10.3390/nu9080861
20. Chen DL, Liess C, Poljak A, et al. Phenotypic Characterization of Insulin-Resistant and Insulin-Sensitive Obesity. *J Clin Endocrinol Metab* 2015;100(11):4082-91. doi: 10.1210/jc.2015-2712
21. Tang A, Coster ACF, Tonks KT, et al. Longitudinal Changes in Insulin Resistance in Normal Weight, Overweight and Obese Individuals. *J Clin Med* 2019;8(5) doi: 10.3390/jcm8050623
22. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2019;156(6):1717-30. doi: 10.1053/j.gastro.2019.01.042
23. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes. *JAMA Netw Open* 2019;2(2):e188102. doi: 10.1001/jamanetworkopen.2018.8102
24. Australian Food, Supplement and Nutrient Database (AUSNUT) 2011-2013: Food Standards Australia New Zealand.
25. Grech A, Rangan A, Allman-Farinelli M. Macronutrient Composition of the Australian Population's Diet; Trends from Three National Nutrition Surveys 1983, 1995 and 2012. *Nutrients* 2018;10(8):1045. doi: 10.3390/nu10081045
26. Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr* 1990;51(2):241-7. doi: 10.1093/ajcn/51.2.241
27. James BL, Loken E, Roe LS, et al. Validation of the Diet Satisfaction Questionnaire: a new measure of satisfaction with diets for weight management. *Obes Sci Pract* 2018;4(6):506-14. doi: 10.1002/osp4.299
28. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther* 2009;11 Suppl 1:S55-67. doi: 10.1089/dia.2008.0132
29. Marjot T, Moolla A, Cobbold JF, et al. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. *Endocrine Reviews* 2019 doi: 10.1210/endrev/bnz009
30. Green CJ, Marjot T, Tomlinson JW, et al. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? *Diabetes Obes Metab* 2018 doi: 10.1111/dom.13592
31. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012;55(4):885-904. doi: 10.1007/s00125-011-2446-4
32. Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. *Medicine (Baltimore)* 2016;95(32):e4529. doi: 10.1097/MD.0000000000004529
33. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. *Drug Saf* 1999;20(6):489-503.
34. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. *Diabetologia* 2016;59(3):426-35. doi: 10.1007/s00125-015-3844-9
35. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *British Medical Journal* 2010;340:c2181. doi: 10.1136/bmj.c2181
36. Reinstatler L, Qi YP, Williamson RS, et al. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements. *Diabetes Care* 2012;35(2):327-33. doi: 10.2337/dc11-1582

- 1  
2  
3 37. DeFronzo R, Fleming GA, Chen K, et al. Metformin-associated lactic acidosis: Current perspectives  
4 on causes and risk. *Metabolism* 2016;65(2):20-29. doi:  
5 <https://doi.org/10.1016/j.metabol.2015.10.014>  
6  
7 38. Jönsson T, Granfeldt Y, Åhrén B, et al. Beneficial effects of a Paleolithic diet on cardiovascular risk  
8 factors in type 2 diabetes: a randomized cross-over pilot study. *Cardiovascular Diabetology*  
9 2009;8(1):35. doi: 10.1186/1475-2840-8-35  
10  
11 39. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes  
12 with lifestyle intervention or metformin. *The New England Journal of Medicine*  
13 2002;346(6):393-403. doi: 10.1056/NEJMoa012512  
14  
15 40. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight  
16 loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374(9702):1677-86.  
17 doi: 10.1016/S0140-6736(09)61457-4  
18  
19 41. Pasolli E, Asnicar F, Manara S, et al. Extensive Unexplored Human Microbiome Diversity Revealed  
20 by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell*  
21 2019;176(3):649-62.e20. doi: 10.1016/j.cell.2019.01.001 [published Online First: 01/17]  
22  
23 42. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature Methods*  
24 2012;9(4):357-59. doi: 10.1038/nmeth.1923  
25  
26 43. Korem T, Zeevi D, Suez J, et al. Growth dynamics of gut microbiota in health and disease inferred  
27 from single metagenomic samples. *Science* 2015;349(6252):1101-06. doi:  
28 10.1126/science.aac4812  
29  
30 44. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community  
31 of software platform partners. *Journal of Biomedical Informatics* 2019;95:103208. doi:  
32 <https://doi.org/10.1016/j.jbi.2019.103208>  
33  
34 45. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-  
35 driven methodology and workflow process for providing translational research informatics  
36 support. *Journal of Biomedical Informatics* 2009;42(2):377-81. doi:  
37 <https://doi.org/10.1016/j.jbi.2008.08.010>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Screenshots of the smartphone application used daily by participants in the PREDICT study. Participants randomized to the personalized diet arm receive scores for each meal. Panels A and B depict two meal options selected by an individual in the study where 2 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

190x112mm (300 x 300 DPI)

# Participant Information Sheet/Consent Form

**Interventional Study - Adult providing own consent**

*Garvan Institute of Medical Research*

<b>Title</b>	<i>Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk</i>
<b>Short Title</b>	<i>Personalised medicine in prediabetes (PREDICT)</i>
<b>Protocol Number</b>	<i>17/080</i>
<b>Project Sponsor</b>	<i>Garvan Institute of Medical Research</i>
<b>Coordinating Principal Investigator/ Principal Investigator</b>	<i>Dr Dorit Samocha-Bonet</i>
<b>Associate Investigator(s)</b> <i>(if required by institution)</i>	<i>Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu, Ms Godneva</i>
<b>Location (where CPI/PI will recruit)</b>	<i>Garvan Institute of Medical Research, Sydney</i>

## Part 1 What does my participation involve?

### 1 Introduction

Type 2 diabetes affects 8.5% of the world's adult population. Prediabetes is a condition developing many years before type 2 diabetes, and is diagnosed by raised glucose (sugar) in the blood stream, either when measured first thing in the morning (fasting) or when measured after a meal. Approximately 30 - 40 % of the world's adult population is affected by prediabetes. Individuals with prediabetes have a higher risk of diabetes and heart disease. Treatment with the most commonly used sugar-lowering medication metformin does not always improve blood sugar levels in individuals with prediabetes or type 2 diabetes. This means that after the treatment, blood sugar concentrations are still higher than normal and the risk of diabetes remains increased.

You are invited to take part in this research project because you either have prediabetes or you have recently been diagnosed with type 2 diabetes. The research project is testing the effect of a personalised diet combined with the medication metformin on sugar control, body weight, and other risk factors.

This Participant Information Sheet/Consent Form tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the research.

Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your General Practitioner.

Participation in this research is voluntary. If you don't wish to take part, you don't have to. You will receive the best possible care whether or not you take part.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 If you decide you want to take part in the research project, you will be asked to sign the consent  
5 section. By signing it you are telling us that you:

- 6  
7
- Understand what you have read
  - Consent to take part in the research project
  - Consent to have the tests and treatments that are described
  - Consent to the use of your personal and health information as described
- 11  
12  
13

14 You will be given a copy of this Participant Information and Consent Form to keep.  
15  
16

## 17 **2 What is the purpose of this research?**

18  
19 The overall aim of the study is to improve the treatment of individuals with prediabetes or type 2  
20 diabetes with a special nutritional intervention.

21 In particular, we would like to find out whether a personalised diet administered with a medication  
22 commonly used to treat diabetes named metformin will achieve better results when compared  
23 with a low fat low sugar diet (the type of diet commonly recommended to individuals with  
24 prediabetes or type 2 diabetes) administered with metformin.

25  
26 We will compare the effects of the different treatments on sugar control, body weight, body fat,  
27 blood lipids, blood pressure and the amount of fat in the liver.  
28  
29

30 The medication used in this research project and listed below is approved in Australia to treat  
31 type 2 diabetes. While it is not routinely prescribed to treat prediabetes, metformin has been used  
32 to treat individuals with prediabetes in a large American trial and has been proven to be safe in  
33 individuals with prediabetes (the Diabetes Prevention Program, United States).  
34  
35

### 36 The following medication/treatments will be used in the study:

- 37  
38
1. Metformin Extended Release (XR) + Low fat low sugar diet (“healthy” diet).
  2. Metformin XR + “Personalised diet” (see further details below).
- 40  
41

42 In both study arms, if your weight falls in the overweight or obese category (i.e. body mass index  
43 [BMI] > 25 kg/m<sup>2</sup>), we will recommend a reduction of approximately 500 Kcal/d from the dietary  
44 energy you are currently on. This will result in moderate weight loss. If your weight is within the  
45 recommended BMI range (equals to or under 25 kg/m<sup>2</sup>), we will recommend the same level of  
46 energy intake you are currently consuming. This will result in weight maintenance.  
47  
48

### 49 Method of administration of medication:

50 Metformin XR – Daily tablet (oral ingestion 1500 mg/d) with evening meal  
51  
52

### 53 Method of administration of diet:

54 The diet will be delivered using a smartphone application. You will be guided and supported by  
55 an Accredited Practising Dietitian  
56  
57  
58  
59  
60

1  
2 You will be participating in a randomised research project. Sometimes we do not know which  
3 treatment is best for treating a condition. To find out, we need to compare different treatments.  
4 We put people into groups and give each group a different treatment. The results are compared  
5 to see if one is better than the other. To try to make sure the groups are the same, each participant  
6 is put into a group by chance (random).  
7

8  
9  
10 We will administer 1 medication in combination with 2 different nutritional interventions. There is  
11 a 1 in 2 chance that you will be allocated to each study arm.  
12

13  
14 This research has been initiated by the study doctors, Dr Dorit Samocha-Bonet and Professor  
15 Jerry R Greenfield.  
16

17  
18 This research has been funded by a Foundation requesting to remain anonymous, funds from the  
19 Garvan Research Foundation and a grant from the St Vincent's Clinic Foundation.  
20

### 21 22 **3 What does participation in this research involve?**

23  
24 If you agree to participate in this study, you will be asked to sign the Participant Consent Form.  
25 We will ask you to sign a separate Participant Consent Form before having blood tests at a  
26 commercial pathology.  
27

28  
29 Participation in this project will involve the following:

30  
31 Initially we will ask you questions regarding your health and medical history over the telephone.  
32 If it sounds like you may be eligible for the study we will ask you to attend a commercial pathology  
33 service in your area for an oral sugar test (oral glucose tolerance test), testing your blood sugar  
34 after drinking a sugary drink, and a blood test measuring glycated haemoglobin (HbA1c, a marker  
35 of average blood sugar levels over the past 3 months). This involves having a blood sample taken  
36 prior to drinking a sugary drink (containing 75 grams of sugar), followed by blood samples taken  
37 one and two hours later.

38  
39 You will be asked to remain in the blood collection centre for the duration of the test (2 hours).

40  
41 Overall the commercial Pathology will collect 20 mL (about 1.5 tablespoons) of blood.  
42

43  
44 These blood tests will tell us if you have diabetes or prediabetes and will help us determine  
45 whether or not you are eligible to participate in our study. We will call you and discuss the test  
46 results and your eligibility to participate in the study within 1 week. We will provide you with a letter  
47 summarising the results which you will be able to share with your General Practitioner.  
48

49  
50 If you are eligible to participate in the study, we will invite you to a Screening / Enrolment visit. We  
51 will send you a special kit for collection of stool at home, with detailed instructions on how to  
52 collect the sample. We will ask you to bring the sample with you to your next visit.

53  
54 Prior to the study we will ask you to reply to questionnaires asking about your usual eating and  
55 physical activity habits and your health. You will be asked to download a smartphone application  
56 which you will use during the study.  
57  
58  
59  
60

### Screening / Enrolment visit (approximately 1.5 hours)

- We will ask that you arrive to the Clinical Research Facility (clinic) at the Garvan Institute of Medical Research, Darlinghurst. During this visit you will have time to ask questions and if you agree to participate, you will sign the consent form. You will change into a hospital gown. The study doctor will ask you about your health and perform a physical examination. We will measure body weight and height, blood pressure, waist and hip circumferences, and body fat composition (estimated using Tanita scales).
- Blood will be drawn to assess your liver and kidney health and your blood cells count. The volume of blood that will be taken during this visit is 20 mL (about 1.5 tablespoons).
- We will attach a small device (sensor) that measures sugar levels for a period of 14 days to your arm. The size of the device is of a fifty cents coin. We will apply the sensor on to the back of the upper arm with a disposable applicator. When the sensor is applied, a thin, flexible sterile fibre is inserted just under the skin. It is held in place with a small adhesive pad. Most people feel no pain when applying the sensor. You will not have to do anything while the sensor measures sugar level. All the information will be stored in the sensor. We will also attach a physical activity sensor. Both sensors are designed to wear for up to 14 days. We will ask that you remove and send the sensors to us after 14 days in a prepaid envelop. You will have your usual diet and record what you eat in a smartphone application.

During this visit, or soon after, you will meet the dietitian (face-to-face or using a video meeting tool like Zoom or Skype). The dietitian will teach you to use the smartphone application. You will use this application to log the food that you eat, and optionally, to log your physical activity (type and duration), and the medications that you take. We will provide you with a light meal at the end of this visit.

After this visit we will randomise you to one of 2 treatment arms.

### Baseline visit (2 hours, we will ask that you fast from 10 pm the night before this visit)

The baseline visit will be performed approximately 6 – 8 weeks after the Screening / Enrolment visit. You will arrive at the clinic in the morning. The following measurements and procedures will take place,

- You will undergo dual-energy X-ray absorptiometry (DXA) at St Vincent's Hospital (next door to the Garvan). DXA will be used to evaluate the amount of fat in your body.
- Liver fibroscan, performed at St Vincent's Hospital. This measurement will provide information about the amount of fat and fibrosis (scarring) in the liver.
- A team member will measure your weight, height, waist and hip circumference and blood pressure, while wearing a hospital gown.
- We will measure how many calories you burn while resting using a plastic hood placed over your shoulders while you are resting in bed (takes 30 minutes).
- We will measure the stiffness of an artery in the wrist (radial artery) using a non-invasive device which looks like a pen. This measurement takes approximately 5 minutes and will provide information about the stiffness of your arteries.
- We will collect blood samples. Overall we will collect 20 mL (2 tablespoons) of blood during this visit.
- We will collect a sample of bacteria from the mouth by swabbing a special collection stick over the gums. We will store this sample for testing the effect of the treatment on the mouth bacteria.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

At the end of the visit we will provide you with 3-months' worth of medication and medication logbooks. We will ask you to take the metformin every evening **with dinner**. You will start with taking a small dose and depending on how you feel (some people experience diarrhoea, nausea, and flatulence, mostly at the beginning of the treatment), we will gradually ask you to increase the dose until you reach the target dose. You will be guided by the study investigator / dietitian regarding using the smartphone application during the treatment period.

We will call you at a time of your convenience once a month or fortnightly to follow up on your progress with the treatment. We will ask you how you feel and whether you have any general health changes that you would like to report (whether you think they are related or unrelated to the treatment), as well as any changes to your usual medications, other than the study treatment.. Follow-up may be performed using Zoom, Skype, text, or over the phone.

4-months visit (2 hours, similar to the baseline visit, we will ask that you fast from 10 pm the night before this visit)

This visit will be similar to the baseline visit (described above) and include the same procedures, except that you will not have a DXA and fibroscan. We will attach another sugar sensor to the arm, and ask you to send it back to us in a prepaid envelope after 14 days. During this visit we will also take a blood sample that will be used to measure the level of metformin in the blood. We will ask you to bring the medication log books.

#### 6.5-months visits

We will invite you to the Garvan to attach the sugar sensor and activity monitor. We will refer you again to perform a sugar challenge test, as you have done before the treatment in a commercial pathology in your area. We will provide you with a special kit for collection of stool and ask you to bring the sample with you to your next visit at the Garvan.

#### 7-months (end-of treatment, performed 6 months from the start of the treatment) visit

Identical to the baseline visit, with the exception that we will collect a blood sample to measure the concentration of the medication in the blood and will ask you to bring back the medication and the logbooks.

#### 12-months survey and blood test (includes a questionnaire and a blood test at a local commercial pathology)

6-months after the completion of the treatment, we will send you a survey and ask you to tell us what your current body weight is, whether you remained on the diet, and whether you are treated with a sugar-lowering medication (and if relevant to specify the medication and dose). We will also ask you to perform a blood test in a commercial pathology in your area. The blood test will measure sugar control and does not require you to be fasting. You will not have to visit the Garvan for this event.

In summary, you will be required to visit and maintain contact with the study team over a period of approximately 6 months, while you're treated. The overall duration of the study is approximately 13 – 14 months.

There are no costs associated with participating in this research project, nor will you be paid. All medications, dietary advice, tests, including all blood tests, some meals and medical care required as part of the research project will be provided to you free of charge.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20



1  
2  
3  
4 You will be provided a \$100 AUD retail voucher. Parking will be provided at the Garvan carpark  
5 on days of visits.  
6  
7

8 If you have a General Practitioner, we strongly recommend that you inform them of your  
9 participation in this research project.  
10  
11

#### 12 **4 What do I have to do?**

13  
14 During the study period, the study team will instruct you regarding what you should be doing  
15 before each of the visits/study events. For example, we may ask you to avoid drinking alcohol or  
16 to avoid vigorous physical activity before some of the visits.

17  
18 During the study you will be able to continue taking your regular medications, but if you will require  
19 a sugar-lowering medication other than metformin (prescribed in the study), you will have to  
20 withdraw from the study.

21 We will ask you to inform us if and when you started taking a new medication, or if and when there  
22 has been a change in dose of any medication you are taking regularly.  
23

24 During the study we will ask you not to donate blood or participate in another study.

25 We will expect you to be compliant with the study instructions and if any problem arises, we expect  
26 that you will contact us.  
27  
28

#### 29 **5 Other relevant information about the research project**

30  
31 We plan to enrol approximately 260 men and women to this study. All participants will be enrolled  
32 at a single site, the Garvan Institute of Medical Research, Darlinghurst, Sydney.  
33

34 Some tests will be performed at the adjacent St Vincent's Hospital.

35 The project involves researchers from a number of academic institutes working in collaboration.  
36 The research team includes researchers and endocrinologists from the Diabetes Division at the  
37 Garvan Institute of Medical Research and St Vincent's Hospital (Sydney), researchers from the  
38 Endocrinology Department at Blacktown & Mount Druitt Hospital (Sydney), and researchers from  
39 the Immunology Department and the Computer Science Department at the Weizmann Institute of  
40 Science (Israel).  
41  
42

#### 43 **6 Do I have to take part in this research project?**

44  
45 Participation in any research project is voluntary. If you do not wish to take part, you do not have  
46 to. If you decide to take part and later change your mind, you are free to withdraw from the project  
47 at any stage.  
48

49 If you do decide to take part, you will be given this Participant Information and Consent Form to  
50 sign and you will be given a copy to keep.

51 Your decision whether to take part or not to take part, or to take part and then withdraw, will not  
52 affect your routine treatment, your relationship with those treating you or your relationship with  
53 the Garvan Institute of Medical Research or St Vincent's Hospital.  
54  
55

#### 56 **7 What are the alternatives to participation?**

57  
58 Other treatment options for your condition are available; these include dietary counselling and  
59 physical activity advice, and / or a sugar-lowering medication. Your study doctor will discuss  
60

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2 these options with you before you decide whether or not to take part in this research project. You  
3 can also discuss the options with your General Practitioner.  
4  
5

## 6 **8 What are the possible benefits of taking part?**

7  
8 We cannot guarantee or promise that you will receive any benefits from this research. You will  
9 have access to a medication regulating blood sugar level that is primarily offered to type 2  
10 diabetes patients and you may lose weight (1 – 5 kg).  
11  
12

13 We are hoping that the information generated in this study will help improve treatment of your  
14 condition.  
15  
16

## 17 **9 What are the possible risks and disadvantages of taking part?**

18  
19 Taking a medication may involve some risks, as detailed below. We will monitor any adverse  
20 events on a regular basis and you will have access to a clinical staff member at all time during  
21 the study.  
22

23 There are potential risks relating to the procedures we will utilise in the course of the study. We  
24 have listed them below.  
25  
26

### 27 Risks related to the medication

28 Medical treatments often cause side effects. You may have none, some or all of the effects listed  
29 below, and they may be mild, moderate or severe. If you have any of these side effects, or are  
30 worried about them, talk with your study doctor. Your study doctor will also be looking out for side  
31 effects regularly.  
32  
33

34 In case you need to have any diagnostic procedure requiring contrast, most radiological services  
35 recommend routine withholding of metformin for 48 hours prior to and after the procedure. Please  
36 let your doctor know that you are taking metformin.  
37  
38

39 There may be side effects that the researchers do not expect and that may be serious. Tell your  
40 study doctor immediately about any new or unusual symptoms that you get.  
41  
42

43 Many side effects go away shortly in the first few weeks of the treatment or after the treatment  
44 ends. However, sometimes side effects can be serious. If a severe side effect or reaction occurs,  
45 your study doctor may need to stop your treatment. Your study doctor will discuss the best way  
46 of managing any side effects with you.  
47  
48

49 The medication we will administer in the present study, metformin, has been administered to  
50 people with type 2 diabetes over many years and has proven to be generally safe. We have listed  
51 below the potential side effects of the medication administered.  
52  
53

- 54 • Mild gastrointestinal symptoms such as diarrhoea, nausea, vomiting, abdominal pain and  
55 loss of appetite are the most frequent reactions to metformin, occurring in approximately  
56 10% of individuals (10 in 100), especially during the initial treatment period. These  
57 symptoms are generally transient and resolve spontaneously during continued treatment.
- 58 • Taste disturbance may occur in 3% (3 in 100).  
59  
60

- Rare adverse reactions occur in less than 0.01% (1 in 10000) of individuals include,
  - Lactic acidosis, often with mild nonspecific symptoms such as feeling of sickness, sleepiness, shortness of breath, and nonspecific abdominal distress.
  - Abnormalities of liver tests have been reported. Liver function tests will be monitored during the treatment.

### *Risks related to the personalised nutrition*

The Personalised Nutrition Project diet (<http://newsite.personalnutrition.org/WebSite/Home.aspx>) has been trialled in various studies for over 5 years by the study co-Investigators Professors Elinav and Segal from the Weizmann Institute in Israel. The nutritional recommendation is different from person to person. This is because it is based on the individual's features and measurements, including sugar rise in response to food. Co-Investigators Elinav and Segal have reported that the individual response depends on blood markers, body measurements and different features of microorganisms in the gut. The individual food recommendation is based on "real" foods.

The effects of the personalised diet on the level of blood lipids in individuals with prediabetes and type 2 diabetes is being investigated. If we find that the baseline level of low-density lipoprotein (LDL)-cholesterol in the blood is elevated, a modified personalised diet containing less saturated fat (the type of dietary fat known to increase the level of LDL) will be prescribed.

### *Risks relating to procedures*

#### Blood sampling

You may have pain, light-headedness, minor infection, bleeding or bruising at the sites of the blood sampling; however, the staff will use proper technique while drawing blood samples in order to reduce the risk for these unwanted effects. These effects are usually temporary, are easily treated, and are expected to resolve completely.

#### Dual-energy X-ray absorptiometry (DXA) scan

This research study involves exposure to a very small amount of radiation. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose from this study is about 0.04 mSv. At this dose level, no harmful effects of radiation have been demonstrated as any effect is too small to measure. The risk is believed to be minimal.

#### Fibroscan test

The fibroscan is a non-invasive method of assessing liver scarring, termed fibrosis. The test is performed at the bedside in a clinic. A mechanical pulse is generated at the skin surface, which is propagated through the liver. The velocity of the wave is measured by ultrasound. The speed of this wave correlates with the stiffness of the liver, which in turn reflects the degree of fibrosis – the stiffer the liver is, the greater the degree of fibrosis. This test also estimates the amount of fat in the liver. This test utilises an ultrasound device and carries no risk.

#### Body sugar monitoring

The device we use in the study is used to monitor blood glucose levels, mostly in diabetes patients. Most people feel no pain when applying the sensor. The sensor is designed for a safe wear of up to 14 days. You can shower and exercise while wearing the sensor. Some individuals

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

develop a skin reaction around the device on the arm. This typically resolves spontaneously over time; an over the counter cream may be recommended if the skin reaction persists. If you experience a skin reaction, we will likely decide to omit this measurement from the follow-up events.

### Indirect calorimetry

A clear plastic hood is placed loosely over your head. Room air flows through the hood and the machine measures how much oxygen you are using and how much carbon-dioxide you produce. This test carries no significant risk. However, some participants may experience claustrophobia. If this occurs, the hood will be removed immediately.

### Arterial stiffness

The stiffness of an artery in your wrist will be measured using a small device, looking like a pen, by applying light pressure to your wrist. There are no risks related to this method.

### Tanita scales

The scales estimate how much energy your body requires based on your body fat and muscle composition. When you stand on a Tanita monitor, a very low, safe electrical signal is sent from four metal electrodes through your feet to your legs and abdomen. The electrical signal passes quickly through water that is present in muscle tissue but meets resistance when it hits fat. This resistance, known as impedance, is measured and used in validated equations to calculate body composition. This measurement will take around 20 seconds. Information from the Tanita measurement will be used to estimate your recommended daily energy intake.

People with an electronic medical implant, such as a pacemaker, should not use a body composition monitor because the electrical signal travelling through the body may interfere with its operation.

### **Pregnancy**

The effects of the medication metformin on the unborn child and on the newborn baby are not known. Because of this, it is important that study participants are not pregnant or breast-feeding and do not become pregnant during the course of the research project. You must not participate in this study if you are pregnant or trying to become pregnant, or breast-feeding. If you are female and child-bearing is a possibility, you will be required to undergo a pregnancy test prior to commencing the research project, and before each of the DXA scans.

Female participants must avoid pregnancy during the course of the research and for a period of 3 months after completion of the research project. You should discuss methods of effective contraception with your study doctor.

If you do become pregnant whilst participating in the research project, you should advise your study doctor immediately. Your study doctor will withdraw you from the research project and advise on further medical attention should this be necessary. You must not continue in the research if you become pregnant.

If you are a male, it is safe to father a child or donate sperm whilst taking the study medication.

## **10 What will happen to my test samples?**

During the study we will store blood and stool samples in -80°C freezer. In this research project, collecting blood and stool samples are mandatory.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2 The blood, oral and stool samples collected are for research purposes, as specified in this  
3 document.  
4

5 All the samples we will collect from you will be coded so they are not identifiable as your sample.  
6 Your identification linked to the sample code will be stored on a password protected computer  
7 and physical hardcopies in a locked filing cabinet at the Garvan Institute of Medical Research.  
8 Only staff involved in this study at the site will have access to this data to maintain  
9 privacy/confidentiality.  
10

11 Some analyses in blood will be performed in commercial Laboratories or at St Vincent's Hospital.  
12 These specimens will be de-identified (coded). Your clinical information will not be sent with the  
13 specimens. The results of these analyses will be returned to the Investigators at the Garvan  
14 Institute of Medical Research. The external sites may retain your re-identifiable, analysed data in  
15 their records. After analysis of your specimen is complete, these external sites will destroy any  
16 remaining tissue or return remaining sample to us for storage.  
17

18 We will store the samples we collect for 15 years.

19 Some samples of your blood, mouth and stool obtained for the purpose of this research project  
20 will be transferred to the Weizmann Institute of Science in Israel. These samples will be de-  
21 identified by coding. Information such as your gender, age, ethnicity, medical history, medications,  
22 food sensitivities and eating habits will be shared with researchers at the Weizmann Institute for  
23 planning your diet. This information will be de-identified.  
24

25 Your samples will not be sold and the Garvan Institute of Medical Research will not knowingly  
26 transfer your samples to anyone who has expressed intent to sell the samples.  
27  
28

### 29 **11 What if new information arises during this research project?**

30 Sometimes during the course of a research project, new information becomes available about the  
31 treatment that is being studied. If this happens, your study doctor will tell you about it and discuss  
32 with you whether you want to continue in the research project. If you decide to withdraw, your  
33 study doctor will make arrangements for your regular health care to continue. Also, on receiving  
34 new information, your study doctor might consider it to be in your best interests to withdraw you  
35 from the research project. If this happens, he / she will explain the reasons and arrange for your  
36 regular health care to continue.  
37

38 When we assess your suitability to participate in the study we may uncover a medical condition  
39 of which you may be unaware. While we may decide that you are not able to participate in the  
40 study because of this new condition, we will refer you to your General Practitioner for further  
41 investigation and management.  
42

43 If during the screening visit we diagnose a previously unknown condition, for example type 2  
44 diabetes, this may affect insurance in the future.  
45  
46

### 47 **12 Can I have other treatments during this research project?**

48 Whilst you are participating in this research project, you may not be able to take some of the  
49 medications or treatments you have been taking for your condition or for other reasons. It is  
50 important to tell your study doctor and the study staff about any treatments or medications you  
51 may be taking, including over-the-counter medications, vitamins or herbal remedies. You should  
52 also tell your study doctor about any changes to these during your participation in the research  
53 project.  
54  
55

### 56 **13 What if I withdraw from this research project?**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

If you decide to withdraw from the project, please notify a member of the research team before you withdraw. This notice will allow that person or the research supervisor to discuss any health risks or special requirements linked to withdrawing.

If you do withdraw your consent during the research project, the study doctor and relevant study staff will not collect additional personal information from you, although personal information already collected will be retained to ensure that the results of the research project can be measured properly and to comply with law. You should be aware that data collected by the sponsor up to the time you withdraw will form part of the research project results. If you do not want them to do this, you must tell them before you join the research project.

#### **14 Could this research project be stopped unexpectedly?**

Sometimes research projects trialling medications need to stop prematurely because of unexpected side effects. However, this research project is unlikely to be stopped unexpectedly, because the medication administered has been studied and is routinely administered in type 2 diabetes and to a lesser degree in people with prediabetes. The medication administered here has been proven safe in type 2 diabetes patients.

#### **15 What happens when the research project ends?**

The medication administered in the present study will not be available after the research finishes through the study (but may be prescribed by your General Practitioner if required and decided). At study completion, you will be able to continue using the app and follow your study diet. We will offer you nutritional counselling on healthy lifestyle that will help you maintain a healthy body weight and decrease your risk of developing diabetes.

After you complete the study treatment (approximately 7 months from when you start), we will send you a detailed results letter, with measurements collected at baseline and after the 6 months' treatment, that will include your weight, BMI, blood pressure, fasting blood sugar, glycated haemoglobin (HbA1c), and the amount of fat in your body and liver.

After we finalise the study of all the participants and analyse the data (approximately in 2022), we will invite you to an information evening at the Garvan Institute of Medical Research (Darlinghurst, Sydney) to share with you the study findings. You will have opportunity to discuss the findings with the study Investigators.

## **Part 2 How is the research project being conducted?**

#### **16 What will happen to information about me?**

By signing the consent form you consent to the study doctor and relevant research staff collecting and using personal information about you for the research project. Any information obtained in connection with this research project that can identify you will remain confidential. All the clinical information and the data that will be collected will be coded. It can be re-identified; however, your identification matching your code will be secured, accessible only by research staff. Data allowing re-identification of your data will be kept on a password protected computer and a locked filing cabinet at the Garvan Institute of Medical Research. Only staff involved in this study will have access to this data to maintain privacy/confidentiality.

All data will be stored for 15 years, after which it will be destroyed.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 Your information will only be used for the purpose of this research project and it will only be  
5 disclosed with your permission, except as required by law.

6  
7 Information about you may be obtained from your health records held at this and other health  
8 services for the purpose of this research. By signing the consent form you agree to the study team  
9 accessing health records if they are relevant to your participation in this research project.

10  
11 Your health records and any information obtained during the research project are subject to  
12 inspection (for the purpose of verifying the procedures and the data) by the relevant authorities  
13 and authorised representatives of the Sponsor, the Garvan Institute of Medical Research, the  
14 institution relevant to this Participant Information Sheet, St Vincent's Hospital, Sydney, or as  
15 required by law. By signing the Consent Form, you authorise release of, or access to, this  
16 confidential information to the relevant study personnel and regulatory authorities as noted above.

17  
18 It is anticipated that the results of this research project will be published and presented in a variety  
19 of forums. In any publication and presentation, information will be provided in such a way that you  
20 cannot be identified. No individual data will be reported in any publication or presentation.

21  
22 Data collected in the study may be made available to other researchers. The data will be coded  
23 and will not reveal your personal details. The data will be made available subject to a review of  
24 applications submitted by interested researchers performed by the study Investigators Dorit  
25 Samocha-Bonet and/or Jerry R Greenfield. Only researchers aiming to achieve the aims of the  
26 project will be considered. Upon approval, access to the de-identified data will be available for a  
27 period of 5 years after publishing the study findings.

28  
29 Information about your participation in this research project may be recorded in your health  
30 records.

31  
32 In accordance with relevant Australian privacy and other relevant laws, you have the right to  
33 request access to your information collected and stored by the research team. You also have the  
34 right to request that any information with which you disagree be corrected. Please contact the  
35 study team member named at the end of this document if you would like to access your  
36 information.

37  
38  
39 Any information obtained for the purpose of this research project that can identify you will be  
40 treated as confidential and securely stored. It will be disclosed only with your permission, or as  
41 required by law.

## 42 43 44 **17 Complaints and compensation**

45  
46 If you suffer any injuries or complications as a result of this research project, you should contact  
47 the study team as soon as possible and you will be assisted with arranging appropriate medical  
48 treatment. If you are eligible for Medicare, you can receive any medical treatment required to treat  
49 the injury or complication, free of charge, as a public patient in any Australian public hospital.

50  
51 In the event of loss or injury, the parties involved in this study have agreed to provide  
52 compensation if the participants' injury or complication is caused by the study procedures or by  
53 the negligence of any of the parties involved in the study. If you suffer any distress or  
54 psychological injury as a result of this study, you should contact the study team as soon as  
55 possible, who will assist you in arranging appropriate treatment and support.

## 56 57 58 **18 Who is organising and funding the research?**

59  
60 This research project is being conducted by Dr Samocha-Bonet and Professor Greenfield.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3 Dr Samocha-Bonet, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu and Ms Godneva have no conflict  
4 of interest to disclose.

5 The study co-Investigators, Prof Eran Elinav and Prof Eran Segal of the Weizmann Institute of  
6 Science are paid consultants of the company DayTwo. DayTwo, established in Israel, provides  
7 personalised nutrition to individuals. The product is based on the technology arising from research  
8 conducted by Prof Elinav and Prof Segal at the Weizmann Institute of Science. The research  
9 findings were published in the journal *Cell* in 2015.

10 The Garvan Institute of Medical Research may benefit financially from this research project if, for  
11 example, the project assists Garvan Institute of Medical Research to obtain approval for a new  
12 treatment tool.

13  
14 By taking part in this research project you agree that samples of your blood or stool (or data  
15 generated from analysis of these materials) may be provided to the Weizmann Institute of Science  
16 (Israel).

17  
18 The Weizmann Institute of Science may directly or indirectly benefit financially from your samples  
19 or from knowledge acquired through analysis of your samples.

20  
21 You will not benefit financially from your involvement in this research project even if, for example,  
22 your samples (or knowledge acquired from analysis of your samples) prove to be of commercial  
23 value to the Garvan Institute of Medical Research.

24 In addition, if knowledge acquired through this research leads to discoveries that are of  
25 commercial value to the Garvan Institute of Medical Research or the Weizmann Institute of  
26 Science, the study doctors or their institutions, there will be no financial benefit to you or your  
27 family from these discoveries.

28  
29 No member of the research team will receive a personal financial benefit from your involvement  
30 in this research project (other than their ordinary wages).

### 31 32 33 **19 Who has reviewed the research project?**

34 All research in Australia involving humans is reviewed by an independent group of people called  
35 a Human Research Ethics Committee (HREC). The ethical aspects of this research project have  
36 been approved by the HREC of St. Vincent's Hospital Sydney (HREC reference number 17/080).

37  
38  
39 This project will be carried out according to the *National Statement on Ethical Conduct in Human  
40 Research (2007)*. This statement has been developed to protect the interests of people who agree  
41 to participate in human research studies.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## 20 Further information and who to contact

The person you may need to contact will depend on the nature of your query.

If you want any further information concerning this project or if you have any medical problems which may be related to your involvement in the project (for example, any side effects), you can contact the principal study doctor Dr Dorit Samocha-Bonet on 02-9295 8309 or 0416-316 111.

### Clinical contact person

Name	Professor Jerry R Greenfield
Position	Associate Investigator
Telephone	SVH Switchboard 8382 1111, ask to page Prof Jerry Greenfield <b>24-hour medical contact</b>
Email	<a href="mailto:predict@garvan.org.au">predict@garvan.org.au</a>

### Research Nurse

Name	Ms Renee Richens
Position	Research Nurse
Telephone	02-92958215 (Working days: Tuesday, Wednesday, Thursday)
Email	<a href="mailto:predict@garvan.org.au">predict@garvan.org.au</a>

For matters relating to research at the site at which you are participating, the details of the local site complaints person are:

### Complaints contact person

Name	Research Office Manager
Position	Research Office Manager
Telephone	02 8382 4960
Email	SVHS.Research@svha.org.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

### Reviewing HREC approving this research and HREC Research Officer details

Reviewing HREC name	St Vincent's Hospital HREC
HREC Research Officer	Research Officer
Telephone	02 8382 4960
Email	SVHS.Research@svha.org.au

### Research Governance Officer

Name	Ms Therese Yim
Position	Research Governance Officer
Telephone	02-9295 8173
Email	<a href="mailto:t.yim@garvan.org.au">t.yim@garvan.org.au</a>

**Consent Form - Adult providing own consent**

<b>Title</b>	<i>Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk</i>
<b>Short Title</b>	<i>Personalised medicine in prediabetes (PREDICT)</i>
<b>Protocol Number</b>	<i>17/080</i>
<b>Project Sponsor</b>	<i>Garvan Institute of Medical Research</i>
<b>Coordinating Principal Investigator/ Principal Investigator</b>	<i>Dr Dorit Samocha-Bonet</i>
<b>Associate Investigator(s)</b>	<i>Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu, Ms Godneva</i>
<b>Location</b>	<i>Garvan Institute of Medical Research</i>

**Declaration by Participant**

I have read the Participant Information Sheet or someone has read it to me in a language that I understand.

I understand the purposes, procedures and risks of the research described in the project.

I give permission for my doctors, other health professionals, hospitals or laboratories outside this hospital to release information to Garvan Institute of Medical Research concerning my disease and treatment for the purposes of this project. I understand that such information will remain confidential.

I have had an opportunity to ask questions and I am satisfied with the answers I have received.

I freely agree to participate in this research project as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand that I will be given a signed copy of this document to keep.

I consent to the storage and use of blood and tissue samples taken from me for use, as described in the relevant section of the Participant Information Sheet, for:

- This specific research project
- Other research that is closely related to this research project

I consent to sharing de-identified (coded) data collected during the study with other researchers aiming to achieve the study aims as listed, subject to approval by the study Principal Investigator Dorit Samocha-Bonet and/or Associate Investigator Jerry R Greenfield.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 Name of Participant (please print) \_\_\_\_\_  
5  
6 Signature \_\_\_\_\_ Date \_\_\_\_\_  
7  
8

9  
10 Name of Witness\* to Participant's  
11 Signature (please print) \_\_\_\_\_  
12

13  
14 Signature \_\_\_\_\_ Date \_\_\_\_\_  
15

16 \* Witness is not to be the investigator, a member of the study team or their delegate. In the event that an interpreter is  
17 used, the interpreter may not act as a witness to the consent process. Witness must be 18 years or older.  
18

19  
20 **Declaration by Study Doctor/Senior Researcher†**  
21

22  
23 I have given a verbal explanation of the research project, its procedures and risks and I believe  
24 that the participant has understood that explanation.  
25

26 Name of Study Doctor/  
27 Senior Researcher† (please  
28 print) \_\_\_\_\_  
29

30  
31 Signature \_\_\_\_\_ Date \_\_\_\_\_  
32

33 † A senior member of the research team must provide the explanation of, and information  
34 concerning, the research project.  
35  
36

37 Note: All parties signing the consent section must date their own signature.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Form for Withdrawal of Participation - Adult providing own consent**  
 2  
 3

4 **Title** *Personalised medicine in prediabetes – Towards*  
 5 *preventing diabetes in individuals at risk*  
 6  
 7 **Short Title** *Personalised medicine in prediabetes (PREDICT)*  
 8  
 9 **Protocol Number** *17/080*  
 10 **Project Sponsor** *Garvan Institute of Medical Research*  
 11  
 12 **Coordinating Principal Investigator/  
 13 Principal Investigator** *Dr Dorit Samocha-Bonet*  
 14  
 15 **Associate Investigator(s)** *Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng,*  
 16 *Dr Snaith, Dr Liu, Ms Godneva*  
 17  
 18 **Location** *Garvan Institute of Medical Research*  
 19  
 20  
 21

22 **Declaration by Participant**  
 23  
 24

25 I wish to withdraw from participation in the above research project and understand that such  
 26 withdrawal will not affect my routine treatment, my relationship with those treating me or my  
 27 relationship with the Garvan Institute of Medical Research.  
 28  
 29

30 Name of Participant (please print) \_\_\_\_\_  
 31  
 32 Signature \_\_\_\_\_ Date \_\_\_\_\_  
 33  
 34

35  
 36 *In the event that the participant's decision to withdraw is communicated verbally, the Study*  
 37 *Doctor/Senior Researcher will need to provide a description of the circumstances below.*  
 38

39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47

48 **Declaration by Study Doctor/Senior Researcher†**  
 49

50  
 51 I have given a verbal explanation of the implications of withdrawal from the research project and  
 52 I believe that the participant has understood that explanation.  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

1  
2  
3  
4 Name of Study Doctor/  
5 Senior Researcher† (please  
6 print)  
7 \_\_\_\_\_

8 Signature \_\_\_\_\_

Date \_\_\_\_\_  
9

10 † A senior member of the research team must provide the explanation of and information  
11 concerning withdrawal from the research project.  
12  
13

14 Note: All parties signing the consent section must date their own signature.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1 and 20 (Authors' contribution)
	5b	Name and contact information for the trial sponsor	20
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

1	<b>Introduction</b>			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5 - 6
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	5 - 6
7				
8	Objectives	7	Specific objectives or hypotheses	6
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7
12				
13				
14	<b>Methods: Participants, interventions, and outcomes</b>			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	6 - 7
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	7 and Table 1
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	11 – 13
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	13
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	13 – 14
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6 – 7 and Table 1
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	15 – 16
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation	
35			(eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits	Table 2
39			for participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7 – 8
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9 – 10
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9 – 10
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9 – 10
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9 – 10
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14 – 16
34	methods			
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	14 – 16 and 17 (Statistical plan)
39				
40				
41				
42				



1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18 – 19
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16 and Table 2
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Approval granted, details page 3
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	3
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9 and Table 2
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18 – 19
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	18 – 19
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	20 - 21
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	20
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Uploaded
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	19
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.

# BMJ Open

## The rationale and design of a randomized controlled trial testing the effect of personalized diet in individuals with prediabetes or type 2 diabetes mellitus treated with metformin

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037859.R2
Article Type:	Protocol
Date Submitted by the Author:	26-Aug-2020
Complete List of Authors:	Htet, Thaw; Garvan Institute of Medical Research Godneva, Anastasia; Weizmann Institute of Science Liu, Zhixin; UNSW, Stats Central Chalmers, Eliza; Garvan Institute of Medical Research Kolobkov, Dmitry; Weizmann Institute of Science Snaith, Jennifer; Garvan Institute of Medical Research Richens, Renee; Garvan Institute of Medical Research Toth, Krisztina; Garvan Institute of Medical Research Danta, Mark; UNSW Hng, Tien-Ming; Blacktown Mount Druitt Hospital, Diabetes & Endocrinology Elinav, Eran; Weizmann Institute of Science, Segal, Eran; Weizmann Institute of Science Greenfield, Jerry; Garvan Institute of Medical Research Samocha-Bonet, Dorit; Garvan Institute of Medical Research, Diabetes Division
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Diabetes & endocrinology < INTERNAL MEDICINE, NUTRITION & DIETETICS, DIABETES & ENDOCRINOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **The rationale and design of a randomized controlled trial testing the effect of**  
4 **personalized diet in individuals with prediabetes or type 2 diabetes mellitus treated with**  
5 **metformin**  
6  
7  
8  
9

10  
11  
12 Thaw D Htet<sup>1,2,3\*</sup>, Anastasia Godneva<sup>4\*</sup>, Zhixin Liu<sup>5</sup>, Eliza Chalmers<sup>1</sup>, Dmitry Kolobkov<sup>4</sup>,  
13 Jennifer R Snaith<sup>1,2,3</sup>, Renee Richens<sup>1</sup>, Krisztina Toth<sup>1</sup>, Mark Danta<sup>2,6</sup>, Tien-Ming Hng<sup>7,8</sup>,  
14 Eran Elinav<sup>9</sup>, Eran Segal<sup>4</sup>, Jerry R Greenfield<sup>1,2,3</sup>, Dorit Samocha-Bonet<sup>1,2#</sup>  
15  
16  
17  
18  
19

20 Affiliations:  
21

- 22  
23 1 Diabetes and Metabolism, Garvan Institute of Medical Research, Sydney, Australia  
24  
25 2 St Vincent's Clinical School, University of NSW, Sydney, Australia  
26  
27 3 Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, Australia  
28  
29 4 Department of Computer Science and Applied Math, Weizmann Institute of Science,  
30 Rehovot, Israel  
31  
32  
33 5 Mark Wainwright Analytical Centre, UNSW, Sydney, Australia  
34  
35 6 Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia  
36  
37 7 Blacktown Mt Druitt Hospital, Western Sydney Local Health District, Sydney,  
38 Australia  
39  
40  
41 8 Blacktown Clinical School, Western Sydney University, Sydney, Australia  
42  
43  
44 9 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel  
45  
46  
47

48 \*Equally contributing Authors  
49

50 #Corresponding Author: Dorit Samocha-Bonet, Garvan Institute of Medical Research,  
51 384 Victoria Street, Darlinghurst, NSW 2010, Australia. Phone: +61 2 92958309, email:  
52 d.samoخابonet@garvan.org.au  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction** Metformin and diets aimed at promoting healthy body weight are the first line in treating type 2 diabetes mellitus (T2DM). Clinical practice, backed by clinical trials, suggests that many individuals do not reach glycaemic targets using this approach alone. The primary aim of the Personalised Medicine in Prediabetes – Towards Preventing Diabetes in Individuals at Risk (PREDICT) study is to test the efficacy of personalized diet as adjuvant to metformin in improving glycaemic control in individuals with dysglycemia.

**Methods and Analysis** PREDICT is a two-arm, parallel group, single-masked randomized controlled trial in adults with prediabetes or early-stage T2DM (with glycated haemoglobin [HbA1c] up to 8.0% [64 mmol/mol]), not treated with glucose-lowering medication. PREDICT is conducted at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Enrolment of participants commenced in December 2018 and expected to complete in December 2021. Participants are commenced on metformin (Extended Release, titrated to a target dose of 1500 mg/d) and randomized with equal allocation to either (1) the Personalized Nutrition Project (PNP) algorithm-based diet or (2) low-fat high dietary fibre (LFHF) diet, designed to provide caloric restriction (75%) in individuals with body mass index >25 kg/m<sup>2</sup>. Treatment duration is 6 months and participants visit the Clinical Research Facility 5 times over approximately 7 months. The primary outcome measure is HbA1c. The secondary outcomes are (1) time of interstitial glucose <7.8 mmol/L and (2) glycaemic variability (continuous glucose monitoring), (3) body weight, (4) fat mass and (5) abdominal visceral fat volume (dual-energy X-ray absorptiometry), serum (6) low-density lipoprotein (LDL)-cholesterol (7) high-density lipoprotein (HDL)-cholesterol and (8) triglycerides concentrations, (9) blood pressure, and (10) liver fat (Fibroscan).

1  
2  
3 **Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human  
4 Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional  
5 Review Board (File 528-3, Rehovot, Israel). The findings will be published in peer-reviewed  
6 open access medical journals.  
7  
8  
9

10  
11  
12  
13 The study has been registered at ClinicalTrials.gov (NCT03558867).  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study**

- 20  
21  
22 • The randomized controlled design testing a novel diet against standard of care may lead  
23 to a novel tool to manage dysglycemia in individuals requiring metformin  
24
- 25  
26 • Conducted in an adult Australian population, the study findings may not be applicable  
27 to other populations  
28
- 29  
30 • The algorithm used to devise the personalized diet relies on accurate recording of the  
31 dietary intake by the participants  
32
- 33  
34 • The dietary intervention requires use of a smartphone application which may limit its  
35 applicability to some populations  
36  
37  
38  
39  
40  
41  
42  
43

44 **Key words:** Prediabetes, Type 2 diabetes, Metformin, Algorithm-based diet, Low fat diet,  
45 Randomized controlled trial  
46  
47  
48  
49

50 **Word count:** 3927  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Type 2 diabetes mellitus (T2DM) and its preceding medical condition, prediabetes are significant risk factors for cardiovascular disease, and most affected individuals demonstrate additional metabolic risk factors, such as hypertension, dyslipidaemia, excess weight and fatty liver<sup>1</sup>. T2DM affects approximately 422 million adults globally, with an additional 352 million individuals at increased risk, having prediabetes<sup>2,3</sup>. Individuals diagnosed with prediabetes or T2DM are encouraged to adopt a healthy lifestyle and, if overweight to lose weight<sup>4</sup>. The majority of individuals with T2DM are treated with metformin, which is the 8<sup>th</sup> most prescribed medication in the United States<sup>5-7</sup>.

Metformin, an oral biguanide, is the first-line treatment for individuals with newly-diagnosed T2DM and, in some cases, for the prevention of diabetes in individuals with prediabetes<sup>6</sup>. Metformin is an ideal medication to initiate for management of T2DM or for prevention of diabetes, because it does not cause hypoglycaemia and has a favourable, albeit modest, effect on body weight<sup>8</sup>. Metformin monotherapy is insufficient to achieve glycaemic control in a large proportion of treated individuals<sup>3,9,10</sup>. Findings from the Diabetes Prevention Program (DPP) in individuals with prediabetes suggested that the glycaemic efficacy of metformin depends on the magnitude of weight loss<sup>11</sup>, explaining 64% of the diabetes risk reduction, with additional 17% explained by decreases in fasting insulin and pro-insulin at 3 years of follow up<sup>11,12</sup>.

The current treatment guidelines in T2DM recommend prescribing metformin in combination with a healthy lifestyle, enabling weight loss<sup>13</sup>. The most recent nutritional guidelines for individuals with T2DM or prediabetes are no longer supporting a universal ideal dietary macronutrient distribution; instead, the guidelines suggest individualized eating plans<sup>4</sup>.



1  
2  
3 In the pioneering Personalized Nutrition Project (PNP)<sup>14</sup>, Segal, Elinav and colleagues  
4 developed an algorithm that predicts an individual's postprandial glycaemic response (PPGR)  
5 to meals. The algorithm incorporates the individual's personal data (e.g. age, gender, body  
6 mass index [BMI]), blood tests (e.g. glycated haemoglobin [HbA1c]), dietary features,  
7 continuous glucose monitor (CGM)-derived data, and gut microbiome features, and trained on  
8 data previously collected in 800 individuals. Personally-tailored dietary plans based on the  
9 algorithm were trialled in a small group of individuals with prediabetes and shown to improve  
10 glycaemic variability and PPGR over 7 days<sup>14</sup>.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The primary objective of the Personalised Medicine in Prediabetes – Towards Preventing  
25 Diabetes in Individuals at Risk (PREDICT) Study is to compare glycaemic control, measured  
26 by HbA1c, following 6 months of metformin, prescribed with either (1) the PNP algorithm-  
27 based diet or (2) low-fat high dietary fibre (LFHF) diet, based on the Australian Healthy Eating  
28 Guide<sup>15</sup> and the American Association of Clinical Endocrinologists guide for medical care of  
29 patients with obesity<sup>16</sup>, in individuals with prediabetes or early-stage T2DM naive to glucose-  
30 lowering pharmacotherapy.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The secondary objectives of the PREDICT study are to compare the effect of the PNP diet  
44 versus LFHF diet when prescribed with metformin on: (1) time of interstitial glucose <7.8  
45 mmol/L, (2) glycaemic variability, (3) weight, (4) body fat mass, (5) abdominal visceral fat  
46 volume, (6) serum low-density lipoprotein (LDL)-cholesterol concentration (7) serum high-  
47 density lipoprotein (HDL)-cholesterol concentration, (8) serum triglycerides concentration, (9)  
48 blood pressure, and (10) liver fat. The exploratory objectives of the study are to test the effect  
49 of the treatment on the gut microbiome.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Study design, setting and population

The study is a two-arm, parallel group, single-masked randomized controlled trial (RCT). Adults with prediabetes or early-stage T2DM who are not treated with glucose-lowering medications are randomized, with equal allocation, to either the PNP or LFHF diet arms, in both arms participants are commenced on metformin Extended Release (XR) 1500 mg/d treatment for 6 months. All the study visits are performed at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Metagenomics and data processing for the personalized dietary interventions are performed at the Weizmann Institute of Science (Rehovot).

### Patient and public involvement

Patients or the public were not involved in the design or other aspects of the research.

### Eligibility

Adults (20-70 years old) with prediabetes or recently (in the last 6-months) diagnosed T2DM with (HbA1c  $\leq$  8.0% [64 mmol/mol]), not pregnant or planning to become pregnant during, and for at least 3 months after the study are recruited (Table 1). A wide age range was selected to encompass different populations of individuals managing their prediabetes for short or long durations and to increase the likelihood to recruit the sample size in a timely manner. The HbA1c cap at 8.0% [64 mmol/mol] was selected to ensure that individuals with T2DM are relatively well-controlled. Blood tests indicative of normo-glycaemia, HbA1c above 8.0% [64 mmol/mol], liver enzymes (ALT and/or AST) over 3 times the normal range limit and eGFR<sup>17</sup> lower than 45 mL/min/1.73m<sup>2</sup> are grounds for exclusion. Individuals treated with glucose-

1  
2  
3 lowering medication other than metformin in the last 24 months, or metformin in the last 3  
4 months, will be excluded. Individuals with conditions or treatments that affect glycaemia (e.g.  
5 oral steroids), impact weight (e.g. bariatric surgery, weight loss medications), or the gut  
6 microbiome (e.g. inflammatory bowel disease, coeliac, frequent antibiotic treatment) will be  
7 excluded. Participants who have had a cardiovascular event in the previous 6 months or  
8 received an investigational new drug within the last 6 months will be excluded. Participants  
9 with conditions that may interfere with the ability to understand the requirements of the study  
10 and those who refuse treatment with metformin or refuse to use the smartphone application  
11 will be excluded (Table 1).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **Recruitment**

28  
29 The study is advertised in general practitioners (GP), endocrinologists and dieticians' practices  
30 in the Sydney metropolitan area, and through targeted social media campaigns. A collaboration  
31 with Blacktown Mt Druitt Hospital (Western Sydney) has been established in 2019 for the  
32 purpose of recruitment. During a hospital screening program ran between 2016 – 2018, 17.3%  
33 and 30.2% of individuals visiting the Emergency Department (ED) at Blacktown Mt Druitt  
34 Hospital have had HbA1c values indicative of diabetes and prediabetes, respectively<sup>18</sup>. Since  
35 September 2019, individuals visiting the ED who have had a blood test indicative of  
36 prediabetes receive a letter prompting them to contact the PREDICT team and encouraging  
37 they share the result with a GP.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 To-date (February 2020), 38 participants were enrolled. Of the 38 participants enrolled, 20  
53 completed, 13 are ongoing, and 5 withdrew before the end of the treatment (13% drop-out rate).  
54 Recruitment of participants is expected to complete in December 2021.  
55  
56  
57  
58  
59  
60

1  
2  
3 Participants contacting the team receive the participant information sheet (Supplementary  
4 material) via email or post. Experienced clinical research nurse/associate provides details about  
5 the study over the phone. Willing participants are referred to a commercial pathology to  
6 perform an oral glucose tolerance test (OGTT, 75 g) and HbA1c test. They are asked to sign a  
7 consent form after reading the participant information sheet explaining the possible risks of  
8 undergoing the OGTT and HbA1c tests prior to performing the blood tests. If the blood tests  
9 indicate either T2DM (with HbA1c  $\leq 8.0\%$  [64 mmol/mol]), or impaired fasting glucose (IFG)  
10 or impaired glucose tolerance (IGT) or HbA1c  $\geq 5.7$  [39 mmol/mol], they are invited to a  
11 screening and enrolment visit at the Garvan Clinical Research Facility.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 A stool collection kit for metagenomics OMNIgene GUT (OMR-200; DNA Genotek) is mailed  
28 to participants prior to the screening/enrolment visit. Participants collect the sample according  
29 to the manufacturer's instructions the day before the visit and keep the sample at room  
30 temperature. At the Clinical Research Facility, the sample is vortexed, centrifuged for a few  
31 seconds and material aliquoted into cryo vials and kept in -70C freezer. One vial is transferred  
32 to facilities at the Weizmann Institute of Science and stored at  $-20^{\circ}\text{C}$  until DNA extraction.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The pre-treatment data are collected across the screening/enrolment and the baseline visits.  
44  
45  
46  
47

### 48 **Screening / enrolment procedures and measurements**

49

50 During the screening/enrolment visit, participants sign the study informed consent form  
51 (Supplementary material) and undergo medical examination by a physician. Participants have  
52 their weight, height, waist and hip circumference and blood pressure measured. Basal  
53 metabolic rate (BMR) is estimated using bioelectrical impedance (BIA, used for calculating  
54 the energy requirement, see "Energy target"). Blood samples are collected to evaluate liver  
55  
56  
57  
58  
59  
60

1  
2  
3 (liver enzymes) and kidney (creatinine and eGFR) function and full blood count. Glucose  
4  
5 monitor (FreeStyle Libre Pro, Abbott, Germany) is attached for a period of 14 days.  
6  
7  
8  
9

10 A link to download the PNP smartphone application is sent to the participants prior to the  
11  
12 screening/enrolment visit along with a short video demonstrating the app use. They are asked  
13  
14 to log-in to the app with a personal (re-identifiable) code provided by email, and to familiarize  
15  
16 with the app in preparation for a training session with the dietician. During the  
17  
18 screening/enrolment visit, the dietitian practices with the participants browsing the food  
19  
20 database, selecting food and beverage items and indicating the amount consumed. Participants  
21  
22 are taught to add frequently consumed foods to a favourites list, which makes future search of  
23  
24 food items easier. When the CGM is on, participants are asked to carry on with their usual  
25  
26 routine and to record all meals, snacks and drinks using the app. The period between the  
27  
28 screening/enrolment and the baseline visits (4 – 6 weeks) serves as the ‘run-in’ period.  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Randomization**

38  
39 Randomization is performed between the screening/enrolment and baseline visits. Individuals  
40  
41 are randomized with 1:1 allocation into the 2 arms in rounds of 4 – 6 individuals each, with  
42  
43 randomization performed within each round using the minimization program for allocation of  
44  
45 subjects to parallel groups, modified from Saghaei et al<sup>19</sup>. They are stratified by gender, age  
46  
47 (20-49 or 50-70 years), BMI (<25.0 or >25.1 kg/m<sup>2</sup>) and HbA1c (<5.7 [39 mmol/mol] or >5.8  
48  
49 % [40 mmol/mol]). To avoid bias, the randomization is performed by a study investigator  
50  
51 located at the Weizmann Institute who does not interact with the study participants. The study  
52  
53 nurses and physicians who have direct contact with the participants are blinded to the  
54  
55 randomization order, however due to the nature of the intervention, the study dietician is not  
56  
57 blinded to the treatment allocation.  
58  
59  
60

### **Baseline visit - Measurements**

The baseline visit is performed approximately 4-6 weeks after the screening/enrolment visit (Table 2). Participants attend the Clinical Research Facility following an overnight fast. Blood is drawn for serum lipids measurement and anthropometric measures and blood pressure are taken. Arterial stiffness (pulse wave analysis, AtCor Medical, Australia) is measured twice and average recorded, as described<sup>20</sup>. This is followed by measurement of resting energy expenditure, carbohydrate and fat oxidation over 30 minutes by indirect calorimetry (Quark, Cosmed, Italy)<sup>21</sup>. Body composition is assessed using dual-energy X-ray absorptiometry (DXA, Lunar Prodigy, GE Healthcare). Specifically, total body fat mass and fat-free mass (enCORE software), the android and gynoid region, and visceral fat (CoreScan software, GE Healthcare) are recorded<sup>22</sup>. Liver steatosis (controlled attenuation parameter, CAP) and liver fibrosis (liver stiffness measurement, LSMs) are assessed using FibroScan (Touch 502 by Echosens) by a trained technician. CAP and LSMs have been reported to correlate closely with steatosis and fibrosis assessed using the gold-standard liver biopsy<sup>23</sup>. A physical activity monitor (ActivePal, Pal Technologies) is applied on the thigh for a period of 14 days. At the end of the baseline visit, the participants practice using the app with the dietician.

### **Prediction of postprandial glucose response using the algorithm**

The prediction of PPGR in PREDICT follows the modelling framework described in Zeevi et al<sup>14</sup> and is performed between the screening/enrolment and baseline visits. Time-stamped food records from the app, CGM and other data collected during the enrolment visit at the Garvan are shared with a mathematician at the Weizmann Institute of Science where data processing occurs, on an Institutional secured server. The data, together with the stool metagenome sequencing data are integrated with the Weizmann Institute's database to develop personalized

1  
2  
3 algorithms for predicting each individual's PPGR. A database of recipes of meals (n=233) and  
4 smaller meals ("snacks", n=249) varying in macronutrient composition to generate feedback  
5 on the PPGR to pre-consumed meals has been created. Using the participants' features,  
6 personalized PPGR are calculated for every meal and snack in the database based on nutrient  
7 composition, and energy-adjusted quintile cut-offs of PPGR are used to create personalized  
8 meal ratings ranging from 1 to 5 (corresponding with "excellent", "good", "medium", "bad",  
9 and "very bad"). The predictive model, originally trained on data collected in an Israeli adult  
10 cohort<sup>14</sup>, has been shown to be predictive of PPGR in a U.S. cohort of healthy adults (n=327)  
11 consuming a Western style diet<sup>24</sup>.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **Interventions**

28  
29 Both arms use the PNP mobile app to select meals/foods. In 2018, the app, developed at the  
30 Weizmann Institute of Science, was adapted to Australian consumers including the Australian  
31 food database (AUSNUT 2011–13)<sup>25</sup> of approximately 5,700 food items.  
32  
33  
34  
35  
36  
37  
38

### 39 *Personalized diet (PNP diet arm)*

40  
41 Participants in the PNP diet arm receive personalized feedback on each of their food item/meal  
42 choice and asked to consult with the app in real-time to select the recommended meal for them.  
43 The feedback is color-coded with a traffic light system; green ("good" and "excellent"), yellow  
44 ("medium") and red ("bad" or "very bad") PPGR (Figure 1 A and B). Participants are advised  
45 to aim for as many "good" and "excellent" scores, occasional "medium", and to avoid "bad"  
46 and "very bad" scores. When receiving bad scores, they are advised to trial substituting, adding  
47 or removing ingredients from the meal to improve the score. In individuals with  
48 hypercholesterolemia, a special set of recipes containing reduced saturated fat are uploaded  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 into the smartphone app. Special recipes are available for individuals practicing vegetarianism  
4  
5 or avoiding dairy, eggs and fish/seafood.  
6  
7  
8  
9

### 10 *Low-fat high fibre diet (LFHF) arm*

11  
12  
13 The diet comparator chosen in the present study (the standard of care, LFHF) follows the  
14  
15 Australian Healthy Eating Guide<sup>15</sup> principles. The LFHF diet is designed to provide  
16  
17 approximately 30% of the total daily energy intake from fat, of which up to 10% of the fat is  
18  
19 saturated fat, 50-55% of energy from low glycaemic load carbohydrates, 20-25% from protein  
20  
21 and 30 g/d of dietary fibre. The diet is rich in legumes, poor in white grains and added sugar.  
22  
23 Overall, the comparator diet chosen is considerably different from the diet of the average adult  
24  
25 Australian<sup>26</sup>. A database of recipes (n=110 meals and n=80 snacks) following the LFHF  
26  
27 nutrient content has been created based on the AUSNUT 2013 recipes<sup>25</sup>. Food items such as  
28  
29 sugary drinks, processed meat, candies, sugar and cream were excluded from the LFHF recipes.  
30  
31 Similar to the PNP arm, recommended meals scaled to the individual's energy target are  
32  
33 uploaded into the participants' app, taking into account the individual's dietary restrictions and  
34  
35 likes. Similar to the PNP arm, participants of the LFHF arm are encouraged to choose from the  
36  
37 recipes uploaded for them or browse the food database (5700 food items) to design their own  
38  
39 meals, as long as they follow the general dietary guidelines. Participants of the LFHF arm are  
40  
41 instructed to consult with the total daily energy and macronutrient breakdown charts to ensure  
42  
43 they follow the recommended diet (Figure 1C).  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 *Energy target and using the app to select meals in real-time (both arms)*

54  
55 The energy requirement calculation is based on BMR estimated by BIA (Tanita, TBF-300 by  
56  
57 Wedderburn) and on the Mifflin equation<sup>27</sup>. The two values are multiplied by a physical  
58  
59 activity factor of 1.4 (lightly active) then averaged, and the value compared with the average  
60



1  
2  
3 daily energy intake of at least 7 days, extracted from the time-stamped meals recorded using  
4 the app. In participants with BMI >25 kg/m<sup>2</sup>, energy target of 75% is prescribed. Participants  
5  
6 of both arms are encouraged to consume 3 bigger (breakfast, lunch, dinner) and 3 smaller  
7  
8 (snack) meals spread throughout the day. An email, along with a short video summarising the  
9  
10 principles of the diet and app use is sent to the participants (different sets of email and video to  
11  
12 each arm) in the first week of the treatment period.  
13  
14  
15  
16  
17  
18  
19

### 20 *Metformin (relevant to both study arms)*

21  
22 Metformin (XR) is dispensed by the St Vincent's Hospital Pharmacy (Sydney) at baseline (for  
23  
24 a period of 3 months) and at the 3 months visit (to last until the end of the study). The target  
25  
26 dose (1500 mg/d) is titrated over 3 weeks to minimize gastrointestinal intolerance. A target  
27  
28 dose of 1000 mg/d is set for participants with mild to moderately decreased eGFR (45 – 59  
29  
30 mL/min/1.73m<sup>2</sup>), or participants who cannot tolerate the higher dose. A standardized dose of  
31  
32 1500 mg/d, rather than 2000 mg/d, was selected to suit both participants with prediabetes and  
33  
34 T2DM, while minimising intolerance. Participants are instructed to take the medication with  
35  
36 the evening meal and record it daily using a medication recording screen in the app or in paper  
37  
38 logbooks.  
39  
40  
41  
42  
43  
44  
45

### 46 **Monitoring and adherence evaluation (relevant to both study arms)**

47  
48 The dietician reviews scores calculated programmatically based on the frequency of using the  
49  
50 app and on meeting the daily energy target, along with the time-stamped meals consumed by  
51  
52 the participants daily. In the PNP arm, the score incorporates the proportion of meals achieving  
53  
54 the desired (“excellent” and “good”) scores, while in the LFHF arm, the proportion of days in  
55  
56 which dietary fat ≤35%, saturated fat ≤10%, carbohydrates ≥45%, and dietary fibre ≥15 g. The  
57  
58 dietician contacts individuals who need encouragement to achieve better scores. Participants  
59  
60

1  
2  
3 of the 2 treatment groups receive the same attention according to their adherence. Time devoted  
4 to each individual by the dietician is recorded for later analysis purposes. Satisfaction with the  
5 diet is assessed using the Diet Satisfaction Questionnaire<sup>28</sup> at 6 months (Table 2).  
6  
7  
8  
9

10  
11  
12 Adherence to the metformin is based on pill counting at the 6-months visit and on logs of daily  
13 dose using the app or logbooks.  
14  
15  
16  
17

### 18 19 20 **Physical activity and other confounders**

21  
22 Participants are asked to maintain the same level of physical activity throughout the study.  
23 Physical activity is monitored at 2 time points during the study using ActivePal (Table 2). The  
24 device records time (start and duration) and type (quiet, standing and steps) of activity and 14-  
25 days' worth of data, stored in the device, downloaded upon return. Information about  
26 background medications and nutritional supplements is collected before the start of the  
27 treatment using questionnaires (Table 2). Participants are asked to report any change in  
28 medications at each of the study visits and using the medication screen in the smartphone app.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Primary and secondary outcomes – Measurements**

43  
44 Participants attend the Clinical Research Facility five times during the study, over  
45 approximately 7 months. Primary and secondary endpoint measures are collected before the  
46 start of the intervention (across 2 visits: screening/enrolment and baseline) and at 3 and 6  
47 months of treatment. Table 2 outlines the measurements obtained at each of the study  
48 visits/events.  
49  
50  
51  
52  
53  
54  
55  
56  
57

### 58 **Study outcomes**

1  
2  
3 The primary outcome measure is change in HbA1c from baseline to 6 months of treatment.  
4  
5 Furthermore, a comprehensive glycaemia assessment is enabled through continuous glucose  
6  
7 monitoring. Interstitial glucose concentrations are recorded every 15 min using CGM for 14  
8  
9 days before the start of the intervention (in the run-in period) and after 3- and 6- months of  
10  
11 intervention. The sensor stores the data for the duration of the recording, while the participants  
12  
13 are blinded to the glucose readings. The data are downloaded upon return of the sensor. Time  
14  
15 of the day with glucose readings below 7.8 mmol/L before versus after the treatment will be  
16  
17 compared. Glycaemic variability<sup>29</sup>, including (1) mean amplitude of glucose excursion  
18  
19 (MAGE, a measure of the variation of glucose concentrations from the mean), (2) the standard  
20  
21 deviation and the (3) mean postprandial area under the curve will also be assessed.  
22  
23 Furthermore, fasting plasma glucose, 1-hr and 2-hr plasma glucose post 75 g glucose  
24  
25 assessment are repeated after 6 months and will be compared to the baseline values. HbA1c  
26  
27 test is repeated 6 months after treatment cessation (at 12-months, Table 2), along with a short  
28  
29 questionnaire, including weight, diet and medication status.  
30  
31  
32  
33  
34  
35  
36  
37

38 Weight, waist and hip circumferences are recorded at 3-months and 6-months of treatment and  
39  
40 compared to baseline. Fat, fat-free mass and android/gynoid fat distribution and visceral fat  
41  
42 measurements by DXA are repeated at 6 months treatment<sup>22</sup>. Similarly, resting energy  
43  
44 expenditure and fat/carbohydrate oxidation is measured after 6 months of treatment.  
45  
46  
47  
48  
49

50 Hepatic steatosis is common in prediabetes and T2DM<sup>1 30</sup> and prevention of liver  
51  
52 steatohepatitis is key target in individuals with prediabetes or T2DM. Metformin primarily  
53  
54 targets the liver, inhibiting lipogenesis and increasing fatty acid oxidation; therefore a  
55  
56 beneficial effect on liver lipid and fibrosis with metformin has been assumed<sup>31</sup>. However,  
57  
58 comprehensive meta-analyses of randomized clinical trials concluded that reduction in both  
59  
60

1  
2  
3 steatosis and fibrosis with metformin were underwhelming<sup>32 33</sup>. Liver fibroscan measure is  
4  
5 repeated after 6 months of treatment.  
6  
7  
8  
9

10  
11 Blood pressure and pulse wave analysis measurements are repeated at 3 and 6 months of  
12  
13 treatment and serum lipids measured after 6 months treatment.  
14  
15

### 16 17 18 19 **Safety / Adverse events monitoring**

20  
21  
22 Gastrointestinal side effects are the most common adverse effects of metformin and may occur  
23  
24 in 20-30% of individuals<sup>34 35</sup>. Specifically, abdominal discomfort, nausea, diarrhoea and  
25  
26 anorexia are common<sup>34</sup>. While the gastrointestinal adverse effects are transient, in  
27  
28 approximately 5% of individuals the symptoms may persist and result in cessation of  
29  
30 metformin<sup>35</sup>. Vitamin B12 concentrations may be lower with metformin, if metformin is  
31  
32 administered for a long duration<sup>36 37</sup>. The mechanism(s) responsible for the lower plasma B12  
33  
34 concentrations are unclear. A very rare, but potentially fatal complication of metformin use is  
35  
36 lactic acidosis, mainly in patients with renal impairment<sup>34 38</sup>. In PREDICT, individuals with  
37  
38 severe renal impairment are excluded. Metformin is titrated over 3 weeks to negate the potential  
39  
40 gastrointestinal side effects. Adverse events are recorded and monitored over the phone and  
41  
42 during the study visits.  
43  
44  
45  
46  
47  
48  
49

### 50 **Statistical analysis**

#### 51 *Sample size calculation*

52  
53  
54 Based on the primary outcome measure HbA1c, to detect a clinically meaningful difference of  
55  
56 0.4% in the change of HbA1c from baseline between the study arms at 6 months, assuming SD  
57  
58 of 1% for both groups<sup>39</sup>, with 80% power at two sided significance level of 0.05, a sample size  
59  
60

1  
2  
3 of 106 for each arm is required. Hence, with an estimated dropout rate of 20%, we aim to enrol  
4  
5 132 individuals to each arm, totalling 264 individuals in the study.  
6  
7  
8  
9

### 10 *Analysis plan*

11  
12  
13 The intention-to-treat (ITT) approach will be used for efficacy analysis. A likelihood-based  
14  
15 mixed model repeated measures (MMRM) approach will be used for the primary efficacy  
16  
17 analysis. The primary outcome measure HbA1c at baseline, 3, and 6 months will be the  
18  
19 dependent variable and intervention by time interaction will be the fixed effects, and  
20  
21 participants will be treated as random effect. The primary time specific comparison will be the  
22  
23 difference in least square mean between intervention (PNP) and control (LFHF) diet at 6  
24  
25 months' treatment. The differences between the groups after 3 months of treatment will also  
26  
27 be examined. Missing data will be handled directly through maximum-likelihood estimation  
28  
29 via mixed modelling. To control for potential confounding effects, demographic and clinical  
30  
31 covariates (e.g. age, gender, baseline BMI and background medications) will be adjusted as  
32  
33 necessary in the model. To account for reduced metformin dose due to intolerance or eGFR 45  
34  
35 – 60 mL/min/1.73m<sup>2</sup>, metformin dose status (1500 mg/d [normal] dose / reduced dose) will be  
36  
37 also adjusted in the model. Piecewise linear mixed model will be used to compare trend change  
38  
39 between arms in different periods (0-3 months, and 3-6 months). Different statistical analysis  
40  
41 strategies including t-test, Mann-Whitney U test, Chi-square test, linear/generalized linear  
42  
43 regression, and mixed model will be used based on the type and distribution of the outcome  
44  
45 measures. Mediation analysis will be carried out to explore if the weight loss mediates the  
46  
47 intervention effect on glycaemia and estimate indirect and direct effects and the proportion  
48  
49 mediated (how much of the total intervention effect works through weight loss). We expect  
50  
51 some degree of weight loss in all participants, as has been reported for metformin<sup>3 40 41</sup>. The  
52  
53 effect of the diet intervention mediated by metformin adherence on the study outcomes will  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 also be tested. Subgroup analyses can be further performed to explore the intervention effect  
4  
5 in specific sub-cohorts, for instance, the group of participants who have diabetes at baseline,  
6  
7 the group of participants who achieve adherence standard and maintain the desired metformin  
8  
9 dose; the group of participants with BMI >25 kg/m<sup>2</sup> at baseline, etc. The potential impact of  
10  
11 the COVID-19 pandemic on the study outcomes may be explored, including comparisons of  
12  
13 adherence and outcomes across groups of participants enrolled and followed-up pre-, during,  
14  
15 and post- pandemic period. Sensitivity analysis related to the impact of COVID-19 may be  
16  
17 conducted.  
18  
19  
20  
21  
22  
23

### 24 **Laboratory testing**

25  
26  
27 HbA1c is analysed using high performance liquid chromatography (Bio-Rad D-100, Bio-Rad  
28  
29 Laboratories, Inc), plasma glucose using the Cobas 8000 (Roche), and liver and renal function  
30  
31 tests using the Atellica platform (Siemens). Serum lipid profile is analysed by a  
32  
33 spectrophotometric assay (Advia® 2400 Chemistry System [Siemens Medical Solutions  
34  
35 Diagnostics]), with low-density lipoprotein (LDL) calculated using the Friedewald equation.  
36  
37 Metagenomic DNA from the stool samples is purified using DNeasy PowerMag Soil DNA  
38  
39 extraction kit (Qiagen) optimized for Tecan automated platform. Next-Generation Sequencing  
40  
41 (NGS) libraries are prepared using Nextera DNA library prep (Illumina) and sequenced on a  
42  
43 NovaSeq sequencing platform (Illumina). Sequencing is performed with 100bp single end  
44  
45 reads with the depth of 10 million reads per sample. Host DNA is detected by mapping reads  
46  
47 to the Human genome with inclusive parameters, and those reads removed. Bacterial relative  
48  
49 abundance estimation is performed by mapping bacterial reads to species-level genome bins  
50  
51 (SGB) representative genomes<sup>42</sup>. Mapping is performed using Bowtie<sup>43</sup> and abundance  
52  
53 estimated by calculating the mean coverage of unique genomic regions across the 50 percent  
54  
55 most densely covered areas, as previously described<sup>44</sup>.  
56  
57  
58  
59  
60

### **Confidentiality and data storage**

Each participant is associated with an individual program-generated code used to identify their study documents, data and specimens collected during the study. The re-identifiable code is documented in the participant's record and on all study documents. Study data are collected and managed using REDCap electronic data capture tools<sup>45 46</sup> hosted at the Garvan Institute of Medical Research. Some coded data are shared with essential personnel at the Weizmann Institute of Science on institutional Dropbox. Data collected in the form of paper hard copies are kept in locked cabinets and electronic files on a password protected folder with access granted to the Garvan study team. Re-identifiable blood, stool, plasma and serum samples will be kept at the Garvan Institute's freezer facility. All the study questionnaires are disseminated using REDCap.

### **Dissemination of results**

The results of the study will be disseminated to healthcare professionals via open access publications in medical journals, without any restrictions. Upon completion of data analysis, the participants will be invited to an information session at the Garvan Institute of Medical Research with the study Investigator(s) where the findings of the study will be shared and discussed. Individual letters are disseminated to the study participants after the 6 months treatment visit (approximately 7 – 8 months from study enrolment) summarising individual results (e.g. baseline and post treatment weight, body fat, liver fat, HbA1c, fasting, 1-hr and 2-hr plasma glucose concentrations). The participants are encouraged to share their individual results with the GP.

1  
2  
3 **Ethics and dissemination** The study has been approved by the St Vincent's Hospital Human  
4 Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional  
5 Review Board (File 528-3, Rehovot, Israel). Protocol modifications are communicated to the  
6 SVH HREC, the Weizmann IRB, the trial registry (ClinicalTrials.gov), the study investigators  
7 and the study participants (if relevant). De-identified participant data that underlie the findings  
8 reported in the research article will be available immediately following publication, ending 5  
9 years following the article publication, to researchers who provide a methodologically sound  
10 proposal with the aim to achieve the aims reported in the approved project proposal. Data may  
11 be obtained from the Principal Investigator Dorit Samocha-Bonet or Associate Investigator  
12 Jerry Greenfield upon enquiries directed to [d.samochabonet@garvan.org.au](mailto:d.samochabonet@garvan.org.au) or  
13 [j.greenfield@garvan.org.au](mailto:j.greenfield@garvan.org.au).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Authors' contributions**

32 DS-B, JRG, ES and EE contributed to the conception and design of the study, TDH, AG and  
33 DS-B drafted the manuscript, AG and ZL contributed to the study design and the statistical  
34 plan, ZL contributed to the sample size estimation, AG, DK, RR, KT, EC, MD, JRS and T-MH  
35 contributed to the collection of the data. All authors revised and approved the final version of  
36 the manuscript and agree to be accountable for all aspects of the work.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Funding**

48 This work is supported by the Garvan Research Foundation and the St Vincent's Clinic  
49 Foundation, Sydney, Australia.  
50  
51

52 The study sponsor is the Garvan Institute of Medical Research, 384 Victoria Street,  
53 Darlinghurst, NSW 2020, Australia, +61 2 92958100.  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The study sponsor and funding bodies have no role in the study design, collection,  
4 management, analysis, and interpretation of data, writing of the report and the decision to  
5 submit the report for publication.  
6  
7  
8  
9

### 10 11 12 **Conflict of interests**

13  
14 Eran Elinav and Eran Segal are paid consultants of the company DayTwo. Mark Danta has  
15 received travel support and speaker fees from Gilead, Abbvie and Merck. All other authors  
16 declare they have no conflict of interest.  
17  
18  
19  
20  
21  
22

### 23 24 **Acknowledgements**

25  
26 We would like to thank Dr David Jung from the University of NSW (Sydney, Australia) for  
27 assistance in the setup of the REDCap data collection tool and Ms Rebecca Hickey for  
28 performing the Fibroscan measurements.  
29  
30  
31  
32  
33  
34

### 35 36 **Figure legends**

37  
38 **Figure 1:** Screenshots of the smartphone application used daily by participants in the  
39 PREDICT study. Participants randomized to the personalized diet arm receive scores for each  
40 meal. Panels A and B depict two meal options selected by an individual in the study where 2  
41 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial  
42 glycaemic responses. The daily energy intake and macronutrient breakdown are provided to  
43 each of the study participants (C).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Inclusion and Exclusion criteria

<b><i>Inclusion criteria</i></b>
Men and women 20-70 years of age
Prediabetes (IFG* or IGT* and/or HbA1c 5.7 – 6.4% [39 – 46 mmol/mol]) or Individuals diagnosed with T2DM in the last 6 months with HbA1c ≤ 8.0% [64 mmol/mol]
Willingness to provide written informed consent, participate and comply with the study
<b><i>Exclusion criteria</i></b>
Women planning pregnancy during the study or 3 months after study completion
Individuals with type 1 diabetes, neoplastic disease (in the last 3 years), cardiovascular event (-6 months), chronic gastrointestinal disorders
Liver enzymes ALT and/or AST >3 times normal range limit
eGFR**<45 mL/min/1.73m <sup>2</sup>
Normo-glycaemia
HbA1c > 8.0% [64 mmol/mol]
Current or recent (within 24 months) treatment with a glucose lowering medication other than metformin, current or recent (within 3 months) treatment with metformin, current treatment with an oral steroid, immunosuppressive medications, antibiotics (within 3 months)
Alcohol or substance abuse
Participants who had received an investigational new drug within the last 6 months
Participants involved in another clinical study
Participants who have had bariatric surgery
Participants who actively lose weight
Participants with conditions that may interfere with the ability to understand the requirements of the study, refuse treatment with metformin or refuse to use the smartphone application

\*Impaired fasting glucose (IFG): FPG 5.6-6.9 mmol/L and/or impaired glucose tolerance  
(IGT): 2-h plasma glucose during 75-g oral glucose tolerance test (OGTT) 7.8-11.0  
mmol/L

\*\*eGFR calculated as reported<sup>17</sup>

**Table 2:** Study timeline of activities and measurements taken at each of the study events and visits

	<i>Location and time</i>	<i>Measurements</i>
Pre-screening	Phone -35 +/- 10 days	<ul style="list-style-type: none"> <li>● Interview (by an experienced staff)</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c tests</li> </ul>
Screening/ enrolment (Non-fasting)	Clinical Research Facility -30 +/- 15 days	<ul style="list-style-type: none"> <li>● Informed consent signed</li> <li>● Medical history, medications &amp; medical examination</li> <li>● Blood (full blood count, liver and kidney function tests)</li> <li>● Height and weight (BMI calculated)</li> <li>● BIA (RMR)</li> <li>● Blood pressure</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Smartphone app training</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● Stool sample</li> <li>● *Study entry questionnaire</li> </ul>
Baseline (Fasting)	Clinical Research Facility 0, treatment clock starts	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin 3-months' supply with instructions and logbooks</li> <li>● Smartphone app training, according to study arm allocation</li> </ul>
3-months (Fasting)	Clinical Research Facility +90 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● FreeStyle Libre Pro (to remove and send back after 14 days in a pre-paid envelope)</li> <li>● Metformin 3-months' supply with logbooks</li> <li>● Adverse events recording and monitoring</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> </ul>
5.5-months (Non-fasting)	Clinical Research Facility +166 days +/- 10 days	<ul style="list-style-type: none"> <li>● FreeStyle Libre Pro and ActivePal</li> </ul>
	Local pathology	<ul style="list-style-type: none"> <li>● 75 g OGTT and HbA1c</li> </ul>

6-months (Fasting)	Clinical Research Facility +180 +/- 10 days	<ul style="list-style-type: none"> <li>● Anthropometry</li> <li>● Blood pressure, pulse wave analysis</li> <li>● Blood (lipids, HbA1c)</li> <li>● Indirect calorimetry (REE, RQ)</li> <li>● DXA, FibroScan</li> <li>● Metformin- unused pills collected and counted</li> <li>● Adverse events recording</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● #Stool sample</li> <li>● ##Diet Satisfaction Questionnaire</li> </ul>
12-months	Local pathology	<ul style="list-style-type: none"> <li>● HbA1c</li> </ul>
	Home	<ul style="list-style-type: none"> <li>● **12-months questionnaire</li> </ul>

\*Questionnaire includes hunger/fullness, dietary habits and dislikes, physical activity, medications, dietary supplements, personal and family history of disease, food-frequency questionnaire

\*\*Questionnaire includes diet (are you following the diet you were allocated to?), metformin (are you continuing the metformin treatment and dosage) and current body weight

#Gut microbiome features from stool samples collected at 3 and 6 months will be compared to baseline (exploratory outcome)

## The Laboratory for the Study of Human Ingestive Behavior, Pennsylvania State University are the copyright holders of the Diet Satisfaction Questionnaire<sup>28</sup>


Abbreviations: BIA, bio impedance analysis; BMR, basal metabolic rate; DXA, dual-energy X-ray absorptiometry; REE, resting energy expenditure; RQ, respiratory quotient

## References

1. Stefan N, Fritsche A, Schick F, et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. *Lancet Diabetes Endocrinol* 2016;4(9):789-98. doi: 10.1016/S2213-8587(16)00082-6
2. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. *The Lancet* 2016;387(10027):1513-30. doi: 10.1016/s0140-6736(16)00618-8
3. Samocha-Bonet D, Debs S, Greenfield JR. Prevention and Treatment of Type 2 Diabetes – A Pathophysiological-Based Approach. *Trends Endocrinol Metab* 2018;29(6):370-79.
4. Evert AB, Dennison M, Gardner CD, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. *Diabetes Care* 2019;42(5):731-54. doi: 10.2337/dci19-0014
5. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *The Lancet Diabetes & Endocrinology* 2018;6(5):361-69. doi: 10.1016/S2213-8587(18)30051-2
6. Bailey CJ. Metformin: historical overview. *Diabetologia* 2017;60(9):1566-76. doi: 10.1007/s00125-017-4318-z
7. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;41(12):2669-701. doi: 10.2337/dci18-0033
8. Florez JC. The pharmacogenetics of metformin. *Diabetologia* 2017;60(9):1648-55. doi: 10.1007/s00125-017-4335-y
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355(23):2427-43. doi: 10.1056/NEJMoa066224
10. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med* 2012;366(24):2247-56. doi: 10.1056/NEJMoa1109333
11. Lachin JM, Christophi CA, Edelstein SL, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. *Diabetes* 2007;56(4):1153-9. doi: 10.2337/db06-0918
12. Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia* 2017;60(9):1601-11. doi: 10.1007/s00125-017-4361-9
13. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2019;42(Supplement 1):S13-S28. doi: 10.2337/dc19-S002
14. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015;163(5):1079-94. doi: 10.1016/j.cell.2015.11.001
15. Australian Government National Health and Medical Research Council. Australian Guide to Healthy Eating 2015 [updated 01-05-2017. Available from: <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating2019>.
16. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract* 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL
17. Lamb EJ, Tomson CR, Roderick PJ, et al. Estimating kidney function in adults using formulae. *Ann Clin Biochem* 2005;42(Pt 5):321-45. doi: 10.1258/0004563054889936
18. Meyerowitz-Katz G, Seelan S, Gaur P, et al. Detecting the hidden burden of pre-diabetes and diabetes in Western Sydney. *Diabetes Research and Clinical Practice* 2019;151:247-51. doi: <https://doi.org/10.1016/j.diabres.2019.04.019>

19. Saghaei M, Saghaei S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. *J Biomed Sci Eng* 2011;4:734-39.
20. Kozan P, Blythe JC, Greenfield JR, et al. The Effect of Buffering High Acid Load Meal with Sodium Bicarbonate on Postprandial Glucose Metabolism in Humans-A Randomized Placebo-Controlled Study. *Nutrients* 2017;9(8) doi: 10.3390/nu9080861
21. Chen DL, Liess C, Poljak A, et al. Phenotypic Characterization of Insulin-Resistant and Insulin-Sensitive Obesity. *J Clin Endocrinol Metab* 2015;100(11):4082-91. doi: 10.1210/jc.2015-2712
22. Tang A, Coster ACF, Tonks KT, et al. Longitudinal Changes in Insulin Resistance in Normal Weight, Overweight and Obese Individuals. *J Clin Med* 2019;8(5) doi: 10.3390/jcm8050623
23. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2019;156(6):1717-30. doi: 10.1053/j.gastro.2019.01.042
24. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes. *JAMA Netw Open* 2019;2(2):e188102. doi: 10.1001/jamanetworkopen.2018.8102
25. Australian Food, Supplement and Nutrient Database (AUSNUT) 2011-2013: Food Standards Australia New Zealand.
26. Grech A, Rangan A, Allman-Farinelli M. Macronutrient Composition of the Australian Population's Diet; Trends from Three National Nutrition Surveys 1983, 1995 and 2012. *Nutrients* 2018;10(8):1045. doi: 10.3390/nu10081045
27. Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr* 1990;51(2):241-7. doi: 10.1093/ajcn/51.2.241
28. James BL, Loken E, Roe LS, et al. Validation of the Diet Satisfaction Questionnaire: a new measure of satisfaction with diets for weight management. *Obes Sci Pract* 2018;4(6):506-14. doi: 10.1002/osp4.299
29. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther* 2009;11 Suppl 1:S55-67. doi: 10.1089/dia.2008.0132
30. Marjot T, Moolla A, Cobbold JF, et al. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. *Endocrine Reviews* 2019 doi: 10.1210/edrev/bnz009
31. Green CJ, Marjot T, Tomlinson JW, et al. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? *Diabetes Obes Metab* 2018 doi: 10.1111/dom.13592
32. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012;55(4):885-904. doi: 10.1007/s00125-011-2446-4
33. Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. *Medicine (Baltimore)* 2016;95(32):e4529. doi: 10.1097/MD.0000000000004529
34. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. *Drug Saf* 1999;20(6):489-503.
35. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. *Diabetologia* 2016;59(3):426-35. doi: 10.1007/s00125-015-3844-9
36. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *British Medical Journal* 2010;340:c2181. doi: 10.1136/bmj.c2181

- 1  
2  
3 37. Reinstatler L, Qi YP, Williamson RS, et al. Association of Biochemical B12 Deficiency With  
4 Metformin Therapy and Vitamin B12 Supplements. *Diabetes Care* 2012;35(2):327-33. doi:  
5 10.2337/dc11-1582  
6  
7 38. DeFronzo R, Fleming GA, Chen K, et al. Metformin-associated lactic acidosis: Current perspectives  
8 on causes and risk. *Metabolism* 2016;65(2):20-29. doi:  
9 <https://doi.org/10.1016/j.metabol.2015.10.014>  
10  
11 39. Jönsson T, Granfeldt Y, Ahrén B, et al. Beneficial effects of a Paleolithic diet on cardiovascular risk  
12 factors in type 2 diabetes: a randomized cross-over pilot study. *Cardiovascular Diabetology*  
13 2009;8(1):35. doi: 10.1186/1475-2840-8-35  
14  
15 40. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes  
16 with lifestyle intervention or metformin. *The New England Journal of Medicine*  
17 2002;346(6):393-403. doi: 10.1056/NEJMoa012512  
18  
19 41. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight  
20 loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374(9702):1677-86.  
21 doi: 10.1016/S0140-6736(09)61457-4  
22  
23 42. Pasolli E, Asnicar F, Manara S, et al. Extensive Unexplored Human Microbiome Diversity Revealed  
24 by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell*  
25 2019;176(3):649-62.e20. doi: 10.1016/j.cell.2019.01.001 [published Online First: 01/17]  
26  
27 43. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature Methods*  
28 2012;9(4):357-59. doi: 10.1038/nmeth.1923  
29  
30 44. Korem T, Zeevi D, Suez J, et al. Growth dynamics of gut microbiota in health and disease inferred  
31 from single metagenomic samples. *Science* 2015;349(6252):1101-06. doi:  
32 10.1126/science.aac4812  
33  
34 45. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community  
35 of software platform partners. *Journal of Biomedical Informatics* 2019;95:103208. doi:  
36 <https://doi.org/10.1016/j.jbi.2019.103208>  
37  
38 46. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-  
39 driven methodology and workflow process for providing translational research informatics  
40 support. *Journal of Biomedical Informatics* 2009;42(2):377-81. doi:  
41 <https://doi.org/10.1016/j.jbi.2008.08.010>  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Screenshots of the smartphone application used daily by participants in the PREDICT study. Participants randomized to the personalized diet arm receive scores for each meal. Panels A and B depict two meal options selected by an individual in the study where 2 iso-caloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

190x112mm (300 x 300 DPI)



# Participant Information Sheet/Consent Form

**Interventional Study** - *Adult providing own consent*

*Garvan Institute of Medical Research*

<b>Title</b>	<i>Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk</i>
<b>Short Title</b>	<i>Personalised medicine in prediabetes (PREDICT)</i>
<b>Protocol Number</b>	<i>17/080</i>
<b>Project Sponsor</b>	<i>Garvan Institute of Medical Research</i>
<b>Coordinating Principal Investigator/ Principal Investigator</b>	<i>Dr Dorit Samocha-Bonet</i>
<b>Associate Investigator(s)</b> <i>(if required by institution)</i>	<i>Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu, Ms Godneva</i>
<b>Location</b> <i>(where CPI/PI will recruit)</i>	<i>Garvan Institute of Medical Research, Sydney</i>

## Part 1 What does my participation involve?

### 1 Introduction

Type 2 diabetes affects 8.5% of the world's adult population. Prediabetes is a condition developing many years before type 2 diabetes, and is diagnosed by raised glucose (sugar) in the blood stream, either when measured first thing in the morning (fasting) or when measured after a meal. Approximately 30 - 40 % of the world's adult population is affected by prediabetes. Individuals with prediabetes have a higher risk of diabetes and heart disease. Treatment with the most commonly used sugar-lowering medication metformin does not always improve blood sugar levels in individuals with prediabetes or type 2 diabetes. This means that after the treatment, blood sugar concentrations are still higher than normal and the risk of diabetes remains increased.

You are invited to take part in this research project because you either have prediabetes or you have recently been diagnosed with type 2 diabetes. The research project is testing the effect of a personalised diet combined with the medication metformin on sugar control, body weight, and other risk factors.

This Participant Information Sheet/Consent Form tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the research.

Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your General Practitioner.

Participation in this research is voluntary. If you don't wish to take part, you don't have to. You will receive the best possible care whether or not you take part.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 If you decide you want to take part in the research project, you will be asked to sign the consent  
5 section. By signing it you are telling us that you:

- 6  
7 • Understand what you have read  
8  
9 • Consent to take part in the research project  
10  
11 • Consent to have the tests and treatments that are described  
12  
13 • Consent to the use of your personal and health information as described

14 You will be given a copy of this Participant Information and Consent Form to keep.  
15  
16

## 17 **2 What is the purpose of this research?**

18  
19 The overall aim of the study is to improve the treatment of individuals with prediabetes or type 2  
20 diabetes with a special nutritional intervention.

21 In particular, we would like to find out whether a personalised diet administered with a medication  
22 commonly used to treat diabetes named metformin will achieve better results when compared  
23 with a low fat low sugar diet (the type of diet commonly recommended to individuals with  
24 prediabetes or type 2 diabetes) administered with metformin.

25  
26 We will compare the effects of the different treatments on sugar control, body weight, body fat,  
27 blood lipids, blood pressure and the amount of fat in the liver.  
28  
29

30 The medication used in this research project and listed below is approved in Australia to treat  
31 type 2 diabetes. While it is not routinely prescribed to treat prediabetes, metformin has been used  
32 to treat individuals with prediabetes in a large American trial and has been proven to be safe in  
33 individuals with prediabetes (the Diabetes Prevention Program, United States).  
34  
35

### 36 The following medication/treatments will be used in the study:

- 37  
38 1. Metformin Extended Release (XR) + Low fat low sugar diet (“healthy” diet).  
39  
40 2. Metformin XR + “Personalised diet” (see further details below).  
41

42 In both study arms, if your weight falls in the overweight or obese category (i.e. body mass index  
43 [BMI] > 25 kg/m<sup>2</sup>), we will recommend a reduction of approximately 500 Kcal/d from the dietary  
44 energy you are currently on. This will result in moderate weight loss. If your weight is within the  
45 recommended BMI range (equals to or under 25 kg/m<sup>2</sup>), we will recommend the same level of  
46 energy intake you are currently consuming. This will result in weight maintenance.  
47  
48

### 49 Method of administration of medication:

50 Metformin XR – Daily tablet (oral ingestion 1500 mg/d) with evening meal  
51  
52

### 53 Method of administration of diet:

54 The diet will be delivered using a smartphone application. You will be guided and supported by  
55 an Accredited Practising Dietitian  
56  
57  
58  
59  
60

1  
2 You will be participating in a randomised research project. Sometimes we do not know which  
3 treatment is best for treating a condition. To find out, we need to compare different treatments.  
4 We put people into groups and give each group a different treatment. The results are compared  
5 to see if one is better than the other. To try to make sure the groups are the same, each participant  
6 is put into a group by chance (random).  
7

8  
9  
10 We will administer 1 medication in combination with 2 different nutritional interventions. There is  
11 a 1 in 2 chance that you will be allocated to each study arm.  
12

13  
14 This research has been initiated by the study doctors, Dr Dorit Samocha-Bonet and Professor  
15 Jerry R Greenfield.  
16

17  
18 This research has been funded by a Foundation requesting to remain anonymous, funds from the  
19 Garvan Research Foundation and a grant from the St Vincent's Clinic Foundation.  
20

### 21 22 **3 What does participation in this research involve?**

23  
24 If you agree to participate in this study, you will be asked to sign the Participant Consent Form.  
25 We will ask you to sign a separate Participant Consent Form before having blood tests at a  
26 commercial pathology.  
27

28  
29 Participation in this project will involve the following:

30  
31 Initially we will ask you questions regarding your health and medical history over the telephone.  
32 If it sounds like you may be eligible for the study we will ask you to attend a commercial pathology  
33 service in your area for an oral sugar test (oral glucose tolerance test), testing your blood sugar  
34 after drinking a sugary drink, and a blood test measuring glycated haemoglobin (HbA1c, a marker  
35 of average blood sugar levels over the past 3 months). This involves having a blood sample taken  
36 prior to drinking a sugary drink (containing 75 grams of sugar), followed by blood samples taken  
37 one and two hours later.

38  
39 You will be asked to remain in the blood collection centre for the duration of the test (2 hours).

40  
41 Overall the commercial Pathology will collect 20 mL (about 1.5 tablespoons) of blood.  
42

43  
44 These blood tests will tell us if you have diabetes or prediabetes and will help us determine  
45 whether or not you are eligible to participate in our study. We will call you and discuss the test  
46 results and your eligibility to participate in the study within 1 week. We will provide you with a letter  
47 summarising the results which you will be able to share with your General Practitioner.  
48

49  
50 If you are eligible to participate in the study, we will invite you to a Screening / Enrolment visit. We  
51 will send you a special kit for collection of stool at home, with detailed instructions on how to  
52 collect the sample. We will ask you to bring the sample with you to your next visit.

53  
54 Prior to the study we will ask you to reply to questionnaires asking about your usual eating and  
55 physical activity habits and your health. You will be asked to download a smartphone application  
56 which you will use during the study.  
57  
58  
59  
60

### Screening / Enrolment visit (approximately 1.5 hours)

- We will ask that you arrive to the Clinical Research Facility (clinic) at the Garvan Institute of Medical Research, Darlinghurst. During this visit you will have time to ask questions and if you agree to participate, you will sign the consent form. You will change into a hospital gown. The study doctor will ask you about your health and perform a physical examination. We will measure body weight and height, blood pressure, waist and hip circumferences, and body fat composition (estimated using Tanita scales).
- Blood will be drawn to assess your liver and kidney health and your blood cells count. The volume of blood that will be taken during this visit is 20 mL (about 1.5 tablespoons).
- We will attach a small device (sensor) that measures sugar levels for a period of 14 days to your arm. The size of the device is of a fifty cents coin. We will apply the sensor on to the back of the upper arm with a disposable applicator. When the sensor is applied, a thin, flexible sterile fibre is inserted just under the skin. It is held in place with a small adhesive pad. Most people feel no pain when applying the sensor. You will not have to do anything while the sensor measures sugar level. All the information will be stored in the sensor. We will also attach a physical activity sensor. Both sensors are designed to wear for up to 14 days. We will ask that you remove and send the sensors to us after 14 days in a prepaid envelop. You will have your usual diet and record what you eat in a smartphone application.

During this visit, or soon after, you will meet the dietitian (face-to-face or using a video meeting tool like Zoom or Skype). The dietitian will teach you to use the smartphone application. You will use this application to log the food that you eat, and optionally, to log your physical activity (type and duration), and the medications that you take. We will provide you with a light meal at the end of this visit.

After this visit we will randomise you to one of 2 treatment arms.

### Baseline visit (2 hours, we will ask that you fast from 10 pm the night before this visit)

The baseline visit will be performed approximately 6 – 8 weeks after the Screening / Enrolment visit. You will arrive at the clinic in the morning. The following measurements and procedures will take place,

- You will undergo dual-energy X-ray absorptiometry (DXA) at St Vincent's Hospital (next door to the Garvan). DXA will be used to evaluate the amount of fat in your body.
- Liver fibroscan, performed at St Vincent's Hospital. This measurement will provide information about the amount of fat and fibrosis (scarring) in the liver.
- A team member will measure your weight, height, waist and hip circumference and blood pressure, while wearing a hospital gown.
- We will measure how many calories you burn while resting using a plastic hood placed over your shoulders while you are resting in bed (takes 30 minutes).
- We will measure the stiffness of an artery in the wrist (radial artery) using a non-invasive device which looks like a pen. This measurement takes approximately 5 minutes and will provide information about the stiffness of your arteries.
- We will collect blood samples. Overall we will collect 20 mL (2 tablespoons) of blood during this visit.
- We will collect a sample of bacteria from the mouth by swabbing a special collection stick over the gums. We will store this sample for testing the effect of the treatment on the mouth bacteria.

1  
2  
3 At the end of the visit we will provide you with 3-months' worth of medication and medication  
4 logbooks. We will ask you to take the metformin every evening **with dinner**. You will start with  
5 taking a small dose and depending on how you feel (some people experience diarrhoea, nausea,  
6 and flatulence, mostly at the beginning of the treatment), we will gradually ask you to increase the  
7 dose until you reach the target dose. You will be guided by the study investigator / dietitian  
8 regarding using the smartphone application during the treatment period.

9 We will call you at a time of your convenience once a month or fortnightly to follow up on your  
10 progress with the treatment. We will ask you how you feel and whether you have any general  
11 health changes that you would like to report (whether you think they are related or unrelated to  
12 the treatment), as well as any changes to your usual medications, other than the study treatment..  
13 Follow-up may be performed using Zoom, Skype, text, or over the phone.

14  
15  
16 4-months visit (2 hours, similar to the baseline visit, we will ask that you fast from 10 pm the night  
17 before this visit)

18  
19 This visit will be similar to the baseline visit (described above) and include the same procedures,  
20 except that you will not have a DXA and fibroscan. We will attach another sugar sensor to the  
21 arm, and ask you to send it back to us in a prepaid envelope after 14 days. During this visit we  
22 will also take a blood sample that will be used to measure the level of metformin in the blood. We  
23 will ask you to bring the medication log books.

#### 24 25 26 6.5-months visits

27 We will invite you to the Garvan to attach the sugar sensor and activity monitor. We will refer you  
28 again to perform a sugar challenge test, as you have done before the treatment in a commercial  
29 pathology in your area. We will provide you with a special kit for collection of stool and ask you to  
30 bring the sample with you to your next visit at the Garvan.

#### 31 32 33 7-months (end-of treatment, performed 6 months from the start of the treatment) visit

34 Identical to the baseline visit, with the exception that we will collect a blood sample to measure  
35 the concentration of the medication in the blood and will ask you to bring back the medication and  
36 the logbooks.

#### 37 38 39 12-months survey and blood test (includes a questionnaire and a blood test at a local commercial 40 pathology)

41 6-months after the completion of the treatment, we will send you a survey and ask you to tell us  
42 what your current body weight is, whether you remained on the diet, and whether you are treated  
43 with a sugar-lowering medication (and if relevant to specify the medication and dose). We will  
44 also ask you to perform a blood test in a commercial pathology in your area. The blood test will  
45 measure sugar control and does not require you to be fasting. You will not have to visit the Garvan  
46 for this event.

47  
48  
49 In summary, you will be required to visit and maintain contact with the study team over a period  
50 of approximately 6 months, while you're treated. The overall duration of the study is approximately  
51 13 – 14 months.

52  
53  
54 There are no costs associated with participating in this research project, nor will you be paid. All  
55 medications, dietary advice, tests, including all blood tests, some meals and medical care required  
56 as part of the research project will be provided to you free of charge.

57  
58  
59 Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
60 PICF version 11 1/06/20

1  
2  
3  
4 You will be provided a \$100 AUD retail voucher. Parking will be provided at the Garvan carpark  
5 on days of visits.  
6  
7

8 If you have a General Practitioner, we strongly recommend that you inform them of your  
9 participation in this research project.  
10  
11

#### 12 **4 What do I have to do?**

13  
14 During the study period, the study team will instruct you regarding what you should be doing  
15 before each of the visits/study events. For example, we may ask you to avoid drinking alcohol or  
16 to avoid vigorous physical activity before some of the visits.

17  
18 During the study you will be able to continue taking your regular medications, but if you will require  
19 a sugar-lowering medication other than metformin (prescribed in the study), you will have to  
20 withdraw from the study.

21  
22 We will ask you to inform us if and when you started taking a new medication, or if and when there  
23 has been a change in dose of any medication you are taking regularly.

24 During the study we will ask you not to donate blood or participate in another study.

25  
26 We will expect you to be compliant with the study instructions and if any problem arises, we expect  
27 that you will contact us.  
28  
29

#### 30 **5 Other relevant information about the research project**

31  
32 We plan to enrol approximately 260 men and women to this study. All participants will be enrolled  
33 at a single site, the Garvan Institute of Medical Research, Darlinghurst, Sydney.

34 Some tests will be performed at the adjacent St Vincent's Hospital.

35  
36 The project involves researchers from a number of academic institutes working in collaboration.  
37 The research team includes researchers and endocrinologists from the Diabetes Division at the  
38 Garvan Institute of Medical Research and St Vincent's Hospital (Sydney), researchers from the  
39 Endocrinology Department at Blacktown & Mount Druitt Hospital (Sydney), and researchers from  
40 the Immunology Department and the Computer Science Department at the Weizmann Institute of  
41 Science (Israel).  
42  
43

#### 44 **6 Do I have to take part in this research project?**

45  
46 Participation in any research project is voluntary. If you do not wish to take part, you do not have  
47 to. If you decide to take part and later change your mind, you are free to withdraw from the project  
48 at any stage.

49  
50 If you do decide to take part, you will be given this Participant Information and Consent Form to  
51 sign and you will be given a copy to keep.

52  
53 Your decision whether to take part or not to take part, or to take part and then withdraw, will not  
54 affect your routine treatment, your relationship with those treating you or your relationship with  
55 the Garvan Institute of Medical Research or St Vincent's Hospital.  
56  
57

#### 58 **7 What are the alternatives to participation?**

59  
60 Other treatment options for your condition are available; these include dietary counselling and  
physical activity advice, and / or a sugar-lowering medication. Your study doctor will discuss

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2 these options with you before you decide whether or not to take part in this research project. You  
3 can also discuss the options with your General Practitioner.  
4  
5

## 6 **8 What are the possible benefits of taking part?**

7  
8 We cannot guarantee or promise that you will receive any benefits from this research. You will  
9 have access to a medication regulating blood sugar level that is primarily offered to type 2  
10 diabetes patients and you may lose weight (1 – 5 kg).  
11  
12

13 We are hoping that the information generated in this study will help improve treatment of your  
14 condition.  
15  
16

## 17 **9 What are the possible risks and disadvantages of taking part?**

18  
19 Taking a medication may involve some risks, as detailed below. We will monitor any adverse  
20 events on a regular basis and you will have access to a clinical staff member at all time during  
21 the study.  
22

23 There are potential risks relating to the procedures we will utilise in the course of the study. We  
24 have listed them below.  
25  
26

### 27 Risks related to the medication

28 Medical treatments often cause side effects. You may have none, some or all of the effects listed  
29 below, and they may be mild, moderate or severe. If you have any of these side effects, or are  
30 worried about them, talk with your study doctor. Your study doctor will also be looking out for side  
31 effects regularly.  
32  
33

34 In case you need to have any diagnostic procedure requiring contrast, most radiological services  
35 recommend routine withholding of metformin for 48 hours prior to and after the procedure. Please  
36 let your doctor know that you are taking metformin.  
37  
38

39 There may be side effects that the researchers do not expect and that may be serious. Tell your  
40 study doctor immediately about any new or unusual symptoms that you get.  
41  
42

43 Many side effects go away shortly in the first few weeks of the treatment or after the treatment  
44 ends. However, sometimes side effects can be serious. If a severe side effect or reaction occurs,  
45 your study doctor may need to stop your treatment. Your study doctor will discuss the best way  
46 of managing any side effects with you.  
47  
48

49 The medication we will administer in the present study, metformin, has been administered to  
50 people with type 2 diabetes over many years and has proven to be generally safe. We have listed  
51 below the potential side effects of the medication administered.  
52  
53

- 54 • Mild gastrointestinal symptoms such as diarrhoea, nausea, vomiting, abdominal pain and  
55 loss of appetite are the most frequent reactions to metformin, occurring in approximately  
56 10% of individuals (10 in 100), especially during the initial treatment period. These  
57 symptoms are generally transient and resolve spontaneously during continued treatment.
- 58 • Taste disturbance may occur in 3% (3 in 100).  
59  
60

- Rare adverse reactions occur in less than 0.01% (1 in 10000) of individuals include,
  - Lactic acidosis, often with mild nonspecific symptoms such as feeling of sickness, sleepiness, shortness of breath, and nonspecific abdominal distress.
  - Abnormalities of liver tests have been reported. Liver function tests will be monitored during the treatment.

### *Risks related to the personalised nutrition*

The Personalised Nutrition Project diet (<http://newsite.personalnutrition.org/WebSite/Home.aspx>) has been trialled in various studies for over 5 years by the study co-Investigators Professors Elinav and Segal from the Weizmann Institute in Israel. The nutritional recommendation is different from person to person. This is because it is based on the individual's features and measurements, including sugar rise in response to food. Co-Investigators Elinav and Segal have reported that the individual response depends on blood markers, body measurements and different features of microorganisms in the gut. The individual food recommendation is based on "real" foods.

The effects of the personalised diet on the level of blood lipids in individuals with prediabetes and type 2 diabetes is being investigated. If we find that the baseline level of low-density lipoprotein (LDL)-cholesterol in the blood is elevated, a modified personalised diet containing less saturated fat (the type of dietary fat known to increase the level of LDL) will be prescribed.

### *Risks relating to procedures*

#### Blood sampling

You may have pain, light-headedness, minor infection, bleeding or bruising at the sites of the blood sampling; however, the staff will use proper technique while drawing blood samples in order to reduce the risk for these unwanted effects. These effects are usually temporary, are easily treated, and are expected to resolve completely.

#### Dual-energy X-ray absorptiometry (DXA) scan

This research study involves exposure to a very small amount of radiation. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose from this study is about 0.04 mSv. At this dose level, no harmful effects of radiation have been demonstrated as any effect is too small to measure. The risk is believed to be minimal.

#### Fibroscan test

The fibroscan is a non-invasive method of assessing liver scarring, termed fibrosis. The test is performed at the bedside in a clinic. A mechanical pulse is generated at the skin surface, which is propagated through the liver. The velocity of the wave is measured by ultrasound. The speed of this wave correlates with the stiffness of the liver, which in turn reflects the degree of fibrosis – the stiffer the liver is, the greater the degree of fibrosis. This test also estimates the amount of fat in the liver. This test utilises an ultrasound device and carries no risk.

#### Body sugar monitoring

The device we use in the study is used to monitor blood glucose levels, mostly in diabetes patients. Most people feel no pain when applying the sensor. The sensor is designed for a safe wear of up to 14 days. You can shower and exercise while wearing the sensor. Some individuals

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

develop a skin reaction around the device on the arm. This typically resolves spontaneously over time; an over the counter cream may be recommended if the skin reaction persists. If you experience a skin reaction, we will likely decide to omit this measurement from the follow-up events.

### Indirect calorimetry

A clear plastic hood is placed loosely over your head. Room air flows through the hood and the machine measures how much oxygen you are using and how much carbon-dioxide you produce. This test carries no significant risk. However, some participants may experience claustrophobia. If this occurs, the hood will be removed immediately.

### Arterial stiffness

The stiffness of an artery in your wrist will be measured using a small device, looking like a pen, by applying light pressure to your wrist. There are no risks related to this method.

### Tanita scales

The scales estimate how much energy your body requires based on your body fat and muscle composition. When you stand on a Tanita monitor, a very low, safe electrical signal is sent from four metal electrodes through your feet to your legs and abdomen. The electrical signal passes quickly through water that is present in muscle tissue but meets resistance when it hits fat. This resistance, known as impedance, is measured and used in validated equations to calculate body composition. This measurement will take around 20 seconds. Information from the Tanita measurement will be used to estimate your recommended daily energy intake.

People with an electronic medical implant, such as a pacemaker, should not use a body composition monitor because the electrical signal travelling through the body may interfere with its operation.

### **Pregnancy**

The effects of the medication metformin on the unborn child and on the newborn baby are not known. Because of this, it is important that study participants are not pregnant or breast-feeding and do not become pregnant during the course of the research project. You must not participate in this study if you are pregnant or trying to become pregnant, or breast-feeding. If you are female and child-bearing is a possibility, you will be required to undergo a pregnancy test prior to commencing the research project, and before each of the DXA scans.

Female participants must avoid pregnancy during the course of the research and for a period of 3 months after completion of the research project. You should discuss methods of effective contraception with your study doctor.

If you do become pregnant whilst participating in the research project, you should advise your study doctor immediately. Your study doctor will withdraw you from the research project and advise on further medical attention should this be necessary. You must not continue in the research if you become pregnant.

If you are a male, it is safe to father a child or donate sperm whilst taking the study medication.

## **10 What will happen to my test samples?**

During the study we will store blood and stool samples in -80°C freezer. In this research project, collecting blood and stool samples are mandatory.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2 The blood, oral and stool samples collected are for research purposes, as specified in this  
3 document.  
4

5 All the samples we will collect from you will be coded so they are not identifiable as your sample.  
6 Your identification linked to the sample code will be stored on a password protected computer  
7 and physical hardcopies in a locked filing cabinet at the Garvan Institute of Medical Research.  
8 Only staff involved in this study at the site will have access to this data to maintain  
9 privacy/confidentiality.  
10

11 Some analyses in blood will be performed in commercial Laboratories or at St Vincent's Hospital.  
12 These specimens will be de-identified (coded). Your clinical information will not be sent with the  
13 specimens. The results of these analyses will be returned to the Investigators at the Garvan  
14 Institute of Medical Research. The external sites may retain your re-identifiable, analysed data in  
15 their records. After analysis of your specimen is complete, these external sites will destroy any  
16 remaining tissue or return remaining sample to us for storage.  
17

18 We will store the samples we collect for 15 years.

19 Some samples of your blood, mouth and stool obtained for the purpose of this research project  
20 will be transferred to the Weizmann Institute of Science in Israel. These samples will be de-  
21 identified by coding. Information such as your gender, age, ethnicity, medical history, medications,  
22 food sensitivities and eating habits will be shared with researchers at the Weizmann Institute for  
23 planning your diet. This information will be de-identified.  
24

25 Your samples will not be sold and the Garvan Institute of Medical Research will not knowingly  
26 transfer your samples to anyone who has expressed intent to sell the samples.  
27  
28

### 29 **11 What if new information arises during this research project?**

30 Sometimes during the course of a research project, new information becomes available about the  
31 treatment that is being studied. If this happens, your study doctor will tell you about it and discuss  
32 with you whether you want to continue in the research project. If you decide to withdraw, your  
33 study doctor will make arrangements for your regular health care to continue. Also, on receiving  
34 new information, your study doctor might consider it to be in your best interests to withdraw you  
35 from the research project. If this happens, he / she will explain the reasons and arrange for your  
36 regular health care to continue.  
37

38 When we assess your suitability to participate in the study we may uncover a medical condition  
39 of which you may be unaware. While we may decide that you are not able to participate in the  
40 study because of this new condition, we will refer you to your General Practitioner for further  
41 investigation and management.  
42

43 If during the screening visit we diagnose a previously unknown condition, for example type 2  
44 diabetes, this may affect insurance in the future.  
45  
46

### 47 **12 Can I have other treatments during this research project?**

48 Whilst you are participating in this research project, you may not be able to take some of the  
49 medications or treatments you have been taking for your condition or for other reasons. It is  
50 important to tell your study doctor and the study staff about any treatments or medications you  
51 may be taking, including over-the-counter medications, vitamins or herbal remedies. You should  
52 also tell your study doctor about any changes to these during your participation in the research  
53 project.  
54  
55

### 56 **13 What if I withdraw from this research project?**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

If you decide to withdraw from the project, please notify a member of the research team before you withdraw. This notice will allow that person or the research supervisor to discuss any health risks or special requirements linked to withdrawing.

If you do withdraw your consent during the research project, the study doctor and relevant study staff will not collect additional personal information from you, although personal information already collected will be retained to ensure that the results of the research project can be measured properly and to comply with law. You should be aware that data collected by the sponsor up to the time you withdraw will form part of the research project results. If you do not want them to do this, you must tell them before you join the research project.

#### **14 Could this research project be stopped unexpectedly?**

Sometimes research projects trialling medications need to stop prematurely because of unexpected side effects. However, this research project is unlikely to be stopped unexpectedly, because the medication administered has been studied and is routinely administered in type 2 diabetes and to a lesser degree in people with prediabetes. The medication administered here has been proven safe in type 2 diabetes patients.

#### **15 What happens when the research project ends?**

The medication administered in the present study will not be available after the research finishes through the study (but may be prescribed by your General Practitioner if required and decided). At study completion, you will be able to continue using the app and follow your study diet. We will offer you nutritional counselling on healthy lifestyle that will help you maintain a healthy body weight and decrease your risk of developing diabetes.

After you complete the study treatment (approximately 7 months from when you start), we will send you a detailed results letter, with measurements collected at baseline and after the 6 months' treatment, that will include your weight, BMI, blood pressure, fasting blood sugar, glycated haemoglobin (HbA1c), and the amount of fat in your body and liver.

After we finalise the study of all the participants and analyse the data (approximately in 2022), we will invite you to an information evening at the Garvan Institute of Medical Research (Darlinghurst, Sydney) to share with you the study findings. You will have opportunity to discuss the findings with the study Investigators.

## **Part 2 How is the research project being conducted?**

#### **16 What will happen to information about me?**

By signing the consent form you consent to the study doctor and relevant research staff collecting and using personal information about you for the research project. Any information obtained in connection with this research project that can identify you will remain confidential. All the clinical information and the data that will be collected will be coded. It can be re-identified; however, your identification matching your code will be secured, accessible only by research staff. Data allowing re-identification of your data will be kept on a password protected computer and a locked filing cabinet at the Garvan Institute of Medical Research. Only staff involved in this study will have access to this data to maintain privacy/confidentiality.

All data will be stored for 15 years, after which it will be destroyed.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 Your information will only be used for the purpose of this research project and it will only be  
5 disclosed with your permission, except as required by law.

6 Information about you may be obtained from your health records held at this and other health  
7 services for the purpose of this research. By signing the consent form you agree to the study team  
8 accessing health records if they are relevant to your participation in this research project.  
9

10 Your health records and any information obtained during the research project are subject to  
11 inspection (for the purpose of verifying the procedures and the data) by the relevant authorities  
12 and authorised representatives of the Sponsor, the Garvan Institute of Medical Research, the  
13 institution relevant to this Participant Information Sheet, St Vincent's Hospital, Sydney, or as  
14 required by law. By signing the Consent Form, you authorise release of, or access to, this  
15 confidential information to the relevant study personnel and regulatory authorities as noted above.  
16

17 It is anticipated that the results of this research project will be published and presented in a variety  
18 of forums. In any publication and presentation, information will be provided in such a way that you  
19 cannot be identified. No individual data will be reported in any publication or presentation.  
20

21 Data collected in the study may be made available to other researchers. The data will be coded  
22 and will not reveal your personal details. The data will be made available subject to a review of  
23 applications submitted by interested researchers performed by the study Investigators Dorit  
24 Samocha-Bonet and/or Jerry R Greenfield. Only researchers aiming to achieve the aims of the  
25 project will be considered. Upon approval, access to the de-identified data will be available for a  
26 period of 5 years after publishing the study findings.  
27

28 Information about your participation in this research project may be recorded in your health  
29 records.  
30

31 In accordance with relevant Australian privacy and other relevant laws, you have the right to  
32 request access to your information collected and stored by the research team. You also have the  
33 right to request that any information with which you disagree be corrected. Please contact the  
34 study team member named at the end of this document if you would like to access your  
35 information.  
36  
37  
38

39 Any information obtained for the purpose of this research project that can identify you will be  
40 treated as confidential and securely stored. It will be disclosed only with your permission, or as  
41 required by law.  
42  
43

## 44 **17 Complaints and compensation**

45 If you suffer any injuries or complications as a result of this research project, you should contact  
46 the study team as soon as possible and you will be assisted with arranging appropriate medical  
47 treatment. If you are eligible for Medicare, you can receive any medical treatment required to treat  
48 the injury or complication, free of charge, as a public patient in any Australian public hospital.  
49

50 In the event of loss or injury, the parties involved in this study have agreed to provide  
51 compensation if the participants' injury or complication is caused by the study procedures or by  
52 the negligence of any of the parties involved in the study. If you suffer any distress or  
53 psychological injury as a result of this study, you should contact the study team as soon as  
54 possible, who will assist you in arranging appropriate treatment and support.  
55  
56  
57

## 58 **18 Who is organising and funding the research?**

59 This research project is being conducted by Dr Samocha-Bonet and Professor Greenfield.  
60

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3 Dr Samocha-Bonet, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu and Ms Godneva have no conflict  
4 of interest to disclose.

5 The study co-Investigators, Prof Eran Elinav and Prof Eran Segal of the Weizmann Institute of  
6 Science are paid consultants of the company DayTwo. DayTwo, established in Israel, provides  
7 personalised nutrition to individuals. The product is based on the technology arising from research  
8 conducted by Prof Elinav and Prof Segal at the Weizmann Institute of Science. The research  
9 findings were published in the journal *Cell* in 2015.

10 The Garvan Institute of Medical Research may benefit financially from this research project if, for  
11 example, the project assists Garvan Institute of Medical Research to obtain approval for a new  
12 treatment tool.

13  
14 By taking part in this research project you agree that samples of your blood or stool (or data  
15 generated from analysis of these materials) may be provided to the Weizmann Institute of Science  
16 (Israel).

17  
18 The Weizmann Institute of Science may directly or indirectly benefit financially from your samples  
19 or from knowledge acquired through analysis of your samples.

20  
21 You will not benefit financially from your involvement in this research project even if, for example,  
22 your samples (or knowledge acquired from analysis of your samples) prove to be of commercial  
23 value to the Garvan Institute of Medical Research.

24  
25 In addition, if knowledge acquired through this research leads to discoveries that are of  
26 commercial value to the Garvan Institute of Medical Research or the Weizmann Institute of  
27 Science, the study doctors or their institutions, there will be no financial benefit to you or your  
28 family from these discoveries.

29  
30 No member of the research team will receive a personal financial benefit from your involvement  
31 in this research project (other than their ordinary wages).

### 32 33 **19 Who has reviewed the research project?**

34  
35 All research in Australia involving humans is reviewed by an independent group of people called  
36 a Human Research Ethics Committee (HREC). The ethical aspects of this research project have  
37 been approved by the HREC of St. Vincent's Hospital Sydney (HREC reference number 17/080).

38  
39  
40 This project will be carried out according to the *National Statement on Ethical Conduct in Human*  
41 *Research (2007)*. This statement has been developed to protect the interests of people who agree  
42 to participate in human research studies.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 20 Further information and who to contact

The person you may need to contact will depend on the nature of your query.

If you want any further information concerning this project or if you have any medical problems which may be related to your involvement in the project (for example, any side effects), you can contact the principal study doctor Dr Dorit Samocha-Bonet on 02-9295 8309 or 0416-316 111.

### Clinical contact person

Name	Professor Jerry R Greenfield
Position	Associate Investigator
Telephone	SVH Switchboard 8382 1111, ask to page Prof Jerry Greenfield <b>24-hour medical contact</b>
Email	<a href="mailto:predict@garvan.org.au">predict@garvan.org.au</a>

### Research Nurse

Name	Ms Renee Richens
Position	Research Nurse
Telephone	02-92958215 (Working days: Tuesday, Wednesday, Thursday)
Email	<a href="mailto:predict@garvan.org.au">predict@garvan.org.au</a>

For matters relating to research at the site at which you are participating, the details of the local site complaints person are:

### Complaints contact person

Name	Research Office Manager
Position	Research Office Manager
Telephone	02 8382 4960
Email	SVHS.Research@svha.org.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

### Reviewing HREC approving this research and HREC Research Officer details

Reviewing HREC name	St Vincent's Hospital HREC
HREC Research Officer	Research Officer
Telephone	02 8382 4960
Email	SVHS.Research@svha.org.au

### Research Governance Officer

Name	Ms Therese Yim
Position	Research Governance Officer
Telephone	02-9295 8173
Email	<a href="mailto:t.yim@garvan.org.au">t.yim@garvan.org.au</a>

**Consent Form - Adult providing own consent**

<b>Title</b>	<i>Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk</i>
<b>Short Title</b>	<i>Personalised medicine in prediabetes (PREDICT)</i>
<b>Protocol Number</b>	<i>17/080</i>
<b>Project Sponsor</b>	<i>Garvan Institute of Medical Research</i>
<b>Coordinating Principal Investigator/ Principal Investigator</b>	<i>Dr Dorit Samocha-Bonet</i>
<b>Associate Investigator(s)</b>	<i>Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng, Dr Snaith, Dr Liu, Ms Godneva</i>
<b>Location</b>	<i>Garvan Institute of Medical Research</i>

**Declaration by Participant**

I have read the Participant Information Sheet or someone has read it to me in a language that I understand.

I understand the purposes, procedures and risks of the research described in the project.

I give permission for my doctors, other health professionals, hospitals or laboratories outside this hospital to release information to Garvan Institute of Medical Research concerning my disease and treatment for the purposes of this project. I understand that such information will remain confidential.

I have had an opportunity to ask questions and I am satisfied with the answers I have received.

I freely agree to participate in this research project as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand that I will be given a signed copy of this document to keep.

I consent to the storage and use of blood and tissue samples taken from me for use, as described in the relevant section of the Participant Information Sheet, for:

- This specific research project
- Other research that is closely related to this research project

I consent to sharing de-identified (coded) data collected during the study with other researchers aiming to achieve the study aims as listed, subject to approval by the study Principal Investigator Dorit Samocha-Bonet and/or Associate Investigator Jerry R Greenfield.

Personalised medicine in prediabetes – Towards preventing diabetes in individuals at risk  
PICF version 11 1/06/20

1  
2  
3  
4 Name of Participant (please print) \_\_\_\_\_  
5  
6 Signature \_\_\_\_\_ Date \_\_\_\_\_  
7  
8

9  
10 Name of Witness\* to Participant's  
11 Signature (please print) \_\_\_\_\_  
12  
13 Signature \_\_\_\_\_ Date \_\_\_\_\_  
14  
15

16 \* Witness is not to be the investigator, a member of the study team or their delegate. In the event that an interpreter is  
17 used, the interpreter may not act as a witness to the consent process. Witness must be 18 years or older.  
18

19  
20 **Declaration by Study Doctor/Senior Researcher†**  
21

22  
23 I have given a verbal explanation of the research project, its procedures and risks and I believe  
24 that the participant has understood that explanation.  
25

26 Name of Study Doctor/  
27 Senior Researcher† (please  
28 print) \_\_\_\_\_  
29  
30 Signature \_\_\_\_\_ Date \_\_\_\_\_  
31  
32

33 † A senior member of the research team must provide the explanation of, and information  
34 concerning, the research project.  
35  
36

37 Note: All parties signing the consent section must date their own signature.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 **Form for Withdrawal of Participation - Adult providing own consent**  
 2  
 3

4 **Title** *Personalised medicine in prediabetes – Towards*  
 5 *preventing diabetes in individuals at risk*  
 6  
 7 **Short Title** *Personalised medicine in prediabetes (PREDICT)*  
 8  
 9 **Protocol Number** *17/080*  
 10 **Project Sponsor** *Garvan Institute of Medical Research*  
 11  
 12 **Coordinating Principal Investigator/  
 13 Principal Investigator** *Dr Dorit Samocha-Bonet*  
 14  
 15 **Associate Investigator(s)** *Prof Segal, Prof Elinav, Prof Greenfield, Dr Hng,  
 16 Dr Snaith, Dr Liu, Ms Godneva*  
 17  
 18 **Location** *Garvan Institute of Medical Research*  
 19  
 20  
 21

22 **Declaration by Participant**  
 23  
 24

25 I wish to withdraw from participation in the above research project and understand that such  
 26 withdrawal will not affect my routine treatment, my relationship with those treating me or my  
 27 relationship with the Garvan Institute of Medical Research.  
 28  
 29

30 Name of Participant (please print) \_\_\_\_\_  
 31  
 32 Signature \_\_\_\_\_ Date \_\_\_\_\_  
 33  
 34

35  
 36 *In the event that the participant's decision to withdraw is communicated verbally, the Study  
 37 Doctor/Senior Researcher will need to provide a description of the circumstances below.*  
 38

39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47

48 **Declaration by Study Doctor/Senior Researcher†**  
 49

50  
 51 I have given a verbal explanation of the implications of withdrawal from the research project and  
 52 I believe that the participant has understood that explanation.  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Name of Study Doctor/ Senior Researcher <sup>†</sup> (please print)	
Signature _____	Date _____

<sup>†</sup> A senior member of the research team must provide the explanation of and information concerning withdrawal from the research project.

Note: All parties signing the consent section must date their own signature.

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1 and 20 (Authors' contribution)
	5b	Name and contact information for the trial sponsor	20
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

1	<b>Introduction</b>			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5 - 6
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	5 - 6
7				
8	Objectives	7	Specific objectives or hypotheses	6
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7
12				
13				
14	<b>Methods: Participants, interventions, and outcomes</b>			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	6 - 7
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	7 and Table 1
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	11 – 13
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	13
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	13 – 14
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6 – 7 and Table 1
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	15 – 16
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation	
35			(eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits	Table 2
39			for participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7 – 8
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9 – 10
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9 – 10
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9 – 10
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9 – 10
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14 – 16
34	methods			
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	14 – 16 and 17 (Statistical plan)
39				
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18 – 19
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16 and Table 2
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Approval granted, details page 3
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	3
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9 and Table 2
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18 – 19
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	18 – 19
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	20 - 21
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	20
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Uploaded
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	19
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.